

**This Page Is Inserted by IFW Operations
and is not a part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representation of
The original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

09/ 806,836

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Jan 25 BLAST(R) searching in REGISTRY available in STN on the Web
NEWS 3 Jan 29 FSTA has been reloaded and moves to weekly updates
NEWS 4 Feb 01 DKILIT now produced by FIZ Karlsruhe and has a new update frequency
NEWS 5 Feb 19 Access via Tymnet and SprintNet Eliminated Effective 3/31/02
NEWS 6 Mar 08 Gene Names now available in BIOSIS
NEWS 7 Mar 22 TOXLIT no longer available
NEWS 8 Mar 22 TRCTHERMO no longer available
NEWS 9 Mar 28 US Provisional Priorities searched with P in CA/Caplus and USPATFULL
NEWS 10 Mar 28 LIPINSKI/CALC added for property searching in REGISTRY
NEWS 11 Apr 02 PAPERCHEM no longer available on STN. Use PAPERCHEM2 instead.
NEWS 12 Apr 08 "Ask CAS" for self-help around the clock
NEWS 13 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 14 Apr 09 ZDB will be removed from STN
NEWS 15 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUIDB
NEWS 16 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 17 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 18 Apr 22 Federal Research in Progress (FEDRIP) now available

NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d,
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:35:33 ON 02 MAY 2002

=> file reg

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

09/ 806,836

FILE 'REGISTRY' ENTERED AT 15:35:41 ON 02 MAY 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 30 APR 2002 HIGHEST RN 409303-45-3
DICTIONARY FILE UPDATES: 30 APR 2002 HIGHEST RN 409303-45-3

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES
for more information. See STN Note 27, Searching Properties in the CAS
Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>


Uploading 09806836.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 15:36:01 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2539 TO ITERATE

39.4% PROCESSED 1000 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 47759 TO 53801
PROJECTED ANSWERS: 8188 TO 10802

L2 50 SEA SSS SAM L1

=> s l1 ful

FULL SEARCH INITIATED 15:36:12 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 51094 TO ITERATE

100.0% PROCESSED 51094 ITERATIONS 9746 ANSWERS

09/ 806,836

SEARCH TIME: 00.00.07

L3 9746 SEA SSS FUL L1

=> s l3 and pyrazol?
445489 PYRAZOL?

L4 249 L3 AND PYRAZOL?

=> file caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
145.80	146.01

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 15:38:45 ON 02 MAY 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 May 2002 VOL 136 ISS 18
FILE LAST UPDATED: 30 Apr 2002 (20020430/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.


CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s l4
L5 24 L4

=> d l5 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 24 ANSWERS - CONTINUE? Y/(N):y

L5 ANSWER 1 OF 24 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:240746 CAPLUS
DOCUMENT NUMBER: 136:279468
TITLE: Preparation of 4-amino-quinazolines useful as glycoprotein IbIX antagonists, and their use for control of thrombotic disorders
INVENTOR(S): Mederski, Werner; Devant, Ralf; Barnickel, Gerhard; Bernotat-Danielowski, Sabine; Vickers, James; Cezanne, Bertram; Dhanoa, Daljit; Zhao, Bao-Ping; Rinker, James; Player, Mark R.; Jaeger, Edward; Soll, Richard
PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany
SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002024667	A1	20020328	WO 2001-EP10705	20010917
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2000-666908	A 20000920
GI				




AB The prepn. of 4-amino-quinazolines [I; wherein R, R1, independently = H, (C1-C6)alkyl, OH, (C1-C6)alkoxy, amino, nitro, cyano, etc.; R2,R3, independently = H, (C1-C6)alkyl, cycloalkyl, mono- or bicycloheterocyclic radical, etc.; R4 = aryl (e.g., Ph, naphthyl, biphenyl, etc.), or thiophen-2-yl substituted with aryl (as described supra) or heterocyclic radical, etc.; each of R, R1-R4 with many provisos] is described. Thus, [2-(4-bromophenyl)-7-chloroquinazolin-4-yl]-phenylamine was prepd. by a multistep synthesis. The prepd. compds. are useful as glycoprotein IbIX antagonists (no data) for the control of thrombotic disorders and sequelae deriving thereof.

IT 405932-33-4P

RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of amino-quinazolines useful as glycoprotein IbIX antagonists)

RN 405932-33-4 CAPLUS

CN 3H-Pyrazol-3-one, 2-[4-[[2-(4-bromophenyl)-7-chloro-4-quinazolinyl]amino]phenyl]-2,4-dihydro-5-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 24 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:220584 CAPLUS

DOCUMENT NUMBER: 136:247584

TITLE: Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease

INVENTOR(S): Bebbington, David; Knegt, Ronald; Golec, Julian M. C.; Li, Pan; Davies, Robert; Charrier, Jean-Damien

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 356 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022608	A1	20020321	WO 2001-US42152	20010914
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			


PRIORITY APPLN. INFO.: US 2000-232795P P 20000915
US 2000-257887P P 20001221
US 2001-286949P P 20010427

OTHER SOURCE(S): MARPAT 136:247584

GI



I



II

AB Title compds. I [wherein G = Ring C or Ring D; Ring C = (un)substituted Ph, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl; Ring D = (un)substituted monocyclic or bicyclic ring selected from aryl, heteroaryl, heterocyclyl, or carbocyclyl; Z1 = N or CR₉; Z2 = N or CH; Z3 = N or CR_x; Z4 = N or CR_y; R_x and R_y = independently TR₃, or taken together with their intervening atoms form an (un)satd. fused ring having 1-3 ring heteroatoms; R2 and R2a = independently R, TWR₆; or C2R2R2a = (un)substituted fused ring contg. 0-3 heteroatoms; T = a bond or alkylidene chain; W = C(R₆)₂O, C(R₆)₂SO-2, C(R₆)₂NR₆, CO, CO₂, CR₆OCO, CR₆CONR₆, C(R₆)₂NR₆CO, C(R₆)₂NR₆CO₂, CR₆:NNR₆, CR₆:NO, C(R₆)₂NR₆NR₆, C(R₆)₂NR₆SO₂NR₆, C(R₆)₂NR₆CONR₆, or CONR₆; R = H or (un)substituted aliph., (hetero)aryl, or heterocyclyl ring; R₃ = R, halo, O, OR, COR, CO₂R, COCOR, COCH₂COR, NO₂, CN, SO₂-2R, N(R₄)₂, CON(R₄)₂, SO₂N(R₄)₂, OCOR, NR₄COR, NR₄CO₂(aliph.), NR₄N(R₄)₂, C:NN(R₄)₂, C:NOR, NR₄CO(R₄)₂, NR₄SO₂N(R₄)₂, NR₄SO₂R, or OCON(R₄)₂; R₄ = R₇, COR₇, CO₂(aliph.), CON(R₇)₂, or SO₂R₇; or N(R₄)₂ = heterocyclyl or heteroaryl; R₆ and R₇ = independently H or (un)substituted aliph. group; or N(R₆)₂ = heterocyclyl or heteroaryl; or N(R₇)₂ = heterocyclyl or heteroaryl; R₉ = R, halo, OR, COR, CO₂R, COCOR, etc.] were prepd. as protein kinase inhibitors, esp. as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes, and Alzheimer's disease. Claims cover (pyrimidinyl)pyrazolamines and indazolamines I [wherein Z1 = CR₉; Z2 and Z3 = N; Z4 = CR_y]. Examples include data for approx. 300 invention compds. prepd. by a variety of synthetic methods and bioassay results for the inhibition of GSK-3, Aurora-2, ERK, and Src. For instance, the N-(4-pyrimidinyl)-3-pyrazolamine II was prepd. and exhibited K_i values of < 0.1 .mu.M for glycogen synthetase kinase 3.beta. (GSK-3.beta.) and 0.1-1.0 .mu.M for Aurora-2.


IT 404828-30-4P, (2-Chloroquinazolin-4-yl)(5-methyl-1H-pyrazol-3-yl)amine

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; prepn. of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)


RN 404828-30-4 CAPLUS

CN 4-Quinazolinamine, 2-chloro-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


IT **404826-20-6P**, [2-(3,4-Dichlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404826-21-7P**, [2-(4-Bromophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404826-22-8P**, (2-Biphenyl-4-ylquinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine **404826-23-9P**, [2-(4-Ethynylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-54-2P**, (5-Methoxycarbonyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-58-6P**, (5-Benzyloxypropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-61-1P**, [5-(3-tert-Butoxycarbonylaminoethyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404829-04-5P**, (5-Methoxycarbonyl-2H-pyrazol-3-yl) [2-(piperidine-1-yl)quinazolin-4-yl]amine
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (protein kinase inhibitor; prepn. of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)
 RN 404826-20-6 CAPLUS
 CN 4-Quinazolinamine, 2-(3,4-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-21-7 CAPLUS
 CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
 (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-22-8 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-4-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-23-9 CAPLUS

CN 4-Quinazolinamine, 2-(4-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-54-2 CAPLUS


09/ 806,836

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 404828-58-6 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-[5-[3-(phenylmethoxy)propyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-61-1 CAPLUS

CN Carbamic acid, [3-[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 404829-04-5 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[[2-(1-piperidinyl)-4-quinazolinyl]amino]-
, methyl ester (9CI) (CA INDEX NAME)

IT 404826-60-4P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-methylphenyl)quinazolin-4-yl]amine 404826-61-5P, [2-(2,4-Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-62-6P, [2-(2,5-Dimethoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-63-7P, [2-(2-Chlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-64-8P, [2-(2-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-65-9P, [2-(2,6-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-66-0P, [2-(2-Acetylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-67-1P, [2-(2,3-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-68-2P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-69-3P, [2-(2-Ethylphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-70-6P, (2-Biphenyl-2-yl)quinazolin-4-yl(5-methyl-2H-pyrazol-3-yl)amine 404826-71-7P, [2-(2-Hydroxyphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-72-8P, [2-(2-Ethoxyphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-73-9P, [5-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-74-0P, [4-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-75-1P, (4-Phenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-76-2P, (5-tert-Butyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-77-3P, (5-Phenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-78-4P, (4,5-Diphenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-79-5P, (4-Carbamoyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-80-8P, (2H-Pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-81-9P, (5-Hydroxy-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-82-0P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-83-1P, (5-Methoxymethyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-28-7P, (1H-Pyrazolo[4,3-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-29-8P, (1H-Pyrazolo[3,4-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-30-1P, (6-Methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)[2-(2-

trifluoromethylphenyl)quinazolin-4-yl]amine **404827-31-2P**,
 (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-56-1P**,
 (5-Methyl-2H-pyrazol-3-yl)[2-(2-naphthyl-1-yl)quinazolin-4-yl]amine **404828-10-0P**, (5-Methyl-2H-pyrazol-3-yl)(2-pyridin-4-yl)quinazolin-4-yl]amine **404828-11-1P**, (7-Chloro-2-pyridin-4-yl)quinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine **404828-12-2P**,
 (6-Chloro-2-pyridin-4-yl)quinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine **404828-13-3P**, (2-Cyclohexyl)quinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine **404828-14-4P**, (5-Methyl-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-15-5P**, [2-(4-Iodophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-16-6P**, [2-(4-Chlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-17-7P**, [2-(3,5-Dichlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-18-8P**, [2-(4-Cyanophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-19-9P**, [2-(3-Iodophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-20-2P**,
 [2-(4-Ethylsulfanylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-21-3P**, (5-Cyclopropyl-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-22-4P**, [2-(4-tert-Butylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-23-5P**, [2-(4-Chlorophenyl)quinazolin-4-yl](5-cyclopropyl-2H-pyrazol-3-yl)amine **404828-24-6P**, (2-Benzo[1,3]dioxol-5-yl)quinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine **404828-25-7P**, [2-(4-Dimethylaminophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-26-8P**, [2-(3-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-27-9P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dichlorophenyl)quinazolin-4-yl]amine **404828-28-0P**, [2-(3-Ethynylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-29-1P**, [2-(3-Methylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-31-5P**, [2-(3,5-Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-32-6P**, [2-(3-Chloro-4-fluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-34-8P**,
 (5-Methyl-2H-pyrazol-3-yl)[2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine **404828-35-9P**, [2-(3-Cyanophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-36-0P**, [2-(3-Isopropylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-37-1P**, (5-Methyl-2H-pyrazol-3-yl)(2-pyridin-3-yl)quinazolin-4-yl)amine **404828-38-2P**, [2-(3-Acetylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-39-3P**, [2-(3,5-Bis(trifluoromethyl)phenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-40-6P**, [2-(3-Hydroxymethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-41-7P**, (5-Methyl-2H-pyrazol-3-yl)[2-(3-phenoxyphenyl)quinazolin-4-yl]amine **404828-42-8P**,
 (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3-phenoxyphenyl)quinazolin-4-yl]amine **404828-43-9P** **404828-44-0P**, (2-Phenyl)quinazolin-4-yl)(2H-pyrazol-3-yl)amine **404828-45-1P**, (2H-Pyrazol-3-yl)(2-pyridin-4-yl)quinazolin-4-yl)amine **404828-46-2P**, (5-Ethyl-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-47-3P**,
 (2-Phenyl)quinazolin-4-yl)(5-propyl-2H-pyrazol-3-yl)amine **404828-48-4P**, (5-Isopropyl-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-49-5P**, (5-tert-Butyl-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-50-8P**, (5-tert-Butyl-2H-pyrazol-3-yl)(2-pyridin-4-yl)quinazolin-4-yl)amine **404828-51-9P**, (5-Cyclopentyl-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-52-0P**, (5-Phenyl-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-53-1P**, (5-Carboxy-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-55-3P**, (5-Hydroxymethyl-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-56-4P**, (5-Methoxymethyl-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-57-5P**, [5-(3-Hydroxypropyl)-2H-pyrazol-3-yl](2-

phenylquinazolin-4-yl)amine 404828-59-7P, [5-(3-Methoxypropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-60-0P, [5-(3-Aminopropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-62-2P, (5-Isopropylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-63-3P, (5-Allylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-64-4P, [5-(2-Methoxyethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-65-5P, (5-Benzylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-66-6P, (5-Cyclohexylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-67-7P, (5-Diethylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-68-8P, [5-(Benzylmethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-69-9P, (2-Phenylquinazolin-4-yl) (5-propylcarbamoyl-2H-pyrazol-3-yl)amine 404828-70-2P, [5-(Ethylisopropylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-71-3P, (5-Cyclopropylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-72-4P, (5-Isobutylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-73-5P, [5-((3S)-3-Methoxymethylpyrrolidine-1-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-74-6P, (2-Phenylquinazolin-4-yl) (5-m-tolylcarbamoyl-2H-pyrazol-3-yl)amine 404828-75-7P, (2-Phenylquinazolin-4-yl) (5-p-tolylcarbamoyl-2H-pyrazol-3-yl)amine 404828-76-8P, (5-Methylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-77-9P, [5-(Morpholine-4-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-78-0P, [5-(1-Methylpiperazine-4-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-79-1P, [5-(2-Hydroxyethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-80-4P, (5-Carbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-82-6P, (4-Bromo-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-83-7P, (4-Bromo-5-methyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-84-8P, (4-Cyano-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-85-9P, (5-Methyl-2H-pyrazol-3-yl) (2-morpholin-4-ylquinazolin-4-yl)amine 404828-86-0P, (5-Methyl-2H-pyrazol-3-yl) (2-piperazin-1-ylquinazolin-4-yl)amine 404828-87-1P, [2-(4-Methylpiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-88-2P, [2-(4-Methylpiperazin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-89-3P, (5-Methyl-2H-pyrazol-3-yl) (2-piperidin-1-ylquinazolin-4-yl)amine 404828-90-6P, [2-(Azepan-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-91-7P, [2-[4-(2-Hydroxyethyl)piperidin-1-yl]quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-92-8P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-methylpiperidin-1-yl)quinazolin-4-yl]amine 404828-95-1P, [2-(4-Cyclopentylaminopiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-96-2P, [2-(4-Hydroxypiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-97-3P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-hydroxy-4-phenylpiperidin-1-yl)quinazolin-4-yl]amine 404828-98-4P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(1,3-dihydroisoindol-2-yl)quinazolin-4-yl]amine 404828-99-5P, [2-(Azepan-1-yl)quinazolin-4-yl] (5-cyclopropyl-2H-pyrazol-3-yl)amine 404829-00-1P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dihydro-1H-isoquinolin-2-yl)quinazolin-4-yl]amine 404829-01-2P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(2,3-dihydroindol-1-yl)quinazolin-4-yl]amine 404829-02-3P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-hydroxymethylpiperidin-1-yl)quinazolin-4-yl]amine 404829-03-4P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dihydro-2H-quinolin-1-yl)quinazolin-4-yl]amine 404829-05-6P, 5-(Piperidine-1-carbonyl)-2H-pyrazol-3-yl-[2-(piperidine-1-yl)quinazolin-4-yl]amine 404829-06-7P, (5-Hydroxymethyl-2H-pyrazol-3-yl) [2-(piperidin-1-yl)quinazolin-4-yl]amine 404829-07-8P, (5-Carbamoyl-2H-pyrazol-3-yl) [2-(piperidin-1-yl)quinazolin-4-yl]amine 404829-08-9P, (5-Carbamoyl-2H-pyrazol-3-


yl) [2-(4-methylpiperidin-1-yl)quinazolin-4-yl]amine **404829-15-8P**, (2-Phenylquinazolin-4-yl) (1H-pyrazolo[4,3-b]pyridin-3-yl)amine **404829-16-9P**, [5-(3-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-17-0P**, (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl) (2-phenylquinazolin-4-yl)amine **404829-18-1P**, [5-(4-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-19-2P**, [5-(2,4-Dichlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-21-6P**, [6-Oxo-5-(3-trifluoromethylphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-22-7P**, [6-Oxo-5-(4-Phenoxyphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-23-8P**, [5-(4-Chlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; prepn. of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-60-4 CAPLUS

CN 4-Quinazolinamine, 2-(2-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-61-5 CAPLUS

CN 4-Quinazolinamine, 2-(2,4-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-62-6 CAPLUS


CN 4-Quinazolinamine, 2-(2,5-dimethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-63-7 CAPLUS

CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-64-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-65-9 CAPLUS

CN 4-Quinazolinamine, 2-(2,6-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-66-0 CAPLUS

CN Ethanone, 1-[2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-67-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,3-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-68-2 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-69-3 CAPLUS

09/ 806,836


CN 4-Quinazolinamine, 2-(2-ethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-70-6 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-2-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-71-7 CAPLUS

CN Phenol, 2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA
INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-72-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-73-9 CAPLUS

CN 4-Quinazolinamine, N-[5-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-74-0 CAPLUS

CN 4-Quinazolinamine, N-[4-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-75-1 CAPLUS


CN 4-Quinazolinamine, N-(4-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-76-2 CAPLUS

CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-77-3 CAPLUS

CN 4-Quinazolinamine, N-(5-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-78-4 CAPLUS


CN 4-Quinazolinamine, N-(4,5-diphenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-79-5 CAPLUS

CN 1H-Pyrazole-4-carboxamide, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-80-8 CAPLUS

09/ 806,836


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404826-81-9 CAPLUS

CN 3H-Pyrazol-3-one, 1,2-dihydro-5-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 404826-82-0 . CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-83-1 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-28-7 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazolo[4,3-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-29-8 CAPLUS

CN 4-Quinazolinamine, N-1H-pyrazolo[3,4-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-30-1 CAPLUS


CN 4-Quinazolinamine, N-(6-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-31-2 CAPLUS

CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-56-1 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-naphthalenyl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-10-0 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-11-1 CAPLUS

CN 4-Quinazolinamine, 7-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-12-2 CAPLUS


CN 4-Quinazolinamine, 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-13-3 CAPLUS

CN 4-Quinazolinamine, 2-cyclohexyl-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA
INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-14-4 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX
NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-15-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-16-6 CAPLUS

CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-17-7 CAPLUS

CN 4-Quinazolinamine, 2-(3,5-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-

09/ 806,836


(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-18-8 CAPLUS

CN Benzonitrile, 4-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-19-9 CAPLUS

CN 4-Quinazolinamine, 2-(3-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-20-2 CAPLUS


CN 4-Quinazolinamine, 2-[4-(ethylthio)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-21-3 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA
INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-22-4 CAPLUS

CN 4-Quinazolinamine, 2-[4-(1,1-dimethylethyl)phenyl]-N-(5-methyl-1H-pyrazol-

09/ 806,836


3-yl) - (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-23-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-24-6 CAPLUS

CN 4-Quinazolinamine, 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-25-7 CAPLUS


CN 4-Quinazolinamine, 2-[4-(dimethylamino)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-26-8 CAPLUS

CN 4-Quinazolinamine, 2-(3-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-27-9 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dichlorophenyl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-28-0 CAPLUS


CN 4-Quinazolinamine, 2-(3-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-29-1 CAPLUS

CN 4-Quinazolinamine, 2-(3-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-31-5 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-32-6 CAPLUS

CN 4-Quinazolinamine, 2-(3-chloro-4-fluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-34-8 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-35-9 CAPLUS


CN Benzonitrile, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-36-0 CAPLUS

CN 4-Quinazolinamine, 2-[3-(1-methylethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-37-1 CAPLUS

09/ 806,836


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-pyridinyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-38-2 CAPLUS


CN Ethanone, 1-[3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-39-3 CAPLUS

CN 4-Quinazolinamine, 2-[3,5-bis(trifluoromethyl)phenyl]-N-(5-methyl-1H-
pyrazol-3-yl)- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-40-6 CAPLUS


CN Benzenemethanol, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-41-7 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-42-8 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)-
(9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-43-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-thienyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-44-0 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazol-3-yl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-45-1 CAPLUS

CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-46-2 CAPLUS


CN 4-Quinazolinamine, N-(5-ethyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-47-3 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-(5-propyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-48-4 CAPLUS

CN 4-Quinazolinamine, N-[5-(1-methylethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-49-5 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-phenyl-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-50-8 CAPLUS

CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-(4-
pyridinyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-51-9 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopentyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA
INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-52-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-53-1 CAPLUS


CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-55-3 CAPLUS


CN 1H-Pyrazole-3-methanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)

09/ 806,836



RN 404828-56-4 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-57-5 CAPLUS


CN 1H-Pyrazole-3-propanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA
INDEX NAME)



RN 404828-59-7 CAPLUS

CN 4-Quinazolinamine, N-[5-(3-methoxypropyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-60-0 CAPLUS


CN 4-Quinazolinamine, N-[5-(3-aminopropyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-62-2 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-63-3 CAPLUS


CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-2-propenyl- (9CI) (CA INDEX NAME)

09/ 806,836




RN 404828-64-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-methoxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-65-5 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(phenylmethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-66-6 CAPLUS


09/ 806,836

CN 1H-Pyrazole-3-carboxamide, N-cyclohexyl-5-[(2-phenyl-4-quinazolinyl)amino] -
(9CI) (CA INDEX NAME)



RN 404828-67-7 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N,N-diethyl-5-[(2-phenyl-4-quinazolinyl)amino] -
(9CI) (CA INDEX NAME)



RN 404828-68-8 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(2-phenylethyl)-5-[(2-phenyl-4-quinazolinyl)amino] - (9CI) (CA INDEX NAME)

09/ 806,836




RN 404828-69-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-propyl-
(9CI) (CA INDEX NAME)



RN 404828-70-2 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-ethyl-N-(1-methylethyl)-5-[(2-phenyl-4-
quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-71-3 CAPLUS


09/ 806,836

CN 1H-Pyrazole-3-carboxamide, N-cyclopropyl-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-72-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-methylpropyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-73-5 CAPLUS

CN Pyrrolidine, 3-(methoxymethyl)-1-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

09/ 806,836



RN 404828-74-6 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(3-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-75-7 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(4-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)

09/ 806,836



RN 404828-76-8 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-methyl-5-[(2-phenyl-4-quinazolinyl)amino]-
(9CI) (CA INDEX NAME)



RN 404828-77-9 CAPLUS


CN Morpholine, 4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

09/ 806,836



RN 404828-78-0 CAPLUS


CN Piperazine, 1-methyl-4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 404828-79-1 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(2-hydroxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)

09/ 806,836




RN 404828-80-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-82-6 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-83-7 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-84-8 CAPLUS


CN 1H-Pyrazole-4-carbonitrile, 3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-85-9 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-86-0 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-87-1 CAPLUS


CN 4-Quinazolinamine, 2-(4-methyl-1-piperidiny)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-88-2 CAPLUS

CN 4-Quinazolinamine, 2-(4-methyl-1-piperazinyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

09/ 806,836

RN 404828-89-3 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-piperidinyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-90-6 CAPLUS


CN 4-Quinazolinamine, 2-(hexahydro-1H-azepin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-91-7 CAPLUS

CN 4-Piperidineethanol, 1-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-92-8 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(4-methyl-1-piperidinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-95-1 CAPLUS

CN 4-Quinazolinamine, 2-[4-(cyclopentylamino)-1-piperidinyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-96-2 CAPLUS

CN 4-Piperidinol, 1-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-97-3 CAPLUS


CN 4-Piperidinol, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-4-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-98-4 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1,3-dihydro-2H-isoindol-2-yl)- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-99-5 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(hexahydro-1H-azepin-1-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-00-1 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-2(1H)-isoquinolinyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-01-2 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2,3-dihydro-1H-indol-1-yl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-02-3 CAPLUS


CN 4-Piperidinemethanol, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-03-4 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-1(2H)-quinolinyl)- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404829-05-6 CAPLUS

CN Piperidine, 1-[[5-[[2-(1-piperidinyl)-4-quinazolinyl]amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 404829-06-7 CAPLUS


CN 1H-Pyrazole-3-methanol, 5-[[2-(1-piperidinyl)-4-quinazolinyl]amino]- (9CI)
(CA INDEX NAME)



RN 404829-07-8 CAPLUS


CN 1H-Pyrazole-3-carboxamide, 5-[[2-(1-piperidinyl)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

09/ 806,836




RN 404829-08-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[[2-(4-methyl-1-piperidinyl)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 404829-15-8 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazolo[4,3-b]pyridin-3-yl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-16-9 CAPLUS

09/ 806,836


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(3-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-17-0 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-18-1 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-19-2 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(2,4-dichlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-21-6 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-22-7 CAPLUS

CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-phenoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-23-8 CAPLUS

CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(4-chlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)

09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


IT 404828-81-5, 5-(2-Phenylquinazolin-4-ylamino)-1H-pyrazole-3-carboxylic acid 2,5-dioxopyrrolidin-1-yl ester 404828-93-9, (5-Cyclopropyl-1H-pyrazol-3-yl) (2-chloroquinazolin-4-yl) amine

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; prepn. of heterocyclpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)


RN 404828-81-5 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyloxy]- (9CI) (CA INDEX NAME)



RN 404828-93-9 CAPLUS

CN 4-Quinazolinamine, 2-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:220583 CAPLUS

DOCUMENT NUMBER: 136:247583

TITLE: Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease

INVENTOR(S): Davies, Robert; Bebbington, David; Knegt, Ronald; Wannamaker, Marion; Li, Pan; Forester, Cornelia; Pierce, Albert; Kay, David

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 373 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022607	A1	20020321	WO 2001-US28940	20010914
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2000-232795P P 20000915
US 2000-257887P P 20001221
US 2001-286949P P 20010427

OTHER SOURCE(S): MARPAT 136:247583

GI



AB Title compds. I [wherein G = Ring C or Ring D; Ring C = (un)substituted Ph, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl; Ring D = (un)substituted monocyclic or bicyclic ring selected from aryl, heteroaryl, heterocyclyl, or carbocyclyl; Z1 = N or CR₉; Z2 = N or CH; Z3 = N or CR_x; Z4 = N or CR_y; R_x and R_y = independently TR₃, or taken together with their intervening atoms form an (un)satd. fused ring having 1-3 ring heteroatoms; R₂ and R_{2a} = independently R, TWR₆; or C₂R₂R_{2a} = (un)substituted fused ring contg. 0-3 heteroatoms; T = a bond or alkylidene chain; W = C(R₆)₂O, C(R₆)₂S₀₋₂, C(R₆)₂NR₆, CO, CO₂, CR₆OCO, CR₆OCONR₆, C(R₆)₂NR₆CO, C(R₆)₂NR₆CO₂, CR₆:NNR₆, CR₆:NO, C(R₆)₂NR₆NR₆, C(R₆)₂NR₆SO₂NR₆, C(R₆)₂NR₆CONR₆, or CONR₆; R = H or (un)substituted aliph., (hetero)aryl, or heterocyclyl ring; R₃ = R, halo, O, OR, COR, CO₂R, COCOR, COCH₂COR, NO₂, CN, SO₀₋₂R, N(R₄)₂, CON(R₄)₂, SO₂N(R₄)₂, OCOR, NR₄COR, NR₄CO₂(aliph.), NR₄N(R₄)₂, C:NN(R₄)₂, C:NOR, NR₄CO(R₄)₂, NR₄SO₂N(R₄)₂, NR₄SO₂R, or OCON(R₄)₂; R₄ = R₇, COR₇, CO₂(aliph.), CON(R₇)₂, or SO₂R₇; or N(R₄)₂ = heterocyclyl or heteroaryl; R₆ and R₇ = independently H or (un)substituted aliph. group; or N(R₆)₂ = heterocyclyl or heteroaryl; or N(R₇)₂ = heterocyclyl or heteroaryl; R₉ = R, halo, OR, COR, CO₂R, COCOR, etc.] were prepd. as protein kinase inhibitors, esp. as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes, and Alzheimer's disease. Claims cover (pyrimidinyl)pyrazolamines and indazolamines I [wherein Z1 and Z2 = N; Z3 = CR_x; Z4 = CR_y; G = Ring C]. Examples include data for approx. 300 invention compds. prepd. by a variety of synthetic methods and bioassay results for the inhibition of GSK-3, Aurora-2, ERK, and Src. For instance, the N-(4-pyrimidinyl)-3-pyrazolamine II was prepd. and exhibited K_i values of < 0.1 .mu.M for glycogen synthetase kinase 3.beta. (GSK-3.beta.) and 0.1-1.0 .mu.M for Aurora-2.


IT **404828-30-4P**, (2-Chloroquinazolin-4-yl)(5-methyl-1H-pyrazol-3-yl)amine

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; prepn. of heterocyclpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)


RN 404828-30-4 CAPLUS

CN 4-Quinazolinamine, 2-chloro-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


IT 404826-20-6P, [2-(3,4-Dichlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-21-7P, [2-(4-Bromophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-22-8P, (2-Biphenyl-4-ylquinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404826-23-9P, [2-(4-Ethynylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-54-2P, (5-Methoxycarbonyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-58-6P, (5-Benzyloxypropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-61-1P, [5-(3-tert-Butoxycarbonylaminoethyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404829-04-5P, (5-Methoxycarbonyl-2H-pyrazol-3-yl) [2-(piperidine-1-yl)quinazolin-4-yl]amine
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (protein kinase inhibitor; prepn. of heterocyclpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)
 RN 404826-20-6 CAPLUS
 CN 4-Quinazolinamine, 2-(3,4-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-21-7 CAPLUS
 CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-22-8 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-4-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-23-9 CAPLUS

CN 4-Quinazolinamine, 2-(4-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-54-2 CAPLUS


09/ 806,836

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 404828-58-6 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-[5-[3-(phenylmethoxy)propyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-61-1 CAPLUS

CN Carbamic acid, [3-[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 404829-04-5 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[[2-(1-piperidinyl)-4-quinazolinyl]amino] -
, methyl ester (9CI) (CA INDEX NAME)

IT 404826-60-4P, (5-Methyl-2H-pyrazol-3-yl) [2-(2-methylphenyl)quinazolin-4-yl]amine 404826-61-5P, [2-(2,4-Difluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-62-6P, [2-(2,5-Dimethoxyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-63-7P, [2-(2-Chlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-64-8P, [2-(2-Methoxyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-65-9P, [2-(2,6-Dimethylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-66-0P, [2-(2-Acetylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-67-1P, [2-(2,3-Dimethylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-68-2P, (5-Methyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-69-3P, [2-(2-Ethylphenyl)quinazolin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine 404826-70-6P, (2-Biphenyl-2-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-71-7P, [2-(2-Hydroxyphenyl)quinazolin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine 404826-72-8P, [2-(2-Ethoxyphenyl)quinazolin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine 404826-73-9P, [5-(Thiophen-2-yl)-2H-pyrazol-3-yl] [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-74-0P, [4-(Thiophen-2-yl)-2H-pyrazol-3-yl] [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-75-1P, (4-Phenyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-76-2P, (5-tert-Butyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-77-3P, (5-Phenyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-78-4P, (4,5-Diphenyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-79-5P, (4-Carbamoyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-80-8P, (2H-Pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-81-9P, (5-Hydroxy-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-82-0P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-83-1P, (5-Methoxymethyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-28-7P, (1H-Pyrazolo[4,3-b]pyridin-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-29-8P, (1H-Pyrazolo[3,4-b]pyridin-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-30-1P, (6-Methyl-1H-pyrazolo[3,4-b]pyridin-3-yl) [2-(2-

trifluoromethylphenyl)quinazolin-4-yl]amine **404827-31-2P**,
 (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-56-1P**,
 (5-Methyl-2H-pyrazol-3-yl)[2-(2-naphthyl-1-yl)quinazolin-4-yl]amine **404828-10-0P**, (5-Methyl-2H-pyrazol-3-yl)(2-pyridin-4-ylquinazolin-4-yl)-amine **404828-11-1P**, (7-Chloro-2-pyridin-4-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine **404828-12-2P**,
 (6-Chloro-2-pyridin-4-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine **404828-13-3P**, (2-Cyclohexylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine **404828-14-4P**, (5-Methyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-15-5P**, [2-(4-Iodophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-16-6P**, [2-(4-Chlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-17-7P**, [2-(3,5-Dichlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-18-8P**, [2-(4-Cyanophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-19-9P**, [2-(3-Iodophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-20-2P**,
 [2-(4-Ethylsulfanyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-21-3P**, (5-Cyclopropyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-22-4P**, [2-(4-tert-Butylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-23-5P**, [2-(4-Chlorophenyl)quinazolin-4-yl](5-cyclopropyl-2H-pyrazol-3-yl)amine **404828-24-6P**, (2-Benzo[1,3]dioxol-5-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine **404828-25-7P**, [2-(4-Dimethylaminophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-26-8P**, [2-(3-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-27-9P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dichlorophenyl)quinazolin-4-yl]amine **404828-28-0P**, [2-(3-Ethynylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-29-1P**, [2-(3-Methylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-31-5P**, [2-(3,5-Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-32-6P**, [2-(3-Chloro-4-fluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-34-8P**,
 (5-Methyl-2H-pyrazol-3-yl)[2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine **404828-35-9P**, [2-(3-Cyanophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-36-0P**, [2-(3-Isopropylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-37-1P**, (5-Methyl-2H-pyrazol-3-yl)(2-pyridin-3-ylquinazolin-4-yl)amine **404828-38-2P**, [2-(3-Acetylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-39-3P**, [2-(3,5-Bis(trifluoromethyl)phenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-40-6P**, [2-(3-Hydroxymethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-41-7P**, (5-Methyl-2H-pyrazol-3-yl)[2-(3-phenoxyphenyl)quinazolin-4-yl]amine **404828-42-8P**,
 (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3-phenoxyphenyl)quinazolin-4-yl]amine **404828-43-9P** **404828-44-0P**, (2-Phenylquinazolin-4-yl)(2H-pyrazol-3-yl)amine **404828-45-1P**, (2H-Pyrazol-3-yl)(2-pyridin-4-ylquinazolin-4-yl)amine **404828-46-2P**, (5-Ethyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-47-3P**,
 (2-Phenylquinazolin-4-yl)(5-propyl-2H-pyrazol-3-yl)amine **404828-48-4P**, (5-Isopropyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-49-5P**, (5-tert-Butyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-50-8P**, (5-tert-Butyl-2H-pyrazol-3-yl)(2-pyridin-4-ylquinazolin-4-yl)amine **404828-51-9P**, (5-Cyclopentyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-52-0P**, (5-Phenyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-53-1P**, (5-Carboxy-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-55-3P**, (5-Hydroxymethyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-56-4P**,
 (5-Methoxymethyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-57-5P**, [5-(3-Hydroxypropyl)-2H-pyrazol-3-yl](2-

phenylquinazolin-4-yl)amine **404828-59-7P**, [5-(3-Methoxypropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-60-0P**, [5-(3-Aminopropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-62-2P**, (5-Isopropylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-63-3P**, (5-Allylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-64-4P**, [5-(2-Methoxyethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-65-5P**, (5-Benzylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-66-6P**, (5-Cyclohexylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-67-7P**, (5-Diethylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-68-8P**, [5-(Benzylmethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-69-9P**, (2-Phenylquinazolin-4-yl) (5-propylcarbamoyl-2H-pyrazol-3-yl)amine **404828-70-2P**, [5-(Ethylisopropylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-71-3P**, (5-Cyclopropylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-72-4P**, (5-Isobutylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-73-5P**, [5-((3S)-3-Methoxymethylpyrrolidine-1-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-74-6P**, (2-Phenylquinazolin-4-yl) (5-m-tolylcarbamoyl-2H-pyrazol-3-yl)amine **404828-75-7P**, (2-Phenylquinazolin-4-yl) (5-p-tolylcarbamoyl-2H-pyrazol-3-yl)amine **404828-76-8P**, (5-Methylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-77-9P**, [5-(Morpholine-4-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-78-0P**, [5-(1-Methylpiperazine-4-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-79-1P**, [5-(2-Hydroxyethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-80-4P**, (5-Carbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-82-6P**, (4-Bromo-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-83-7P**, (4-Bromo-5-methyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-84-8P**, (4-Cyano-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-85-9P**, (5-Methyl-2H-pyrazol-3-yl) (2-morpholin-4-yl)quinazolin-4-yl)amine **404828-86-0P**, (5-Methyl-2H-pyrazol-3-yl) (2-piperazin-1-yl)quinazolin-4-yl)amine **404828-87-1P**, [2-(4-Methylpiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-88-2P**, [2-(4-Methylpiperazin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-89-3P**, (5-Methyl-2H-pyrazol-3-yl) (2-piperidin-1-yl)quinazolin-4-yl)amine **404828-90-6P**, [2-(Azepan-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-91-7P**, [2-[4-(2-Hydroxyethyl)piperidin-1-yl]quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-92-8P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-methylpiperidin-1-yl)quinazolin-4-yl]amine **404828-95-1P**, [2-(4-Cyclopentylaminopiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-96-2P**, [2-(4-Hydroxypiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-97-3P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-hydroxy-4-phenylpiperidin-1-yl)quinazolin-4-yl]amine **404828-98-4P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(1,3-dihydroisoindol-2-yl)quinazolin-4-yl]amine **404828-99-5P**, [2-(Azepan-1-yl)quinazolin-4-yl] (5-cyclopropyl-2H-pyrazol-3-yl)amine **404829-00-1P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dihydro-1H-isoquinolin-2-yl)quinazolin-4-yl]amine **404829-01-2P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(2,3-dihydroindol-1-yl)quinazolin-4-yl]amine **404829-02-3P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-hydroxymethylpiperidin-1-yl)quinazolin-4-yl]amine **404829-03-4P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dihydro-2H-quinolin-1-yl)quinazolin-4-yl]amine **404829-05-6P**, 5-(Piperidine-1-carbonyl)-2H-pyrazol-3-yl-[2-(piperidin-1-yl)quinazolin-4-yl]amine **404829-06-7P**, (5-Hydroxymethyl-2H-pyrazol-3-yl) [2-(piperidin-1-yl)quinazolin-4-yl]amine **404829-07-8P**, (5-Carbamoyl-2H-pyrazol-3-yl) [2-(piperidin-1-yl)quinazolin-4-yl]amine **404829-08-9P**, (5-Carbamoyl-2H-pyrazol-3-


yl) [2-(4-methylpiperidin-1-yl)quinazolin-4-yl]amine **404829-15-8P**,
 (2-Phenylquinazolin-4-yl) (1H-pyrazolo[4,3-b]pyridin-3-yl)amine
404829-16-9P, [5-(3-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-
 pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine
404829-17-0P, (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-
 c]pyridazin-3-yl) - (2-phenylquinazolin-4-yl)amine **404829-18-1P**,
 [5-(4-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-
 phenylquinazolin-4-yl)amine **404829-19-2P**, [5-(2,4-
 Dichlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-
 phenylquinazolin-4-yl)amine **404829-21-6P**, [6-Oxo-5-(3-
 trifluoromethylphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-
 phenylquinazolin-4-yl)amine **404829-22-7P**, [6-Oxo-5-(4-
 Phenoxyphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-
 phenylquinazolin-4-yl)amine **404829-23-8P**, [5-(4-Chlorophenyl)-6-
 oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-
 yl)amine **404873-45-6P 404873-47-8P 404873-48-9P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(protein kinase inhibitor; prepn. of heterocyclylpyrazolamines and
 analogs as protein kinase inhibitors for treatment of cancer, diabetes,
 and Alzheimer's disease)

RN 404826-60-4 CAPLUS

CN 4-Quinazolinamine, 2-(2-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
 (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-61-5 CAPLUS

CN 4-Quinazolinamine, 2-(2,4-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
 (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-62-6 CAPLUS


CN 4-Quinazolinamine, 2-(2,5-dimethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-63-7 CAPLUS

CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-64-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-65-9 CAPLUS

CN 4-Quinazolinamine, 2-(2,6-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-66-0 CAPLUS

CN Ethanone, 1-[2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-67-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,3-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-68-2 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-69-3 CAPLUS

09/ 806,836


CN 4-Quinazolinamine, 2-(2-ethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-70-6 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-2-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-71-7 CAPLUS

CN Phenol, 2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA
INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-72-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-73-9 CAPLUS

CN 4-Quinazolinamine, N-[5-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-74-0 CAPLUS

CN 4-Quinazolinamine, N-[4-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Cc1ccc(cc1)N2C3CCCCC3N(C2)N4C=C(C=C4N)C5=CC=CC=C5S

RN 404826-75-1 CAPLUS

Cc1ccc(cc1)C2N(C3CCCCC3)NC(C4=CC=CC=C4)N5C=CC(=C5)N


RN 404826-76-2 CAPLUS

Cc1cc(C23CCCCC2N3C4C(=O)C(=O)C5=CC(=CC=C5)C(F)(F)F)nn1

RN 404826-77-3 CAPLUS

CN 4-Quinazolinamine, N-(5-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-78-4 CAPLUS


CN 4-Quinazolinamine, N-(4,5-diphenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-79-5 CAPLUS

CN 1H-Pyrazole-4-carboxamide, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-80-8 CAPLUS

09/ 806,836


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404826-81-9 CAPLUS

CN 3H-Pyrazol-3-one, 1,2-dihydro-5-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 404826-82-0 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-83-1 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-28-7 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazolo[4,3-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-29-8 CAPLUS

CN 4-Quinazolinamine, N-1H-pyrazolo[3,4-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-30-1 CAPLUS


CN 4-Quinazolinamine, N-(6-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-31-2 CAPLUS

CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-56-1 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-naphthalenyl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-10-0 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-11-1 CAPLUS

CN 4-Quinazolinamine, 7-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-12-2 CAPLUS


CN 4-Quinazolinamine, 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-13-3 CAPLUS

CN 4-Quinazolinamine, 2-cyclohexyl-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA
INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-14-4 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX
NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-15-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-16-6 CAPLUS

CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-17-7 CAPLUS

CN 4-Quinazolinamine, 2-(3,5-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-

09/ 806,836


(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-18-8 CAPLUS

CN Benzonitrile, 4-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-19-9 CAPLUS

CN 4-Quinazolinamine, 2-(3-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-20-2 CAPLUS


CN 4-Quinazolinamine, 2-[4-(ethylthio)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-21-3 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA
INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-22-4 CAPLUS

CN 4-Quinazolinamine, 2-[4-(1,1-dimethylethyl)phenyl]-N-(5-methyl-1H-pyrazol-

09/ 806,836


3-yl) - (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-23-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl) -
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-24-6 CAPLUS

CN 4-Quinazolinamine, 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-1H-pyrazol-3-yl) -
(9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-25-7 CAPLUS


CN 4-Quinazolinamine, 2-[4-(dimethylamino)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-26-8 CAPLUS

CN 4-Quinazolinamine, 2-(3-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-27-9 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dichlorophenyl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-28-0 CAPLUS


CN 4-Quinazolinamine, 2-(3-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-29-1 CAPLUS

CN 4-Quinazolinamine, 2-(3-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-31-5 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-32-6 CAPLUS

CN 4-Quinazolinamine, 2-(3-chloro-4-fluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-34-8 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[3-(trifluoromethyl)phenyl]-
(9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-35-9 CAPLUS


CN Benzonitrile, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-36-0 CAPLUS

CN 4-Quinazolinamine, 2-[3-(1-methylethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-
yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-37-1 CAPLUS

09/ 806,836


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-pyridinyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-38-2 CAPLUS


CN Ethanone, 1-[3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-39-3 CAPLUS

CN 4-Quinazolinamine, 2-[3,5-bis(trifluoromethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-40-6 CAPLUS


CN Benzenemethanol, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-41-7 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-42-8 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)-
(9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-43-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-thienyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-44-0 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazol-3-yl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-45-1 CAPLUS

CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-46-2 CAPLUS


CN 4-Quinazolinamine, N-(5-ethyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-47-3 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-(5-propyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-48-4 CAPLUS

CN 4-Quinazolinamine, N-[5-(1-methylethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-49-5 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-phenyl-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-50-8 CAPLUS

CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-(4-
pyridinyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-51-9 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopentyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA
INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-52-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-53-1 CAPLUS


CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-55-3 CAPLUS


CN 1H-Pyrazole-3-methanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)

09/ 806,836



RN 404828-56-4 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-57-5 CAPLUS


CN 1H-Pyrazole-3-propanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA
INDEX NAME)



RN 404828-59-7 CAPLUS

CN 4-Quinazolinamine, N-[5-(3-methoxypropyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-60-0 CAPLUS


CN 4-Quinazolinamine, N-[5-(3-aminopropyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-62-2 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-63-3 CAPLUS


CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-2-propenyl- (9CI) (CA INDEX NAME)

09/ 806,836




RN 404828-64-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-methoxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]-(9CI) (CA INDEX NAME)



RN 404828-65-5 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(phenylmethyl)-5-[(2-phenyl-4-quinazolinyl)amino]-(9CI) (CA INDEX NAME)



RN 404828-66-6 CAPLUS


09/ 806,836

CN 1H-Pyrazole-3-carboxamide, N-cyclohexyl-5-[(2-phenyl-4-quinazolinyl)amino] -
(9CI) (CA INDEX NAME)



RN 404828-67-7 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N,N-diethyl-5-[(2-phenyl-4-quinazolinyl)amino] -
(9CI) (CA INDEX NAME)



RN 404828-68-8 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(2-phenylethyl)-5-[(2-phenyl-4-quinazolinyl)amino] - (9CI) (CA INDEX NAME)

09/ 806,836




RN 404828-69-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-propyl-
(9CI) (CA INDEX NAME)



RN 404828-70-2 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-ethyl-N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-71-3 CAPLUS


09/ 806,836

CN 1H-Pyrazole-3-carboxamide, N-cyclopropyl-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-72-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-methylpropyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-73-5 CAPLUS

CN Pyrrolidine, 3-(methoxymethyl)-1-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

09/ 806,836



RN 404828-74-6 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(3-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-75-7 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(4-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)

09/ 806,836



RN 404828-76-8 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-methyl-5-[(2-phenyl-4-quinazolinyl)amino] -
(9CI) (CA INDEX NAME)



RN 404828-77-9 CAPLUS


CN Morpholine, 4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl] - (9CI) (CA INDEX NAME)

09/ 806,836



RN 404828-78-0 CAPLUS


CN Piperazine, 1-methyl-4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404828-79-1 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-hydroxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)


09/ 806,836



RN 404828-80-4 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-82-6 CAPLUS
CN 4-Quinazolinamine, N-(4-bromo-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-83-7 CAPLUS
CN 4-Quinazolinamine, N-(4-bromo-5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-84-8 CAPLUS


CN 1H-Pyrazole-4-carbonitrile, 3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-85-9 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-86-0 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-87-1 CAPLUS


CN 4-Quinazolinamine, 2-(4-methyl-1-piperidiny)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-88-2 CAPLUS

CN 4-Quinazolinamine, 2-(4-methyl-1-piperazinyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

09/ 806,836

RN 404828-89-3 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-piperidinyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-90-6 CAPLUS


CN 4-Quinazolinamine, 2-(hexahydro-1H-azepin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-91-7 CAPLUS

CN 4-Piperidineethanol, 1-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-92-8 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(4-methyl-1-piperidinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-95-1 CAPLUS

CN 4-Quinazolinamine, 2-[4-(cyclopentylamino)-1-piperidinyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-96-2 CAPLUS

CN 4-Piperidinol, 1-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-97-3 CAPLUS


CN 4-Piperidinol, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-4-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-98-4 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1,3-dihydro-2H-isoindol-2-yl)- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-99-5 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(hexahydro-1H-azepin-1-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-00-1 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-2(1H)-isoquinoliny)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-01-2 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2,3-dihydro-1H-indol-1-yl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-02-3 CAPLUS


CN 4-Piperidinemethanol, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-03-4 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-1(2H)-quinolinyl)- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404829-05-6 CAPLUS

CN Piperidine, 1-[[5-[[2-(1-piperidiny)]-4-quinazolinyl]amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 404829-06-7 CAPLUS


CN 1H-Pyrazole-3-methanol, 5-[[2-(1-piperidiny)]-4-quinazolinyl]amino]- (9CI)
(CA INDEX NAME)



RN 404829-07-8 CAPLUS


CN 1H-Pyrazole-3-carboxamide, 5-[[2-(1-piperidiny)]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

09/ 806,836




RN 404829-08-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[[2-(4-methyl-1-piperidiny)]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 404829-15-8 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazolo[4,3-b]pyridin-3-yl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-16-9 CAPLUS

09/ 806,836


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(3-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-17-0 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-18-1 CAPLUS

CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-19-2 CAPLUS

CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(2,4-dichlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-21-6 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-22-7 CAPLUS

CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-phenoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-23-8 CAPLUS

CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(4-chlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-45-6 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-naphthalenyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-47-8 CAPLUS

CN 4-Quinazolinamine, 2-(1-isoquinolinyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-48-9 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-isoquinolinyl)-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

IT 404828-81-5, 5-(2-Phenylquinazolin-4-ylamino)-1H-pyrazole-3-carboxylic acid 2,5-dioxopyrrolidin-1-yl ester 404828-93-9,
(5-Cyclopropyl-1H-pyrazol-3-yl) (2-chloroquinazolin-4-yl)amine
RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; prepn. of heterocyclpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)


RN 404828-81-5 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]oxy]- (9CI) (CA INDEX NAME)



RN 404828-93-9 CAPLUS

CN 4-Quinazolinamine, 2-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 24 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:220582 CAPLUS

DOCUMENT NUMBER: 136:247582

TITLE: Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease

INVENTOR(S): Bebbington, David; Binch, Hayley; Knegt, Ronald; Golec, Julian M. C.; Patel, Sanjay; Charrier, Jean-Damien; Kay, David; Davies, Robert; Li, Pan; Wannamaker, Marion; Forster, Cornelia; Pierce, Albert

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 355 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022606	A1	20020321	WO 2001-US28803	20010914
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				


PRIORITY APPLN. INFO.: US 2000-232795P P 20000915

US 2000-257887P P 20001221

US 2001-286949P P 20010427

OTHER SOURCE(S): MARPAT 136:247582

GI



AB Title compds. I [wherein G = Ring C or Ring D; Ring C = (un)substituted Ph, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl; Ring D = (un)substituted monocyclic or bicyclic ring selected from aryl, heteroaryl, heterocyclyl, or carbocyclyl; Z1 = N or CR₉; Z2 = N or CH; Z3 = N or CR_x; Z4 = N or CR_y; R_x and R_y = independently TR₃, or taken together with their intervening atoms form an (un)satd. fused ring having 1-3 ring heteroatoms; R2 and R2a = independently R, TWR₆; or C2R2R2a = (un)substituted fused ring contg. 0-3 heteroatoms; T = a bond or alkylidene chain; W = C(R₆)₂O, C(R₆)₂SO-2, C(R₆)₂NR₆, CO, CO₂, CR₆OCO, CR₆OCONR₆, C(R₆)₂NR₆CO, C(R₆)₂NR₆CO₂, CR₆:NNR₆, CR₆:NO, C(R₆)₂NR₆NR₆, C(R₆)₂NR₆SO₂NR₆, C(R₆)₂NR₆CONR₆, or CONR₆; R = H or (un)substituted aliph., (hetero)aryl, or heterocyclyl ring; R₃ = R, halo, O, OR, COR, CO₂R, COCOR, COCH₂COR, NO₂, CN, SO₂-2R, N(R₄)₂, CON(R₄)₂, SO₂N(R₄)₂, OCOR, NR₄COR, NR₄CO₂(aliph.), NR₄N(R₄)₂, C:NN(R₄)₂, C:NOR, NR₄CO(R₄)₂, NR₄SO₂N(R₄)₂, NR₄SO₂R, or OCON(R₄)₂; R₄ = R₇, COR₇, CO₂(aliph.), CON(R₇)₂, or SO₂R₇; or N(R₄)₂ = heterocyclyl or heteroaryl; R₆ and R₇ = independently H or (un)substituted aliph. group; or N(R₆)₂ = heterocyclyl or heteroaryl; or N(R₇)₂ = heterocyclyl or heteroaryl; R₉ = R, halo, OR, COR, CO₂R, COCOR, etc.] were prepd. as protein kinase inhibitors, esp. as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes, and Alzheimer's disease. Claims cover (pyrimidinyl)pyrazolamines and indazolamines I [wherein Z1 and Z2 = N; Z3 = CR_x; Z4 = CR_y; G = Ring D]. Examples include data for approx. 300 invention compds. prepd. by a variety of synthetic methods and bioassay results for the inhibition of GSK-3.β, Aurora-2, ERK, and Src. For instance, the N-(4-pyrimidinyl)-3-pyrazolamine II was prepd. and exhibited K_i values of < 0.1 .μM for glycogen synthetase kinase 3.β. (GSK-3.β.) and 0.1-1.0 .μM for Aurora-2.


IT **404828-30-4P**, (2-Chloroquinazolin-4-yl)(5-methyl-1H-pyrazol-3-yl)amine

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; prepn. of heterocyclpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404828-30-4 CAPLUS

CN 4-Quinazolinamine, 2-chloro-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

IT 404826-20-6P, [2-(3,4-Dichlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-21-7P, [2-(4-Bromophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-22-8P, (2-Biphenyl-4-ylquinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404826-23-9P, [2-(4-Ethynylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-54-2P, (5-Methoxycarbonyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-58-6P, (5-Benzyloxypropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-61-1P, [5-(3-tert-Butoxycarbonylaminopropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404829-04-5P, (5-Methoxycarbonyl-2H-pyrazol-3-yl) [2-(piperidine-1-yl)quinazolin-4-yl]amine
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (protein kinase inhibitor; prepn. of heterocyclpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-20-6 CAPLUS

CN 4-Quinazolinamine, 2-(3,4-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-21-7 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-(9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-22-8 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-4-yl-N-(5-methyl-1H-pyrazol-3-yl) -
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-23-9 CAPLUS

CN 4-Quinazolinamine, 2-(4-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl) - (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-54-2 CAPLUS


09/ 806,836

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 404828-58-6 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-[5-[3-(phenylmethoxy)propyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-61-1 CAPLUS

CN Carbamic acid, [3-[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 404829-04-5 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[[2-(1-piperidinyl)-4-quinazolinyl]amino]-
, methyl ester (9CI) (CA INDEX NAME)

IT 404826-60-4P, (5-Methyl-2H-pyrazol-3-yl) [2-(2-methylphenyl)quinazolin-4-yl]amine 404826-61-5P, [2-(2,4-Difluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-62-6P, [2-(2,5-Dimethoxyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-63-7P, [2-(2-Chlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-64-8P, [2-(2-Methoxyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-65-9P, [2-(2,6-Dimethylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-66-0P, [2-(2-Acetylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-67-1P, [2-(2,3-Dimethylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-68-2P, (5-Methyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-69-3P, [2-(2-Ethylphenyl)quinazolin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine 404826-70-6P, (2-Biphenyl-2-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-71-7P, [2-(2-Hydroxyphenyl)quinazolin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine 404826-72-8P, [2-(2-Ethoxyphenyl)quinazolin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine 404826-73-9P, [5-(Thiophen-2-yl)-2H-pyrazol-3-yl] [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-74-0P, [4-(Thiophen-2-yl)-2H-pyrazol-3-yl] [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-75-1P, (4-Phenyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-76-2P, (5-tert-Butyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-77-3P, (5-Phenyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-78-4P, (4,5-Diphenyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-79-5P, (4-Carbamoyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-80-8P, (2H-Pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-81-9P, (5-Hydroxy-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-82-0P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-83-1P, (5-Methoxymethyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-28-7P, (1H-Pyrazolo[4,3-b]pyridin-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-29-8P, (1H-Pyrazolo[3,4-b]pyridin-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-30-1P, (6-Methyl-1H-pyrazolo[3,4-b]pyridin-3-yl) [2-(2-

trifluoromethylphenyl)quinazolin-4-yl]amine **404827-31-2P**,
 (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-56-1P**,
 (5-Methyl-2H-pyrazol-3-yl)[2-(2-naphthyl-1-yl)quinazolin-4-yl]amine **404828-10-0P**, (5-Methyl-2H-pyrazol-3-yl)(2-pyridin-4-yl)quinazolin-4-yl)-amine **404828-11-1P**, (7-Chloro-2-pyridin-4-yl)quinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine **404828-12-2P**,
 (6-Chloro-2-pyridin-4-yl)quinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine **404828-13-3P**, (2-Cyclohexyl)quinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine **404828-14-4P**, (5-Methyl-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-15-5P**, [2-(4-Iodophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-16-6P**, [2-(4-Chlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-17-7P**, [2-(3,5-Dichlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-18-8P**, [2-(4-Cyanophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-19-9P**, [2-(3-Iodophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-20-2P**,
 [2-(4-Ethylsulfanyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-21-3P**, (5-Cyclopropyl-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-22-4P**, [2-(4-tert-Butylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-23-5P**, [2-(4-Chlorophenyl)quinazolin-4-yl](5-cyclopropyl-2H-pyrazol-3-yl)amine **404828-24-6P**, (2-Benzo[1,3]dioxol-5-yl)quinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine **404828-25-7P**, [2-(4-Dimethylaminophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-26-8P**, [2-(3-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-27-9P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dichlorophenyl)quinazolin-4-yl]amine **404828-28-0P**, [2-(3-Ethynylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-29-1P**, [2-(3-Methylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-31-5P**, [2-(3,5-Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-32-6P**, [2-(3-Chloro-4-fluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-34-8P**,
 (5-Methyl-2H-pyrazol-3-yl)[2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine **404828-35-9P**, [2-(3-Cyanophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-36-0P**, [2-(3-Isopropylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-37-1P**, (5-Methyl-2H-pyrazol-3-yl)(2-pyridin-3-yl)quinazolin-4-yl)amine **404828-38-2P**, [2-(3-Acetylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-39-3P**, [2-(3,5-Bis(trifluoromethyl)phenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-40-6P**, [2-(3-Hydroxymethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-41-7P**, (5-Methyl-2H-pyrazol-3-yl)[2-(3-phenoxyphenyl)quinazolin-4-yl]amine **404828-42-8P**,
 (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3-phenoxyphenyl)quinazolin-4-yl]amine **404828-43-9P** **404828-44-0P**, (2-Phenyl)quinazolin-4-yl)(2H-pyrazol-3-yl)amine **404828-45-1P**, (2H-Pyrazol-3-yl)(2-pyridin-4-yl)quinazolin-4-yl)amine **404828-46-2P**, (5-Ethyl-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-47-3P**,
 (2-Phenyl)quinazolin-4-yl)(5-propyl-2H-pyrazol-3-yl)amine **404828-48-4P**, (5-Isopropyl-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-49-5P**, (5-tert-Butyl-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-50-8P**, (5-tert-Butyl-2H-pyrazol-3-yl)(2-pyridin-4-yl)quinazolin-4-yl)amine **404828-51-9P**, (5-Cyclopentyl-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-52-0P**, (5-Phenyl-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-53-1P**, (5-Carboxy-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-55-3P**, (5-Hydroxymethyl-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-56-4P**,
 (5-Methoxymethyl-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-57-5P**, [5-(3-Hydroxypropyl)-2H-pyrazol-3-yl](2-

phenylquinazolin-4-yl)amine **404828-59-7P**, [5-(3-Methoxypropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-60-0P**, [5-(3-Aminopropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-62-2P**, (5-Isopropylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-63-3P**, (5-Allylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-64-4P**, [5-(2-Methoxyethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-65-5P**, (5-Benzylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-66-6P**, (5-Cyclohexylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-67-7P**, (5-Diethylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-68-8P**, [5-(Benzylmethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-69-9P**, (2-Phenylquinazolin-4-yl) (5-propylcarbamoyl-2H-pyrazol-3-yl)amine **404828-70-2P**, [5-(Ethylisopropylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-71-3P**, (5-Cyclopropylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-72-4P**, (5-Isobutylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-73-5P**, [5-((3S)-3-Methoxymethylpyrrolidine-1-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-74-6P**, (2-Phenylquinazolin-4-yl) (5-m-tolylcarbamoyl-2H-pyrazol-3-yl)amine **404828-75-7P**, (2-Phenylquinazolin-4-yl) (5-p-tolylcarbamoyl-2H-pyrazol-3-yl)amine **404828-76-8P**, (5-Methylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-77-9P**, [5-(Morpholine-4-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-78-0P**, [5-(1-Methylpiperazine-4-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-79-1P**, [5-(2-Hydroxyethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-80-4P**, (5-Carbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-82-6P**, (4-Bromo-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-83-7P**, (4-Bromo-5-methyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-84-8P**, (4-Cyano-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-85-9P**, (5-Methyl-2H-pyrazol-3-yl) (2-morpholin-4-ylquinazolin-4-yl)amine **404828-86-0P**, (5-Methyl-2H-pyrazol-3-yl) (2-piperazin-1-ylquinazolin-4-yl)amine **404828-87-1P**, [2-(4-Methylpiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-88-2P**, [2-(4-Methylpiperazin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-89-3P**, (5-Methyl-2H-pyrazol-3-yl) (2-piperidin-1-ylquinazolin-4-yl)amine **404828-90-6P**, [2-(Azepan-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-91-7P**, [2-[4-(2-Hydroxyethyl)piperidin-1-yl]quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-92-8P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-methylpiperidin-1-yl)quinazolin-4-yl]amine **404828-95-1P**, [2-(4-Cyclopentylaminopiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-96-2P**, [2-(4-Hydroxypiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-97-3P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-hydroxy-4-phenylpiperidin-1-yl)quinazolin-4-yl]amine **404828-98-4P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(1,3-dihydroisoindol-2-yl)quinazolin-4-yl]amine **404828-99-5P**, [2-(Azepan-1-yl)quinazolin-4-yl] (5-cyclopropyl-2H-pyrazol-3-yl)amine **404829-00-1P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dihydro-1H-isoquinolin-2-yl)quinazolin-4-yl]amine **404829-01-2P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(2,3-dihydroindol-1-yl)quinazolin-4-yl]amine **404829-02-3P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-hydroxymethylpiperidin-1-yl)quinazolin-4-yl]amine **404829-03-4P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dihydro-2H-quinolin-1-yl)quinazolin-4-yl]amine **404829-05-6P**, 5-(Piperidine-1-carbonyl)-2H-pyrazol-3-yl-[2-(piperidine-1-yl)quinazolin-4-yl]amine **404829-06-7P**, (5-Hydroxymethyl-2H-pyrazol-3-yl) [2-(piperidin-1-yl)quinazolin-4-yl]amine **404829-07-8P**, (5-Carbamoyl-2H-pyrazol-3-yl) [2-(piperidin-1-yl)quinazolin-4-yl]amine **404829-08-9P**, (5-Carbamoyl-2H-pyrazol-3-


yl) [2-(4-methylpiperidin-1-yl)quinazolin-4-yl]amine **404829-15-8P**, (2-Phenylquinazolin-4-yl) (1H-pyrazolo[4,3-b]pyridin-3-yl) amine **404829-16-9P**, [5-(3-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl) amine **404829-17-0P**, (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl) - (2-phenylquinazolin-4-yl) amine **404829-18-1P**, [5-(4-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl) amine **404829-19-2P**, [5-(2,4-Dichlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl) amine **404829-21-6P**, [6-Oxo-5-(3-trifluoromethylphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl) amine **404829-22-7P**, [6-Oxo-5-(4-Phenoxyphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl) amine **404829-23-8P**, [5-(4-Chlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl) amine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; prepn. of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-60-4 CAPLUS

CN 4-Quinazolinamine, 2-(2-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-61-5 CAPLUS

CN 4-Quinazolinamine, 2-(2,4-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-62-6 CAPLUS


CN 4-Quinazolinamine, 2-(2,5-dimethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-63-7 CAPLUS

CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-64-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-65-9 CAPLUS

CN 4-Quinazolinamine, 2-(2,6-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-66-0 CAPLUS

CN Ethanone, 1-[2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-67-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,3-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-68-2 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-69-3 CAPLUS

09/ 806,836


CN 4-Quinazolinamine, 2-(2-ethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-70-6 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-2-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-71-7 CAPLUS

CN Phenol, 2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA
INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-72-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-73-9 CAPLUS

CN 4-Quinazolinamine, N-[5-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-74-0 CAPLUS

CN 4-Quinazolinamine, N-[4-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-75-1 CAPLUS


CN 4-Quinazolinamine, N-(4-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-76-2 CAPLUS

CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-77-3 CAPLUS

CN 4-Quinazolinamine, N-(5-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-78-4 CAPLUS


CN 4-Quinazolinamine, N-(4,5-diphenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-79-5 CAPLUS

CN 1H-Pyrazole-4-carboxamide, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-80-8 CAPLUS

09/ 806,836


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404826-81-9 CAPLUS

CN 3H-Pyrazol-3-one, 1,2-dihydro-5-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 404826-82-0 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-83-1 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-28-7 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazolo[4,3-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-29-8 CAPLUS

CN 4-Quinazolinamine, N-1H-pyrazolo[3,4-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-30-1 CAPLUS


CN 4-Quinazolinamine, N-(6-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-31-2 CAPLUS

CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-56-1 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-naphthalenyl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-10-0 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-11-1 CAPLUS

CN 4-Quinazolinamine, 7-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-12-2 CAPLUS


CN 4-Quinazolinamine, 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-13-3 CAPLUS

CN 4-Quinazolinamine, 2-cyclohexyl-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA
INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-14-4 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX
NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-15-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-16-6 CAPLUS

CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-17-7 CAPLUS

CN 4-Quinazolinamine, 2-(3,5-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-

09/ 806,836


(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-18-8 CAPLUS

CN Benzonitrile, 4-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-19-9 CAPLUS

CN 4-Quinazolinamine, 2-(3-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-20-2 CAPLUS


CN 4-Quinazolinamine, 2-[4-(ethylthio)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-21-3 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA
INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-22-4 CAPLUS

CN 4-Quinazolinamine, 2-[4-(1,1-dimethylethyl)phenyl]-N-(5-methyl-1H-pyrazol-

09/ 806,836


3-yl) - (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-23-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl) -
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-24-6 CAPLUS

CN 4-Quinazolinamine, 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-1H-pyrazol-3-yl) -
(9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-25-7 CAPLUS


CN 4-Quinazolinamine, 2-[4-(dimethylamino)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-26-8 CAPLUS

CN 4-Quinazolinamine, 2-(3-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-27-9 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dichlorophenyl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-28-0 CAPLUS


CN 4-Quinazolinamine, 2-(3-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-29-1 CAPLUS

CN 4-Quinazolinamine, 2-(3-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-31-5 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-32-6 CAPLUS

CN 4-Quinazolinamine, 2-(3-chloro-4-fluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-34-8 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-35-9 CAPLUS


CN Benzonitrile, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-36-0 CAPLUS

CN 4-Quinazolinamine, 2-[3-(1-methylethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-37-1 CAPLUS

09/ 806,836


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-pyridinyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-38-2 CAPLUS


CN Ethanone, 1-[3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-39-3 CAPLUS

CN 4-Quinazolinamine, 2-[3,5-bis(trifluoromethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-40-6 CAPLUS


CN Benzenemethanol, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-41-7 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-42-8 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)-
(9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-43-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-thienyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-44-0 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazol-3-yl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-45-1 CAPLUS

CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-46-2 CAPLUS


CN 4-Quinazolinamine, N-(5-ethyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-47-3 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-(5-propyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-48-4 CAPLUS

CN 4-Quinazolinamine, N-[5-(1-methylethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-49-5 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-phenyl-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-50-8 CAPLUS

CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-(4-
pyridinyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-51-9 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopentyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA
INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-52-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-53-1 CAPLUS


CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-55-3 CAPLUS


CN 1H-Pyrazole-3-methanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)

09/ 806,836



RN 404828-56-4 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-57-5 CAPLUS


CN 1H-Pyrazole-3-propanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA
INDEX NAME)



RN 404828-59-7 CAPLUS

CN 4-Quinazolinamine, N-[5-(3-methoxypropyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-60-0 CAPLUS


CN 4-Quinazolinamine, N-[5-(3-aminopropyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-62-2 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-63-3 CAPLUS


CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-2-propenyl- (9CI) (CA INDEX NAME)

09/ 806,836




RN 404828-64-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-methoxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-65-5 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(phenylmethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-66-6 CAPLUS


09/ 806,836

CN 1H-Pyrazole-3-carboxamide, N-cyclohexyl-5-[(2-phenyl-4-quinazolinyl)amino] -
(9CI) (CA INDEX NAME)



RN 404828-67-7 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N,N-diethyl-5-[(2-phenyl-4-quinazolinyl)amino] -
(9CI) (CA INDEX NAME)



RN 404828-68-8 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(2-phenylethyl)-5-[(2-phenyl-4-quinazolinyl)amino] - (9CI) (CA INDEX NAME)

09/ 806,836




RN 404828-69-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-propyl-
(9CI) (CA INDEX NAME)



RN 404828-70-2 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-ethyl-N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-71-3 CAPLUS


09/ 806,836

CN 1H-Pyrazole-3-carboxamide, N-cyclopropyl-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-72-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-methylpropyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-73-5 CAPLUS

CN Pyrrolidine, 3-(methoxymethyl)-1-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

09/ 806,836



RN 404828-74-6 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(3-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-75-7 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(4-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)

09/ 806,836



RN 404828-76-8 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-methyl-5-[(2-phenyl-4-quinazolinyl)amino] -
(9CI) (CA INDEX NAME)



RN 404828-77-9 CAPLUS


CN Morpholine, 4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl] - (9CI) (CA INDEX NAME)

09/ 806,836



RN 404828-78-0 CAPLUS


CN Piperazine, 1-methyl-4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404828-79-1 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-hydroxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)


09/ 806,836



RN 404828-80-4 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-82-6 CAPLUS
CN 4-Quinazolinamine, N-(4-bromo-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-83-7 CAPLUS
CN 4-Quinazolinamine, N-(4-bromo-5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-84-8 CAPLUS


CN 1H-Pyrazole-4-carbonitrile, 3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-85-9 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-86-0 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-87-1 CAPLUS


CN 4-Quinazolinamine, 2-(4-methyl-1-piperidinyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-88-2 CAPLUS

CN 4-Quinazolinamine, 2-(4-methyl-1-piperazinyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

09/ 806,836

RN 404828-89-3 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-piperidinyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-90-6 CAPLUS


CN 4-Quinazolinamine, 2-(hexahydro-1H-azepin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-91-7 CAPLUS

CN 4-Piperidineethanol, 1-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-92-8 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(4-methyl-1-piperidinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-95-1 CAPLUS

CN 4-Quinazolinamine, 2-[4-(cyclopentylamino)-1-piperidinyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-96-2 CAPLUS

CN 4-Piperidinol, 1-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-97-3 CAPLUS


CN 4-Piperidinol, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-4-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-98-4 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1,3-dihydro-2H-isoindol-2-yl)- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-99-5 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(hexahydro-1H-azepin-1-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-00-1 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-2(1H)-isoquinoliny)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-01-2 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2,3-dihydro-1H-indol-1-yl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-02-3 CAPLUS


CN 4-Piperidinemethanol, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-03-4 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-1(2H)-quinolinyl)- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404829-05-6 CAPLUS

CN Piperidine, 1-[[5-[[2-(1-piperidiny)]-4-quinazolinyl]amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 404829-06-7 CAPLUS


CN 1H-Pyrazole-3-methanol, 5-[[2-(1-piperidiny)]-4-quinazolinyl]amino]- (9CI)
(CA INDEX NAME)



RN 404829-07-8 CAPLUS


CN 1H-Pyrazole-3-carboxamide, 5-[[2-(1-piperidiny)]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

09/ 806,836




RN 404829-08-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[[2-(4-methyl-1-piperidiny)]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 404829-15-8 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazolo[4,3-b]pyridin-3-yl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-16-9 CAPLUS

09/ 806,836


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(3-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-17-0 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-18-1 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-19-2 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(2,4-dichlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-21-6 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-22-7 CAPLUS

CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-phenoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-23-8 CAPLUS

CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(4-chlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)

09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


IT 404828-81-5, 5-(2-Phenylquinazolin-4-ylamino)-1H-pyrazole-3-carboxylic acid 2,5-dioxopyrrolidin-1-yl ester 404828-93-9, (5-Cyclopropyl-1H-pyrazol-3-yl) (2-chloroquinazolin-4-yl) amine

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; prepn. of heterocyclpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)


RN 404828-81-5 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]oxy]- (9CI) (CA INDEX NAME)



RN 404828-93-9 CAPLUS

CN 4-Quinazolinamine, 2-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 24 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:220581 CAPLUS

DOCUMENT NUMBER: 136:247581

TITLE: Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease

INVENTOR(S): Golec, Julian M. C.; Charrier, Jean-Damien; Knegt, Ronald; Bebbington, David; Davies, Robert; Li, Pan

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 357 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022605	A1	20020321	WO 2001-US28793	20010914
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2000-232795P	P 20000915
			US 2000-257887P	P 20001221
			US 2001-286949P	P 20010427

OTHER SOURCE(S): MARPAT 136:247581

GI



AB Title compds. I [wherein G = Ring C or Ring D; Ring C = (un)substituted Ph, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl; Ring D = (un)substituted monocyclic or bicyclic ring selected from aryl, heteroaryl, heterocyclyl, or carbocyclyl; Z1 = N or CR₉; Z2 = N or CH; Z3 = N or CR_x; Z4 = N or CR_y; R_x and R_y = independently TR₃, or taken together with their intervening atoms form an (un)satd. fused ring having 1-3 ring heteroatoms; R₂ and R_{2a} = independently R, TWR₆; or C₂R₂R_{2a} = (un)substituted fused ring contg. 0-3 heteroatoms; T = a bond or alkylidene chain; W = C(R₆)₂O, C(R₆)₂SO-₂, C(R₆)₂NR₆, CO, CO₂, CR₆OCO, CR₆OCONR₆, C(R₆)₂NR₆CO, C(R₆)₂NR₆CO₂, CR₆:NNR₆, CR₆:NO, C(R₆)₂NR₆NR₆, C(R₆)₂NR₆SO₂NR₆, C(R₆)₂NR₆CONR₆, or CONR₆; R = H or (un)substituted aliph., (hetero)aryl, or heterocyclyl ring; R₃ = R, halo, O, OR, COR, CO₂R, COCOR, COCH₂COR, NO₂, CN, SO₂-₂R, N(R₄)₂, CON(R₄)₂, SO₂N(R₄)₂, OCOR, NR₄COR, NR₄CO₂(aliph.), NR₄N(R₄)₂, C:NN(R₄)₂, C:NOR, NR₄CO(R₄)₂, NR₄SO₂N(R₄)₂, NR₄SO₂R, or OCON(R₄)₂; R₄ = R₇, COR₇, CO₂(aliph.), CON(R₇)₂, or SO₂R₇; or N(R₄)₂ = heterocyclyl or heteroaryl; R₆ and R₇ = independently H or (un)substituted aliph. group; or N(R₆)₂ = heterocyclyl or heteroaryl; or N(R₇)₂ = heterocyclyl or heteroaryl; R₉ = R, halo, OR, COR, CO₂R, COCOR, etc.] were prepd. as protein kinase inhibitors, esp. as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes, and Alzheimer's disease. Claims cover pyrazolamines and indazolamines I [wherein Z1 = N or CR₉; Z2 = N or CH; Z3 = N or CR_x; Z4 = N; at least one of Z1 or Z3 = N]. Examples include data for approx. 300 invention compds. prepd. by a variety of synthetic methods and bioassay results for the inhibition of GSK-3.β, Aurora-2, ERK, and Src. For instance, the N-(4-pyrimidinyl)-3-pyrazolamine II was prepd. and exhibited K_i values of < 0.1 μM for glycogen synthetase kinase 3.β. (GSK-3.β.) and 0.1-1.0 μM for Aurora-2.


IT **404828-30-4P**, (2-Chloroquinazolin-4-yl)(5-methyl-1H-pyrazol-3-yl)amine

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; prepn. of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404828-30-4 CAPLUS

CN 4-Quinazolinamine, 2-chloro-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

IT **404826-20-6P**, [2-(3,4-Dichlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404826-21-7P**, [2-(4-Bromophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404826-22-8P**, (2-Biphenyl-4-ylquinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine **404826-23-9P**, [2-(4-Ethynylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-54-2P**, (5-Methoxycarbonyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-58-6P**, (5-Benzoyloxypropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-61-1P**, [5-(3-tert-Butoxycarbonylaminoethyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404829-04-5P**, (5-Methoxycarbonyl-2H-pyrazol-3-yl) [2-(piperidine-1-yl)quinazolin-4-yl]amine
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (protein kinase inhibitor; prepn. of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-20-6 CAPLUS

CN 4-Quinazolinamine, 2-(3,4-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-21-7 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-22-8 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-4-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-23-9 CAPLUS

CN 4-Quinazolinamine, 2-(4-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-54-2 CAPLUS


09/ 806,836

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 404828-58-6 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-[5-[3-(phenylmethoxy)propyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-61-1 CAPLUS

CN Carbamic acid, [3-[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 404829-04-5 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[[2-(1-piperidinyl)-4-quinazolinyl]amino]-
, methyl ester (9CI) (CA INDEX NAME)

IT 404826-60-4P, (5-Methyl-2H-pyrazol-3-yl) [2-(2-methylphenyl)quinazolin-4-yl]amine 404826-61-5P, [2-(2,4-Difluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-62-6P, [2-(2,5-Dimethoxyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-63-7P, [2-(2-Chlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-64-8P, [2-(2-Methoxyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-65-9P, [2-(2,6-Dimethylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-66-0P, [2-(2-Acetylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-67-1P, [2-(2,3-Dimethylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-68-2P, (5-Methyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-69-3P, [2-(2-Ethylphenyl)quinazolin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine 404826-70-6P, (2-Biphenyl-2-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-71-7P, [2-(2-Hydroxyphenyl)quinazolin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine 404826-72-8P, [2-(2-Ethoxyphenyl)quinazolin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine 404826-73-9P, [5-(Thiophen-2-yl)-2H-pyrazol-3-yl] [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-74-0P, [4-(Thiophen-2-yl)-2H-pyrazol-3-yl] [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-75-1P, (4-Phenyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-76-2P, (5-tert-Butyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-77-3P, (5-Phenyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-78-4P, (4,5-Diphenyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-79-5P, (4-Carbamoyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-80-8P, (2H-Pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-81-9P, (5-Hydroxy-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-82-0P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-83-1P, (5-Methoxymethyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-28-7P, (1H-Pyrazolo[4,3-b]pyridin-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-29-8P, (1H-Pyrazolo[3,4-b]pyridin-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-30-1P, (6-Methyl-1H-pyrazolo[3,4-b]pyridin-3-yl) [2-(2-

trifluoromethylphenyl)quinazolin-4-yl]amine **404827-31-2P**,
 (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-56-1P**,
 (5-Methyl-2H-pyrazol-3-yl)[2-(2-naphthyl-1-yl)quinazolin-4-yl]amine **404828-10-0P**, (5-Methyl-2H-pyrazol-3-yl)(2-pyridin-4-yl)quinazolin-4-yl]-amine **404828-11-1P**, (7-Chloro-2-pyridin-4-yl)quinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine **404828-12-2P**,
 (6-Chloro-2-pyridin-4-yl)quinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine **404828-13-3P**, (2-Cyclohexyl)quinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine **404828-14-4P**, (5-Methyl-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-15-5P**, [2-(4-Iodophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-16-6P**, [2-(4-Chlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-17-7P**, [2-(3,5-Dichlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-18-8P**, [2-(4-Cyanophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-19-9P**, [2-(3-Iodophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-20-2P**,
 [2-(4-Ethylsulfanylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-21-3P**, (5-Cyclopropyl-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-22-4P**, [2-(4-tert-Butylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-23-5P**, [2-(4-Chlorophenyl)quinazolin-4-yl](5-cyclopropyl-2H-pyrazol-3-yl)amine **404828-24-6P**, (2-Benzo[1,3]dioxol-5-yl)quinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine **404828-25-7P**, [2-(4-Dimethylaminophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-26-8P**, [2-(3-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-27-9P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dichlorophenyl)quinazolin-4-yl]amine **404828-28-0P**, [2-(3-Ethynylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-29-1P**, [2-(3-Methylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-31-5P**, [2-(3,5-Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-32-6P**, [2-(3-Chloro-4-fluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-34-8P**,
 (5-Methyl-2H-pyrazol-3-yl)[2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine **404828-35-9P**, [2-(3-Cyanophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-36-0P**, [2-(3-Isopropylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-37-1P**, (5-Methyl-2H-pyrazol-3-yl)(2-pyridin-3-yl)quinazolin-4-yl)amine **404828-38-2P**, [2-(3-Acetylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-39-3P**, [2-(3,5-Bis(trifluoromethyl)phenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-40-6P**, [2-(3-Hydroxymethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-41-7P**, (5-Methyl-2H-pyrazol-3-yl)[2-(3-phenoxyphenyl)quinazolin-4-yl]amine **404828-42-8P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3-phenoxyphenyl)quinazolin-4-yl]amine **404828-43-9P** **404828-44-0P**, (2-Phenyl)quinazolin-4-yl)(2H-pyrazol-3-yl)amine **404828-45-1P**, (2H-Pyrazol-3-yl)(2-pyridin-4-yl)quinazolin-4-yl)amine **404828-46-2P**, (5-Ethyl-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-47-3P**,
 (2-Phenyl)quinazolin-4-yl)(5-propyl-2H-pyrazol-3-yl)amine **404828-48-4P**, (5-Isopropyl-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-49-5P**, (5-tert-Butyl-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-50-8P**, (5-tert-Butyl-2H-pyrazol-3-yl)(2-pyridin-4-yl)quinazolin-4-yl)amine **404828-51-9P**, (5-Cyclopentyl-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-52-0P**, (5-Phenyl-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-53-1P**, (5-Carboxy-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-55-3P**, (5-Hydroxymethyl-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-56-4P**, (5-Methoxymethyl-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-57-5P**, [5-(3-Hydroxypropyl)-2H-pyrazol-3-yl](2-

phenylquinazolin-4-yl)amine 404828-59-7P, [5-(3-Methoxypropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-60-0P, [5-(3-Aminopropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-62-2P, (5-Isopropylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-63-3P, (5-Allylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-64-4P, [5-(2-Methoxyethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-65-5P, (5-Benzylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-66-6P, (5-Cyclohexylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-67-7P, (5-Diethylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-68-8P, [5-(Benzylmethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-69-9P, (2-Phenylquinazolin-4-yl) (5-propylcarbamoyl-2H-pyrazol-3-yl)amine 404828-70-2P, [5-(Ethylisopropylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-71-3P, (5-Cyclopropylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-72-4P, (5-Isobutylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-73-5P, [5-((3S)-3-Methoxymethylpyrrolidine-1-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-74-6P, (2-Phenylquinazolin-4-yl) (5-m-tolylcarbamoyl-2H-pyrazol-3-yl)amine 404828-75-7P, (2-Phenylquinazolin-4-yl) (5-p-tolylcarbamoyl-2H-pyrazol-3-yl)amine 404828-76-8P, (5-Methylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-77-9P, [5-(Morpholine-4-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-78-0P, [5-(1-Methylpiperazine-4-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-79-1P, [5-(2-Hydroxyethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-80-4P, (5-Carbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-82-6P, (4-Bromo-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-83-7P, (4-Bromo-5-methyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-84-8P, (4-Cyano-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-85-9P, (5-Methyl-2H-pyrazol-3-yl) (2-morpholin-4-ylquinazolin-4-yl)amine 404828-86-0P, (5-Methyl-2H-pyrazol-3-yl) (2-piperazin-1-ylquinazolin-4-yl)amine 404828-87-1P, [2-(4-Methylpiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-88-2P, [2-(4-Methylpiperazin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-89-3P, (5-Methyl-2H-pyrazol-3-yl) (2-piperidin-1-ylquinazolin-4-yl)amine 404828-90-6P, [2-(Azepan-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-91-7P, [2-[4-(2-Hydroxyethyl)piperidin-1-yl]quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-92-8P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-methylpiperidin-1-yl)quinazolin-4-yl]amine 404828-95-1P, [2-(4-Cyclopentylaminopiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-96-2P, [2-(4-Hydroxypiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-97-3P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-hydroxy-4-phenylpiperidin-1-yl)quinazolin-4-yl]amine 404828-98-4P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(1,3-dihydroisoindol-2-yl)quinazolin-4-yl]amine 404828-99-5P, [2-(Azepan-1-yl)quinazolin-4-yl] (5-cyclopropyl-2H-pyrazol-3-yl)amine 404829-00-1P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dihydro-1H-isoquinolin-2-yl)quinazolin-4-yl]amine 404829-01-2P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(2,3-dihydroindol-1-yl)quinazolin-4-yl]amine 404829-02-3P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-hydroxymethylpiperidin-1-yl)quinazolin-4-yl]amine 404829-03-4P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dihydro-2H-quinolin-1-yl)quinazolin-4-yl]amine 404829-05-6P, 5-(Piperidine-1-carbonyl)-2H-pyrazol-3-yl-[2-(piperidine-1-yl)quinazolin-4-yl]amine 404829-06-7P, (5-Hydroxymethyl-2H-pyrazol-3-yl) [2-(piperidin-1-yl)quinazolin-4-yl]amine 404829-07-8P, (5-Carbamoyl-2H-pyrazol-3-yl) [2-(piperidin-1-yl)quinazolin-4-yl]amine 404829-08-9P, (5-Carbamoyl-2H-pyrazol-3-


yl) [2-(4-methylpiperidin-1-yl)quinazolin-4-yl]amine **404829-15-8P**, (2-Phenylquinazolin-4-yl) (1H-pyrazolo[4,3-b]pyridin-3-yl) amine **404829-16-9P**, [5-(3-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl) amine **404829-17-0P**, (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl) - (2-phenylquinazolin-4-yl) amine **404829-18-1P**, [5-(4-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl) amine **404829-19-2P**, [5-(2,4-Dichlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl) amine **404829-21-6P**, [6-Oxo-5-(3-trifluoromethylphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl) amine **404829-22-7P**, [6-Oxo-5-(4-Phenoxyphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl) amine **404829-23-8P**, [5-(4-Chlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl) amine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; prepn. of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-60-4 CAPLUS

CN 4-Quinazolinamine, 2-(2-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-61-5 CAPLUS

CN 4-Quinazolinamine, 2-(2,4-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-62-6 CAPLUS


CN 4-Quinazolinamine, 2-(2,5-dimethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-63-7 CAPLUS

CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-64-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-65-9 CAPLUS

CN 4-Quinazolinamine, 2-(2,6-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-66-0 CAPLUS

CN Ethanone, 1-[2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-67-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,3-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-68-2 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-69-3 CAPLUS

09/ 806,836


CN 4-Quinazolinamine, 2-(2-ethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-70-6 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-2-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-71-7 CAPLUS

CN Phenol, 2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA
INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-72-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-73-9 CAPLUS

CN 4-Quinazolinamine, N-[5-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-74-0 CAPLUS

CN 4-Quinazolinamine, N-[4-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-75-1 CAPLUS


CN 4-Quinazolinamine, N-(4-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-76-2 CAPLUS

CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-77-3 CAPLUS

CN 4-Quinazolinamine, N-(5-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-78-4 CAPLUS


CN 4-Quinazolinamine, N-(4,5-diphenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-79-5 CAPLUS

CN 1H-Pyrazole-4-carboxamide, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-80-8 CAPLUS

09/ 806,836


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404826-81-9 CAPLUS

CN 3H-Pyrazol-3-one, 1,2-dihydro-5-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 404826-82-0 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-83-1 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-28-7 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazolo[4,3-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-29-8 CAPLUS

CN 4-Quinazolinamine, N-1H-pyrazolo[3,4-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-30-1 CAPLUS


CN 4-Quinazolinamine, N-(6-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-31-2 CAPLUS

CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-56-1 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-naphthalenyl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-10-0 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-11-1 CAPLUS

CN 4-Quinazolinamine, 7-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-12-2 CAPLUS


CN 4-Quinazolinamine, 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-13-3 CAPLUS

CN 4-Quinazolinamine, 2-cyclohexyl-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA
INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-14-4 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX
NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-15-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-16-6 CAPLUS

CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-17-7 CAPLUS

CN 4-Quinazolinamine, 2-(3,5-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-

09/ 806,836


(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-18-8 CAPLUS

CN Benzonitrile, 4-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-19-9 CAPLUS

CN 4-Quinazolinamine, 2-(3-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-20-2 CAPLUS


CN 4-Quinazolinamine, 2-[4-(ethylthio)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-21-3 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-22-4 CAPLUS

CN 4-Quinazolinamine, 2-[4-(1,1-dimethylethyl)phenyl]-N-(5-methyl-1H-pyrazol-

09/ 806,836


3-yl) - (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-23-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl) -
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-24-6 CAPLUS

CN 4-Quinazolinamine, 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-1H-pyrazol-3-yl) -
(9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-25-7 CAPLUS


CN 4-Quinazolinamine, 2-[4-(dimethylamino)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-26-8 CAPLUS

CN 4-Quinazolinamine, 2-(3-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-27-9 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dichlorophenyl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-28-0 CAPLUS


CN 4-Quinazolinamine, 2-(3-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-29-1 CAPLUS

CN 4-Quinazolinamine, 2-(3-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-31-5 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-32-6 CAPLUS

CN 4-Quinazolinamine, 2-(3-chloro-4-fluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-34-8 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-35-9 CAPLUS


CN Benzonitrile, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-36-0 CAPLUS

CN 4-Quinazolinamine, 2-[3-(1-methylethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-
yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-37-1 CAPLUS

09/ 806,836


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-pyridinyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-38-2 CAPLUS


CN Ethanone, 1-[3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-39-3 CAPLUS

CN 4-Quinazolinamine, 2-[3,5-bis(trifluoromethyl)phenyl]-N-(5-methyl-1H-
pyrazol-3-yl)- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-40-6 CAPLUS


CN Benzenemethanol, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-41-7 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-42-8 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)-
(9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-43-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-thienyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-44-0 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazol-3-yl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-45-1 CAPLUS

CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-46-2 CAPLUS


CN 4-Quinazolinamine, N-(5-ethyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-47-3 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-(5-propyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-48-4 CAPLUS

CN 4-Quinazolinamine, N-[5-(1-methylethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-49-5 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-phenyl-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-50-8 CAPLUS

CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-(4-
pyridinyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-51-9 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopentyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA
INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-52-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-53-1 CAPLUS


CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-55-3 CAPLUS


CN 1H-Pyrazole-3-methanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)

09/ 806,836



RN 404828-56-4 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-57-5 CAPLUS


CN 1H-Pyrazole-3-propanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA
INDEX NAME)



RN 404828-59-7 CAPLUS

CN 4-Quinazolinamine, N-[5-(3-methoxypropyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-60-0 CAPLUS


CN 4-Quinazolinamine, N-[5-(3-aminopropyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-62-2 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-63-3 CAPLUS


CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-2-propenyl- (9CI) (CA INDEX NAME)

09/ 806,836




RN 404828-64-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-methoxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-65-5 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(phenylmethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-66-6 CAPLUS


09/ 806,836

CN 1H-Pyrazole-3-carboxamide, N-cyclohexyl-5-[(2-phenyl-4-quinazolinyl)amino] -
(9CI) (CA INDEX NAME)



RN 404828-67-7 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N,N-diethyl-5-[(2-phenyl-4-quinazolinyl)amino] -
(9CI) (CA INDEX NAME)



RN 404828-68-8 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(2-phenylethyl)-5-[(2-phenyl-4-quinazolinyl)amino] - (9CI) (CA INDEX NAME)

09/ 806,836




RN 404828-69-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-propyl-
(9CI) (CA INDEX NAME)



RN 404828-70-2 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-ethyl-N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-71-3 CAPLUS


09/ 806,836

CN 1H-Pyrazole-3-carboxamide, N-cyclopropyl-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-72-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-methylpropyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-73-5 CAPLUS

CN Pyrrolidine, 3-(methoxymethyl)-1-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

09/ 806,836



RN 404828-74-6 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(3-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]-(9CI) (CA INDEX NAME)



RN 404828-75-7 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(4-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]-(9CI) (CA INDEX NAME)

09/ 806,836



RN 404828-76-8 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-methyl-5-[(2-phenyl-4-quinazolinyl)amino] -
(9CI) (CA INDEX NAME)



RN 404828-77-9 CAPLUS


CN Morpholine, 4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl] - (9CI) (CA INDEX NAME)

09/ 806,836



RN 404828-78-0 CAPLUS


CN Piperazine, 1-methyl-4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 404828-79-1 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(2-hydroxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)

09/ 806,836




RN 404828-80-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-82-6 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-83-7 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-84-8 CAPLUS


CN 1H-Pyrazole-4-carbonitrile, 3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-85-9 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-86-0 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-87-1 CAPLUS


CN 4-Quinazolinamine, 2-(4-methyl-1-piperidiny)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-88-2 CAPLUS

CN 4-Quinazolinamine, 2-(4-methyl-1-piperazinyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

09/ 806,836

RN 404828-89-3 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-piperidinyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-90-6 CAPLUS


CN 4-Quinazolinamine, 2-(hexahydro-1H-azepin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-91-7 CAPLUS

CN 4-Piperidineethanol, 1-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-92-8 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(4-methyl-1-piperidinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-95-1 CAPLUS

CN 4-Quinazolinamine, 2-[4-(cyclopentylamino)-1-piperidinyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-96-2 CAPLUS

CN 4-Piperidinol, 1-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-97-3 CAPLUS


CN 4-Piperidinol, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-4-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-98-4 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1,3-dihydro-2H-isoindol-2-yl)- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-99-5 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(hexahydro-1H-azepin-1-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-00-1 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-2(1H)-isoquinoliny)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-01-2 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2,3-dihydro-1H-indol-1-yl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-02-3 CAPLUS


CN 4-Piperidinemethanol, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-03-4 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-1(2H)-quinolinyl)- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404829-05-6 CAPLUS

CN Piperidine, 1-[[5-[[2-(1-piperidinyl)-4-quinazolinyl]amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 404829-06-7 CAPLUS


CN 1H-Pyrazole-3-methanol, 5-[[2-(1-piperidinyl)-4-quinazolinyl]amino]- (9CI)
(CA INDEX NAME)



RN 404829-07-8 CAPLUS


CN 1H-Pyrazole-3-carboxamide, 5-[[2-(1-piperidinyl)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

09/ 806,836




RN 404829-08-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[[2-(4-methyl-1-piperidiny)]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 404829-15-8 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazolo[4,3-b]pyridin-3-yl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-16-9 CAPLUS

09/ 806,836


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(3-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-17-0 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-18-1 CAPLUS

CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-19-2 CAPLUS

CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(2,4-dichlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-21-6 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-22-7 CAPLUS

CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-phenoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-23-8 CAPLUS

CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(4-chlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)

09/ 806,836




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

IT 404828-81-5, 5-(2-Phenylquinazolin-4-ylamino)-1H-pyrazole-3-carboxylic acid 2,5-dioxopyrrolidin-1-yl ester 404828-93-9, (5-Cyclopropyl-1H-pyrazol-3-yl) (2-chloroquinazolin-4-yl)amine
RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; prepn. of heterocyclpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)


RN 404828-81-5 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]oxy]- (9CI) (CA INDEX NAME)



RN 404828-93-9 CAPLUS

CN 4-Quinazolinamine, 2-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 24 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:220580 CAPLUS

DOCUMENT NUMBER: 136:247606

TITLE: Preparation of 3-(4-pyrimidinylamino)pyrazole derivatives as protein kinase inhibitors, especially of Aurora-2 and GSK-3, for treating cancer, diabetes and Alzheimer's disease.

INVENTOR(S): Davies, Robert; Bebbington, David; Binch, Haley; Knechtel, Ronald; Golec, Julian M. C.; Patel, Sanjay; Charrier, Jean-Damien; Kay, David; Davies, Robert

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 357 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022604	A1	20020321	WO 2001-US28792	20010914
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				


PRIORITY APPLN. INFO.: US 2000-232795P P 20000915

US 2000-257887P P 20001221


US 2001-286949P P 20010427

OTHER SOURCE(S): MARPAT 136:247606


GI



I



II



III

AB The prepn. of title compds. I and their pharmaceutically acceptable salts or prodrugs is described [wherein: R1, R2 = dependently form (un)substituted fused, unsatd. or partially unsatd., 5-8 membered carbocyclo ring; R3, R4 = independently H, aliph., aryl, heteroaryl, heterocyclyl, or wide variety of functionalized sidechains; or dependently form a fused, 5-8 membered, unsatd. or partially unsatd. ring having 0-3 ring heteroatoms (N, S, O); R5 = fused, (un)substituted 5-7 membered monocyclic ring or 8-10 membered bicyclic ring (aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms (N, S, O))]. For example, chlorination of quinazolinone II with phosphorus oxychloride, followed by condensation with 3-amino-5-methylpyrazole afforded claimed compd. III. Compds. I are inhibitors of GSK-3 and Aurora-2 protein kinases. The invention also relates to methods of treating diseases assocd. with these protein kinases, such as diabetes, cancer and Alzheimer's disease. In bioassays, compds. I inhibited the following kinases with Kis reported < 100 nM: GSK-3.beta. (163 compds.), AURORA-2 (65 compds.), CDK-2 (no data), ERK2 (8 compds.), AKT (no data), and Human Src kinase (21 compds.). Claims included 146 specific compds., and 188 examples were given. The syntheses of 6 compds. and 46 intermediates are described.


IT 404826-21-7P 404828-54-2P 404828-58-6P
404828-61-1P 404829-04-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of 3-(4-pyrimidinylamino)pyrazole compds. as protein kinase inhibitors)

RN 404826-21-7 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404828-54-2 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 404828-58-6 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-[5-[3-(phenylmethoxy)propyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-61-1 CAPLUS

CN Carbamic acid, [3-[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-


09/ 806,836

yl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 404829-04-5 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[[2-(1-piperidinyl)-4-quinazolinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



IT 404826-20-6P 404826-22-8P 404826-23-9P
404826-60-4P 404826-61-5P 404826-63-7P
404826-64-8P 404826-65-9P 404826-66-0P
404826-67-1P 404826-68-2P 404826-69-3P
404826-70-6P 404826-71-7P 404826-72-8P
404826-73-9P 404826-74-0P 404826-75-1P
404826-76-2P 404826-77-3P 404826-78-4P
404826-79-5P 404826-80-8P 404826-81-9P
404826-82-0P 404826-83-1P 404827-28-7P
404827-29-8P 404827-31-2P 404827-56-1P
404828-10-0P 404828-11-1P 404828-12-2P
404828-13-3P 404828-14-4P 404828-15-5P
404828-16-6P 404828-17-7P 404828-18-8P
404828-19-9P 404828-20-2P 404828-21-3P
404828-22-4P 404828-23-5P 404828-24-6P
404828-25-7P 404828-26-8P 404828-27-9P
404828-28-0P 404828-29-1P 404828-31-5P
404828-32-6P 404828-34-8P 404828-35-9P
404828-36-0P 404828-37-1P 404828-38-2P
404828-39-3P 404828-40-6P 404828-41-7P


404828-42-8P 404828-43-9P 404828-44-0P
 404828-45-1P 404828-46-2P 404828-47-3P
 404828-48-4P 404828-49-5P 404828-50-8P
 404828-51-9P 404828-52-0P 404828-53-1P
 404828-55-3P 404828-56-4P 404828-57-5P
 404828-59-7P 404828-60-0P 404828-62-2P
 404828-63-3P 404828-64-4P 404828-65-5P
 404828-66-6P 404828-67-7P 404828-69-9P
 404828-71-3P 404828-72-4P 404828-73-5P
 404828-74-6P 404828-75-7P 404828-76-8P
 404828-77-9P 404828-78-0P 404828-79-1P
 404828-80-4P 404828-82-6P 404828-83-7P
 404828-84-8P 404828-85-9P 404828-86-0P
 404828-88-2P 404828-89-3P 404828-90-6P
 404828-91-7P 404828-92-8P 404828-96-2P
 404828-97-3P 404828-98-4P 404828-99-5P
 404829-00-1P 404829-01-2P 404829-02-3P
 404829-03-4P 404829-05-6P 404829-06-7P
 404829-07-8P 404829-08-9P 404829-16-9P
 404829-17-0P 404829-18-1P 404829-19-2P
 404829-21-6P 404829-22-7P 404829-23-8P
 404844-79-7P 404844-80-0P 404844-82-2P
 404844-83-3P 404844-85-5P 404844-86-6P
 404844-88-8P 404844-89-9P 404844-90-2P
 404844-91-3P 404844-92-4P 404844-93-5P
 404844-94-6P 404844-95-7P 404844-96-8P
 404844-97-9P 404844-98-0P 404844-99-1P
 404845-00-7P 404845-01-8P 404845-02-9P
 404845-03-0P 404845-04-1P 404845-11-0P
 404845-18-7P 404845-32-5P 404845-34-7P
 404845-35-8P 404845-36-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(prepn. of 3-(4-pyrimidinylamino)pyrazole compds. as protein kinase inhibitors)

RN 404826-20-6 CAPLUS

CN 4-Quinazolinamine, 2-(3,4-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
 (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-22-8 CAPLUS

CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-4-yl-N-(5-methyl-1H-pyrazol-3-yl)-
 (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-23-9 CAPLUS


CN 4-Quinazolinamine, 2-(4-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-60-4 CAPLUS

CN 4-Quinazolinamine, 2-(2-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

09/ 806,836

RN 404826-61-5 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-63-7 CAPLUS

CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-64-8 CAPLUS

CN 4-Quinazolinamine, 2-(2-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-65-9 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-66-0 CAPLUS

CN Ethanone, 1-[2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-67-1 CAPLUS

09/ 806,836


CN 4-Quinazolinamine, 2-(2,3-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-68-2 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-69-3 CAPLUS

CN 4-Quinazolinamine, 2-(2-ethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-70-6 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-2-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-71-7 CAPLUS

CN Phenol, 2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA
INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-72-8 CAPLUS

CN 4-Quinazolinamine, 2-(2-ethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-73-9 CAPLUS


CN 4-Quinazolinamine, N-[5-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-74-0 CAPLUS

CN 4-Quinazolinamine, N-[4-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

09/ 806,836

RN 404826-75-1 CAPLUS


CN 4-Quinazolinamine, N-(4-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-76-2 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-77-3 CAPLUS

CN 4-Quinazolinamine, N-(5-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-78-4 CAPLUS


CN 4-Quinazolinamine, N-(4,5-diphenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-79-5 CAPLUS

CN 1H-Pyrazole-4-carboxamide, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-80-8 CAPLUS

CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404826-81-9 CAPLUS

CN 3H-Pyrazol-3-one, 1,2-dihydro-5-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 404826-82-0 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-83-1 CAPLUS

CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-[2-

09/ 806,836


(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-28-7 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazolo[4,3-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-29-8 CAPLUS

CN 4-Quinazolinamine, N-1H-pyrazolo[3,4-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-31-2 CAPLUS

09/ 806,836


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino] - (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-56-1 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-naphthalenyl) - (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-10-0 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl) - (9CI)
(CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-11-1 CAPLUS


CN 4-Quinazolinamine, 7-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-12-2 CAPLUS

CN 4-Quinazolinamine, 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-13-3 CAPLUS

09/ 806,836


CN 4-Quinazolinamine, 2-cyclohexyl-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-14-4 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-15-5 CAPLUS

CN 4-Quinazolinamine, 2-(4-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-16-6 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-17-7 CAPLUS

CN 4-Quinazolinamine, 2-(3,5-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-18-8 CAPLUS

CN Benzonitrile, 4-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-19-9 CAPLUS


CN 4-Quinazolinamine, 2-(3-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-20-2 CAPLUS

CN 4-Quinazolinamine, 2-[4-(ethylthio)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-21-3 CAPLUS

09/ 806,836


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-22-4 CAPLUS


CN 4-Quinazolinamine, 2-[4-(1,1-dimethylethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-23-5 CAPLUS

CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-24-6 CAPLUS


CN 4-Quinazolinamine, 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-25-7 CAPLUS

CN 4-Quinazolinamine, 2-[4-(dimethylamino)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-26-8 CAPLUS

CN 4-Quinazolinamine, 2-(3-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-27-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dichlorophenyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-28-0 CAPLUS

CN 4-Quinazolinamine, 2-(3-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-29-1 CAPLUS


CN 4-Quinazolinamine, 2-(3-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-31-5 CAPLUS

CN 4-Quinazolinamine, 2-(3,5-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-32-6 CAPLUS

CN 4-Quinazolinamine, 2-(3-chloro-4-fluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-34-8 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-35-9 CAPLUS

CN Benzonitrile, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-36-0 CAPLUS


CN 4-Quinazolinamine, 2-[3-(1-methylethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-37-1 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-38-2 CAPLUS

CN Ethanone, 1-[3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-39-3 CAPLUS


CN 4-Quinazolinamine, 2-[3,5-bis(trifluoromethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-40-6 CAPLUS

CN Benzenemethanol, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-41-7 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-42-8 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-43-9 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-thienyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-44-0 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazol-3-yl- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-45-1 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-46-2 CAPLUS

CN 4-Quinazolinamine, N-(5-ethyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-47-3 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-(5-propyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-48-4 CAPLUS


CN 4-Quinazolinamine, N-[5-(1-methylethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-49-5 CAPLUS

CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-50-8 CAPLUS

CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-(4-pyridinyl)- (9CI)
(CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-51-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopentyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-52-0 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-53-1 CAPLUS


09/ 806,836

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI)
(CA INDEX NAME)




RN 404828-55-3 CAPLUS

CN 1H-Pyrazole-3-methanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA
INDEX NAME)



RN 404828-56-4 CAPLUS

CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-57-5 CAPLUS


CN 1H-Pyrazole-3-propanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA
INDEX NAME)

09/ 806,836



RN 404828-59-7 CAPLUS


CN 4-Quinazolinamine, N-[5-(3-methoxypropyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-60-0 CAPLUS

CN 4-Quinazolinamine, N-[5-(3-aminopropyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-62-2 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)

09/ 806,836




RN 404828-63-3 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-2-propenyl-
(9CI) (CA INDEX NAME)



RN 404828-64-4 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(2-methoxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-65-5 CAPLUS


09/ 806,836

CN 1H-Pyrazole-3-carboxamide, N-(phenylmethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-66-6 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-cyclohexyl-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-67-7 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N,N-diethyl-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)

09/ 806,836



RN 404828-69-9 CAPLUS


CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-propyl-
(9CI) (CA INDEX NAME)



RN 404828-71-3 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-cyclopropyl-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)

09/ 806,836



RN 404828-72-4 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(2-methylpropyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-73-5 CAPLUS

CN Pyrrolidine, 3-(methoxymethyl)-1-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



09/ 806,836


RN 404828-74-6 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(3-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino] - (9CI) (CA INDEX NAME)



RN 404828-75-7 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(4-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino] - (9CI) (CA INDEX NAME)



RN 404828-76-8 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-methyl-5-[(2-phenyl-4-quinazolinyl)amino] - (9CI) (CA INDEX NAME)

09/ 806,836



RN 404828-77-9 CAPLUS


CN Morpholine, 4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 404828-78-0 CAPLUS


CN Piperazine, 1-methyl-4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

09/ 806,836



RN 404828-79-1 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(2-hydroxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-80-4 CAPLUS


CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)

09/ 806,836



RN 404828-82-6 CAPLUS


CN 4-Quinazolinamine, N-(4-bromo-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-83-7 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-84-8 CAPLUS

CN 1H-Pyrazole-4-carbonitrile, 3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-85-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-morpholinyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-86-0 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-piperazinyl)- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-88-2 CAPLUS

CN 4-Quinazolinamine, 2-(4-methyl-1-piperazinyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-89-3 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-piperidinyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-90-6 CAPLUS

CN 4-Quinazolinamine, 2-(hexahydro-1H-azepin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-91-7 CAPLUS

09/ 806,836


CN 4-Piperidineethanol, 1-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-92-8 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(4-methyl-1-piperidinyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-96-2 CAPLUS

CN 4-Piperidinol, 1-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-97-3 CAPLUS


CN 4-Piperidinol, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-4-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-98-4 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1,3-dihydro-2H-isoindol-2-yl)- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-99-5 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(hexahydro-1H-azepin-1-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-00-1 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-2(1H)-isoquinolinyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-01-2 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2,3-dihydro-1H-indol-1-yl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-02-3 CAPLUS


CN 4-Piperidinemethanol, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-03-4 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-1(2H)-quinolinyl)- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404829-05-6 CAPLUS

CN Piperidine, 1-[[5-[[2-(1-piperidinyl)-4-quinazolinyl]amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 404829-06-7 CAPLUS


CN 1H-Pyrazole-3-methanol, 5-[[2-(1-piperidinyl)-4-quinazolinyl]amino]- (9CI)
(CA INDEX NAME)



RN 404829-07-8 CAPLUS


CN 1H-Pyrazole-3-carboxamide, 5-[[2-(1-piperidinyl)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

09/ 806,836




RN 404829-08-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[[2-(4-methyl-1-piperidiny)]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 404829-16-9 CAPLUS

CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(3-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-17-0 CAPLUS

09/ 806,836


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-18-1 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-19-2 CAPLUS

CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(2,4-dichlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-21-6 CAPLUS

CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-22-7 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-phenoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-23-8 CAPLUS

CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(4-chlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404844-79-7 CAPLUS

CN 4-Quinazolinamine, 7-chloro-2-(4-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404844-80-0 CAPLUS


CN 4-Quinazolinamine, 6-methoxy-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404844-82-2 CAPLUS

CN Acetamide, N-[2-(4-chlorophenyl)-4-[(5-methyl-1H-pyrazol-3-yl)amino]-7-quinazolinyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404844-83-3 CAPLUS

CN Ethanone, 1-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-phenyl-7-quinazolinyl]-

09/ 806,836


(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404844-85-5 CAPLUS


CN 4,7-Quinazolin-2-amine, 2-(4-chlorophenyl)-N7-ethyl-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404844-86-6 CAPLUS

CN 4-Quinazolin-2-amine, 2-(3-methoxyphenyl)-7-methyl-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

09/ 806,836

RN 404844-88-8 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-7-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404844-89-9 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(2-naphthalenyl)- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404844-90-2 CAPLUS

CN 4-Quinazolinamine, 8-ethoxy-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI)
(CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404844-91-3 CAPLUS


CN 7-Quinazolinol, 2-(4-chlorophenyl)-4-[(5-methyl-1H-pyrazol-3-yl)amino]-, methylcarbamate (ester) (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404844-92-4 CAPLUS

CN 7-Quinazolinecarbonitrile, 2-(3-methylphenyl)-4-[(5-methyl-1H-pyrazol-3-yl)amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

09/ 806,836

RN 404844-93-5 CAPLUS


CN 4-Quinazolinamine, 7-methoxy-8-methyl-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404844-94-6 CAPLUS

CN 4-Quinazolinamine, 2-(4-chlorophenyl)-7-methoxy-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404844-95-7 CAPLUS

CN 7-Quinazolinecarboxamide, N-methyl-2-(3-methylphenyl)-4-[(5-methyl-1H-pyrazol-3-yl)amino]- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404844-96-8 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-7-(methylsulfonyl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404844-97-9 CAPLUS

CN 4-Quinazolinamine, 7-(1-methylethyl)-2-(1-methyl-4-piperidinyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404844-98-0 CAPLUS


CN 4-Quinazolinamine, 2-(1-methyl-2-piperidinyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404844-99-1 CAPLUS

CN 1(2H)-Isoquinolinone, 3,4-dihydro-2-methyl-3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404845-00-7 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-methyl-N-(phenylmethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)

09/ 806,836




RN 404845-01-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-ethyl-5-[(2-phenyl-4-quinazolinyl) amino]-N-propyl- (9CI) (CA INDEX NAME)



RN 404845-02-9 CAPLUS


CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl) amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)



RN 404845-03-0 CAPLUS

09/ 806,836


CN 1H-Pyrazole-4-carbonitrile, 3-[[2-(4-methyl-1-piperidinyl)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404845-04-1 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[4-(1-pyrrolidinyl)-1-piperidinyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404845-11-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-2H-pyrazolo[4,3-b]pyridin-3-yl- (9CI) (CA INDEX NAME)



RN 404845-18-7 CAPLUS

CN 4-Quinazolinamine, 2-(2,4-dimethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404845-32-5 CAPLUS


CN 4-Quinazolinamine, N-(4,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404845-34-7 CAPLUS

CN 4-Quinazolinamine, 8-methyl-N-(5-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404845-35-8 CAPLUS

09/ 806,836


CN 4-Quinazolinamine, N-[5-(2-furanyl)-1H-pyrazol-3-yl]-8-methyl-2-[2-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404845-36-9 CAPLUS

CN 4-Quinazolinamine, 8-ethyl-N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


IT 404828-81-5, 5-(2-Phenylquinazolin-4-ylamino)-1H-pyrazole-3-carboxylic acid 2,5-dioxopyrrolidin-1-yl ester 404828-93-9, (5-Cyclopropyl-1H-pyrazol-3-yl) (2-chloroquinazolin-4-yl) amine
RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of 3-(4-pyrimidinylamino)pyrazole compds. as protein kinase inhibitors)

RN 404828-81-5 CAPLUS


CN 2,5-Pyrrolidinedione, 1-[[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyloxy]- (9CI) (CA INDEX NAME)

09/ 806,836



RN 404828-93-9 CAPLUS

CN 4-Quinazolinamine, 2-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

IT 404828-30-4P, (2-Chloroquinazolin-4-yl) (5-methyl-1H-pyrazol-3-yl)amine

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of 3-(4-pyrimidinylamino)pyrazole compds. as protein kinase inhibitors)

RN 404828-30-4 CAPLUS

CN 4-Quinazolinamine, 2-chloro-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 24 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:220579 CAPLUS

DOCUMENT NUMBER: 136:247580

TITLE: Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease

INVENTOR(S): Davies, Robert; Li, Pan; Golec, Julian; Bebbington, David

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 406 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022603	A1	20020321	WO 2001-US28738	20010914
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				


PRIORITY APPLN. INFO.: US 2000-232795P P 20000915

US 2000-257887P P 20001221

US 2001-286949P P 20010427

OTHER SOURCE(S): MARPAT 136:247580

GI



AB Title compds. I [wherein G = Ring C or Ring D; Ring C = (un)substituted Ph, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl; Ring D = (un)substituted monocyclic or bicyclic ring selected from aryl, heteroaryl, heterocyclyl, or carbocyclyl; Z1 = N or CR₉; Z2 = N or CH; Z3 = N or CR_x; Z4 = N or CR_y; R_x and R_y = independently TR₃, or taken together with their intervening atoms form an (un)satd. fused ring having 1-3 ring heteroatoms; R2 and R2a = independently R, TWR₆; or C2R2R2a = (un)substituted fused ring contg. 0-3 heteroatoms; T = a bond or alkylidene chain; W = C(R₆)2O, C(R₆)2S0-2, C(R₆)2NR₆, CO, CO₂, CR₆OCO, CR₆CONR₆, C(R₆)2NR₆CO, C(R₆)2NR₆CO₂, CR₆:NNR₆, CR₆:NO, C(R₆)2NR₆NR₆, C(R₆)2NR₆SO₂NR₆, C(R₆)2NR₆CONR₆, or CONR₆; R = H or (un)substituted aliph., (hetero)aryl, or heterocyclyl ring; R₃ = R, halo, O, OR, COR, CO₂R, COCOR, COCH₂COR, NO₂, CN, SO₀-2R, N(R₄)₂, CON(R₄)₂, SO₂N(R₄)₂, OCOR, NR₄COR, NR₄CO₂(aliph.), NR₄N(R₄)₂, C:NN(R₄)₂, C:NOR, NR₄CO(R₄)₂, NR₄SO₂N(R₄)₂, NR₄SO₂R, or OCON(R₄)₂; R₄ = R₇, COR₇, CO₂(aliph.), CON(R₇)₂, or SO₂R₇; or N(R₄)₂ = heterocyclyl or heteroaryl; R₆ and R₇ = independently H or (un)substituted aliph. group; or N(R₆)₂ = heterocyclyl or heteroaryl; or N(R₇)₂ = heterocyclyl or heteroaryl; R₉ = R, halo, OR, COR, CO₂R, COCOR, etc.] were prepd. as protein kinase inhibitors, esp. as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes, and Alzheimer's disease. Claims cover (triazinyl)pyrazolamines and indazolamines I [wherein Z1, Z2, and Z3 = N; Z4 = CR_y]. Examples include data for approx. 300 invention compds. prepd. by a variety of synthetic methods and bioassay results for the inhibition of GSK-3, Aurora-2, ERK, and Src. For instance, the N-(4-pyrimidinyl)-3-pyrazolamine II was prepd. and exhibited K_i values of < 0.1 .mu.M for glycogen synthetase kinase 3.beta. (GSK-3.beta.) and 0.1-1.0 .mu.M for Aurora-2.


IT 404828-30-4P, (2-Chloroquinazolin-4-yl)(5-methyl-1H-pyrazol-3-yl)amine

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; prepn. of heterocyclpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404828-30-4 CAPLUS

CN 4-Quinazolinamine, 2-chloro-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

IT 404826-20-6P, [2-(3,4-Dichlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-21-7P, [2-(4-Bromophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-22-8P, (2-Biphenyl-4-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-23-9P, [2-(4-Ethynylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-54-2P, (5-Methoxycarbonyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-58-6P, (5-Benzoyloxypropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-61-1P, [5-(3-tert-Butoxycarbonylamino)propyl]-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404829-04-5P, (5-Methoxycarbonyl-2H-pyrazol-3-yl) [2-(piperidine-1-yl)quinazolin-4-yl]amine

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(protein kinase inhibitor; prepn. of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-20-6 CAPLUS

CN 4-Quinazolinamine, 2-(3,4-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-21-7 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-(9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-22-8 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-4-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-23-9 CAPLUS

CN 4-Quinazolinamine, 2-(4-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-54-2 CAPLUS


09/ 806,836

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 404828-58-6 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-[5-[3-(phenylmethoxy)propyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-61-1 CAPLUS

CN Carbamic acid, [3-[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 404829-04-5 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[[2-(1-piperidinyl)-4-quinazolinyl]amino]-
, methyl ester (9CI) (CA INDEX NAME)

IT 404826-60-4P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-methylphenyl)quinazolin-4-yl]amine 404826-61-5P, [2-(2,4-Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-62-6P, [2-(2,5-Dimethoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-63-7P, [2-(2-Chlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-64-8P, [2-(2-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-65-9P, [2-(2,6-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-66-0P, [2-(2-Acetylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-67-1P, [2-(2,3-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-68-2P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-69-3P, [2-(2-Ethylphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-70-6P, (2-Biphenyl-2-yl)quinazolin-4-yl(5-methyl-2H-pyrazol-3-yl)amine 404826-71-7P, [2-(2-Hydroxyphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-72-8P, [2-(2-Ethoxyphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-73-9P, [5-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-74-0P, [4-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-75-1P, (4-Phenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-76-2P, (5-tert-Butyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-77-3P, (5-Phenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-78-4P, (4,5-Diphenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-79-5P, (4-Carbamoyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-80-8P, (2H-Pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-81-9P, (5-Hydroxy-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-82-0P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-83-1P, (5-Methoxymethyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-28-7P, (1H-Pyrazolo[4,3-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-29-8P, (1H-Pyrazolo[3,4-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-30-1P, (6-Methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)[2-(2-

trifluoromethylphenyl)quinazolin-4-yl]amine **404827-31-2P**,
 (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-56-1P**,
 (5-Methyl-2H-pyrazol-3-yl)[2-(2-naphthyl-1-yl)quinazolin-4-yl]amine **404828-10-0P**, (5-Methyl-2H-pyrazol-3-yl)(2-pyridin-4-yl)quinazolin-4-yl]amine **404828-11-1P**, (7-Chloro-2-pyridin-4-yl)quinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine **404828-12-2P**,
 (6-Chloro-2-pyridin-4-yl)quinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine **404828-13-3P**, (2-Cyclohexyl)quinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine **404828-14-4P**, (5-Methyl-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-15-5P**, [2-(4-Iodophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-16-6P**, [2-(4-Chlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-17-7P**, [2-(3,5-Dichlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-18-8P**, [2-(4-Cyanophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-19-9P**, [2-(3-Iodophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-20-2P**,
 [2-(4-Ethylsulfanylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-21-3P**, (5-Cyclopropyl-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-22-4P**, [2-(4-tert-Butylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-23-5P**, [2-(4-Chlorophenyl)quinazolin-4-yl](5-cyclopropyl-2H-pyrazol-3-yl)amine **404828-24-6P**, (2-Benzo[1,3]dioxol-5-yl)quinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine **404828-25-7P**, [2-(4-Dimethylaminophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-26-8P**, [2-(3-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-27-9P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dichlorophenyl)quinazolin-4-yl]amine **404828-28-0P**, [2-(3-Ethynylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-29-1P**, [2-(3-Methylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-31-5P**, [2-(3,5-Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-32-6P**, [2-(3-Chloro-4-fluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-34-8P**,
 (5-Methyl-2H-pyrazol-3-yl)[2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine **404828-35-9P**, [2-(3-Cyanophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-36-0P**, [2-(3-Isopropylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-37-1P**, (5-Methyl-2H-pyrazol-3-yl)(2-pyridin-3-yl)quinazolin-4-yl)amine **404828-38-2P**, [2-(3-Acetylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-39-3P**, [2-(3,5-Bis(trifluoromethyl)phenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-40-6P**, [2-(3-Hydroxymethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-41-7P**, (5-Methyl-2H-pyrazol-3-yl)[2-(3-phenoxyphenyl)quinazolin-4-yl]amine **404828-42-8P**,
 (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3-phenoxyphenyl)quinazolin-4-yl]amine **404828-43-9P** **404828-44-0P**, (2-Phenyl)quinazolin-4-yl)(2H-pyrazol-3-yl)amine **404828-45-1P**, (2H-Pyrazol-3-yl)(2-pyridin-4-yl)quinazolin-4-yl)amine **404828-46-2P**, (5-Ethyl-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-47-3P**,
 (2-Phenyl)quinazolin-4-yl)(5-propyl-2H-pyrazol-3-yl)amine **404828-48-4P**, (5-Isopropyl-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-49-5P**, (5-tert-Butyl-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-50-8P**, (5-tert-Butyl-2H-pyrazol-3-yl)(2-pyridin-4-yl)quinazolin-4-yl)amine **404828-51-9P**, (5-Cyclopentyl-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-52-0P**, (5-Phenyl-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-53-1P**, (5-Carboxy-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-55-3P**, (5-Hydroxymethyl-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-56-4P**,
 (5-Methoxymethyl-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-57-5P**, [5-(3-Hydroxypropyl)-2H-pyrazol-3-yl](2-

phenylquinazolin-4-yl)amine 404828-59-7P, [5-(3-Methoxypropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-60-0P, [5-(3-Aminopropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-62-2P, (5-Isopropylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-63-3P, (5-Allylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-64-4P, [5-(2-Methoxyethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-65-5P, (5-Benzylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-66-6P, (5-Cyclohexylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-67-7P, (5-Diethylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-68-8P, [5-(Benzylmethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-69-9P, (2-Phenylquinazolin-4-yl) (5-propylcarbamoyl-2H-pyrazol-3-yl)amine 404828-70-2P, [5-(Ethylisopropylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-71-3P, (5-Cyclopropylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-72-4P, (5-Isobutylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-73-5P, [5-((3S)-3-Methoxymethylpyrrolidine-1-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-74-6P, (2-Phenylquinazolin-4-yl) (5-m-tolylcarbamoyl-2H-pyrazol-3-yl)amine 404828-75-7P, (2-Phenylquinazolin-4-yl) (5-p-tolylcarbamoyl-2H-pyrazol-3-yl)amine 404828-76-8P, (5-Methylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-77-9P, [5-(Morpholine-4-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-78-0P, [5-(1-Methylpiperazine-4-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-79-1P, [5-(2-Hydroxyethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-80-4P, (5-Carbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-82-6P, (4-Bromo-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-83-7P, (4-Bromo-5-methyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-84-8P, (4-Cyano-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-85-9P, (5-Methyl-2H-pyrazol-3-yl) (2-morpholin-4-ylquinazolin-4-yl)amine 404828-86-0P, (5-Methyl-2H-pyrazol-3-yl) (2-piperazin-1-ylquinazolin-4-yl)amine 404828-87-1P, [2-(4-Methylpiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-88-2P, [2-(4-Methylpiperazin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-89-3P, (5-Methyl-2H-pyrazol-3-yl) (2-piperidin-1-ylquinazolin-4-yl)amine 404828-90-6P, [2-(Azepan-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-91-7P, [2-[4-(2-Hydroxyethyl)piperidin-1-yl]quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-92-8P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-methylpiperidin-1-yl)quinazolin-4-yl]amine 404828-95-1P, [2-(4-Cyclopentylaminopiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-96-2P, [2-(4-Hydroxypiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-97-3P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-hydroxy-4-phenylpiperidin-1-yl)quinazolin-4-yl]amine 404828-98-4P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(1,3-dihydroisoindol-2-yl)quinazolin-4-yl]amine 404828-99-5P, [2-(Azepan-1-yl)quinazolin-4-yl] (5-cyclopropyl-2H-pyrazol-3-yl)amine 404829-00-1P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dihydro-1H-isoquinolin-2-yl)quinazolin-4-yl]amine 404829-01-2P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(2,3-dihydroindol-1-yl)quinazolin-4-yl]amine 404829-02-3P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-hydroxymethylpiperidin-1-yl)quinazolin-4-yl]amine 404829-03-4P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dihydro-2H-quinolin-1-yl)quinazolin-4-yl]amine 404829-05-6P, 5-(Piperidine-1-carbonyl)-2H-pyrazol-3-yl-[2-(piperidin-1-yl)quinazolin-4-yl]amine 404829-06-7P, (5-Hydroxymethyl-2H-pyrazol-3-yl) [2-(piperidin-1-yl)quinazolin-4-yl]amine 404829-07-8P, (5-Carbamoyl-2H-pyrazol-3-yl) [2-(piperidin-1-yl)quinazolin-4-yl]amine 404829-08-9P, (5-Carbamoyl-2H-pyrazol-3-


yl) [2-(4-methylpiperidin-1-yl)quinazolin-4-yl]amine **404829-15-8P**,
 (2-Phenylquinazolin-4-yl) (1H-pyrazolo[4,3-b]pyridin-3-yl)amine
404829-16-9P, [5-(3-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-
 pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine
404829-17-0P, (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-
 c]pyridazin-3-yl) - (2-phenylquinazolin-4-yl)amine **404829-18-1P**,
 [5-(4-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-
 phenylquinazolin-4-yl)amine **404829-19-2P**, [5-(2,4-
 Dichlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-
 phenylquinazolin-4-yl)amine **404829-21-6P**, [6-Oxo-5-(3-
 trifluoromethylphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-
 phenylquinazolin-4-yl)amine **404829-22-7P**, [6-Oxo-5-(4-
 Phenoxyphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-
 phenylquinazolin-4-yl)amine **404829-23-8P**, [5-(4-Chlorophenyl)-6-
 oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-
 yl)amine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(protein kinase inhibitor; prepn. of heterocyclylpyrazolamines and
 analogs as protein kinase inhibitors for treatment of cancer, diabetes,
 and Alzheimer's disease)

RN 404826-60-4 CAPLUS

CN 4-Quinazolinamine, 2-(2-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
 (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-61-5 CAPLUS

CN 4-Quinazolinamine, 2-(2,4-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
 (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-62-6 CAPLUS


CN 4-Quinazolinamine, 2-(2,5-dimethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-63-7 CAPLUS

CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-64-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-65-9 CAPLUS

CN 4-Quinazolinamine, 2-(2,6-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-66-0 CAPLUS

CN Ethanone, 1-[2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-67-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,3-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-68-2 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-69-3 CAPLUS

09/ 806,836


CN 4-Quinazolinamine, 2-(2-ethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-70-6 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-2-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-71-7 CAPLUS

CN Phenol, 2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA
INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-72-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-73-9 CAPLUS

CN 4-Quinazolinamine, N-[5-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-74-0 CAPLUS

CN 4-Quinazolinamine, N-[4-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-75-1 CAPLUS


CN 4-Quinazolinamine, N-(4-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-76-2 CAPLUS

CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-77-3 CAPLUS

CN 4-Quinazolinamine, N-(5-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-78-4 CAPLUS


CN 4-Quinazolinamine, N-(4,5-diphenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-79-5 CAPLUS

CN 1H-Pyrazole-4-carboxamide, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-80-8 CAPLUS

09/ 806,836


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404826-81-9 CAPLUS

CN 3H-Pyrazol-3-one, 1,2-dihydro-5-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 404826-82-0 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-83-1 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-28-7 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazolo[4,3-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-29-8 CAPLUS

CN 4-Quinazolinamine, N-1H-pyrazolo[3,4-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-30-1 CAPLUS


CN 4-Quinazolinamine, N-(6-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-31-2 CAPLUS

CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-56-1 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-naphthalenyl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-10-0 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-11-1 CAPLUS

CN 4-Quinazolinamine, 7-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-12-2 CAPLUS


CN 4-Quinazolinamine, 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-13-3 CAPLUS

CN 4-Quinazolinamine, 2-cyclohexyl-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA
INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-14-4 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX
NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-15-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-16-6 CAPLUS

CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-17-7 CAPLUS

CN 4-Quinazolinamine, 2-(3,5-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-

09/ 806,836


(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-18-8 CAPLUS

CN Benzonitrile, 4-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl] -
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-19-9 CAPLUS

CN 4-Quinazolinamine, 2-(3-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl) - (9CI)
(CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-20-2 CAPLUS


CN 4-Quinazolinamine, 2-[4-(ethylthio)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-21-3 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA
INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-22-4 CAPLUS

CN 4-Quinazolinamine, 2-[4-(1,1-dimethylethyl)phenyl]-N-(5-methyl-1H-pyrazol-

09/ 806,836


3-yl) - (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-23-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl) -
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-24-6 CAPLUS

CN 4-Quinazolinamine, 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-1H-pyrazol-3-yl) -
(9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-25-7 CAPLUS


CN 4-Quinazolinamine, 2-[4-(dimethylamino)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-26-8 CAPLUS

CN 4-Quinazolinamine, 2-(3-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-27-9 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dichlorophenyl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-28-0 CAPLUS


CN 4-Quinazolinamine, 2-(3-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-29-1 CAPLUS

CN 4-Quinazolinamine, 2-(3-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-31-5 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-32-6 CAPLUS

CN 4-Quinazolinamine, 2-(3-chloro-4-fluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-34-8 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[3-(trifluoromethyl)phenyl]-
(9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-35-9 CAPLUS


CN Benzonitrile, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-36-0 CAPLUS

CN 4-Quinazolinamine, 2-[3-(1-methylethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-37-1 CAPLUS

09/ 806,836


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-pyridinyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-38-2 CAPLUS


CN Ethanone, 1-[3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-39-3 CAPLUS

CN 4-Quinazolinamine, 2-[3,5-bis(trifluoromethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-40-6 CAPLUS


CN Benzenemethanol, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-41-7 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-42-8 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)-
(9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-43-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-thienyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-44-0 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazol-3-yl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-45-1 CAPLUS

CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-46-2 CAPLUS


CN 4-Quinazolinamine, N-(5-ethyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-47-3 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-(5-propyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-48-4 CAPLUS

CN 4-Quinazolinamine, N-[5-(1-methylethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-49-5 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-phenyl-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-50-8 CAPLUS

CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-(4-
pyridinyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-51-9 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopentyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA
INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-52-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-53-1 CAPLUS


CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-55-3 CAPLUS


CN 1H-Pyrazole-3-methanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)

09/ 806,836



RN 404828-56-4 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-57-5 CAPLUS


CN 1H-Pyrazole-3-propanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA
INDEX NAME)



RN 404828-59-7 CAPLUS

CN 4-Quinazolinamine, N-[5-(3-methoxypropyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-60-0 CAPLUS


CN 4-Quinazolinamine, N-[5-(3-aminopropyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-62-2 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-63-3 CAPLUS


CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-2-propenyl- (9CI) (CA INDEX NAME)

09/ 806,836




RN 404828-64-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-methoxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-65-5 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(phenylmethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-66-6 CAPLUS


09/ 806,836

CN 1H-Pyrazole-3-carboxamide, N-cyclohexyl-5-[(2-phenyl-4-quinazolinyl)amino] -
(9CI) (CA INDEX NAME)



RN 404828-67-7 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N,N-diethyl-5-[(2-phenyl-4-quinazolinyl)amino] -
(9CI) (CA INDEX NAME)



RN 404828-68-8 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(2-phenylethyl)-5-[(2-phenyl-4-quinazolinyl)amino] - (9CI) (CA INDEX NAME)

09/ 806,836




RN 404828-69-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-propyl-
(9CI) (CA INDEX NAME)



RN 404828-70-2 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-ethyl-N-(1-methylethyl)-5-[(2-phenyl-4-
quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-71-3 CAPLUS


09/ 806,836

CN 1H-Pyrazole-3-carboxamide, N-cyclopropyl-5-[(2-phenyl-4-quinazolinyl)amino] - (9CI) (CA INDEX NAME)



RN 404828-72-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-methylpropyl)-5-[(2-phenyl-4-quinazolinyl)amino] - (9CI) (CA INDEX NAME)




RN 404828-73-5 CAPLUS

CN Pyrrolidine, 3-(methoxymethyl)-1-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

09/ 806,836



RN 404828-74-6 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(3-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]-(9CI) (CA INDEX NAME)



RN 404828-75-7 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(4-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]-(9CI) (CA INDEX NAME)

09/ 806,836



RN 404828-76-8 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-methyl-5-[(2-phenyl-4-quinazolinyl)amino] -
(9CI) (CA INDEX NAME)



RN 404828-77-9 CAPLUS


CN Morpholine, 4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl] - (9CI) (CA INDEX NAME)

09/ 806,836



RN 404828-78-0 CAPLUS


CN Piperazine, 1-methyl-4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 404828-79-1 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(2-hydroxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)

09/ 806,836




RN 404828-80-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-82-6 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-83-7 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-84-8 CAPLUS


CN 1H-Pyrazole-4-carbonitrile, 3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-85-9 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-86-0 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-87-1 CAPLUS


CN 4-Quinazolinamine, 2-(4-methyl-1-piperidinyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-88-2 CAPLUS

CN 4-Quinazolinamine, 2-(4-methyl-1-piperazinyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

09/ 806,836

RN 404828-89-3 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-piperidinyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-90-6 CAPLUS


CN 4-Quinazolinamine, 2-(hexahydro-1H-azepin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-91-7 CAPLUS

CN 4-Piperidineethanol, 1-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-92-8 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(4-methyl-1-piperidinyl) - (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-95-1 CAPLUS

CN 4-Quinazolinamine, 2-[4-(cyclopentylamino)-1-piperidinyl]-N-(5-methyl-1H-pyrazol-3-yl) - (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-96-2 CAPLUS

CN 4-Piperidinol, 1-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl] - (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-97-3 CAPLUS


CN 4-Piperidinol, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-4-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-98-4 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1,3-dihydro-2H-isoindol-2-yl)- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-99-5 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(hexahydro-1H-azepin-1-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-00-1 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-2(1H)-isoquinoliny)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-01-2 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2,3-dihydro-1H-indol-1-yl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-02-3 CAPLUS


CN 4-Piperidinemethanol, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-03-4 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-1(2H)-quinolinyl)- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404829-05-6 CAPLUS

CN Piperidine, 1-[[5-[[2-(1-piperidinyl)-4-quinazolinyl]amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 404829-06-7 CAPLUS


CN 1H-Pyrazole-3-methanol, 5-[[2-(1-piperidinyl)-4-quinazolinyl]amino]- (9CI)
(CA INDEX NAME)



RN 404829-07-8 CAPLUS


CN 1H-Pyrazole-3-carboxamide, 5-[[2-(1-piperidinyl)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

09/ 806,836




RN 404829-08-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[[2-(4-methyl-1-piperidinyl)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 404829-15-8 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazolo[4,3-b]pyridin-3-yl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-16-9 CAPLUS

09/ 806,836


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(3-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-17-0 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-18-1 CAPLUS

CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-19-2 CAPLUS

CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(2,4-dichlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-21-6 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-22-7 CAPLUS

CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-phenoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-23-8 CAPLUS

CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(4-chlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)

09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


IT 404828-81-5, 5-(2-Phenylquinazolin-4-ylamino)-1H-pyrazole-3-carboxylic acid 2,5-dioxopyrrolidin-1-yl ester 404828-93-9, (5-Cyclopropyl-1H-pyrazol-3-yl) (2-chloroquinazolin-4-yl)amine

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; prepn. of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)


RN 404828-81-5 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]oxy]- (9CI) (CA INDEX NAME)



RN 404828-93-9 CAPLUS

CN 4-Quinazolinamine, 2-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 24 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:220578 CAPLUS

DOCUMENT NUMBER: 136:263164

TITLE: Preparation of triazolamines as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease

INVENTOR(S): Bebbington, David; Knegt, Ronald; Binch, Haley; Golec, Julian M. C.; Li, Pan; Charrier, Jean-Damien

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 377 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8




PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022602	A2	20020321	WO 2001-US42162	20010914
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2000-232795P P 20000915
US 2000-257887P P 20001221
US 2001-286949P P 20010427

OTHER SOURCE(S): MARPAT 136:263164

GI



AB Triazolamines I and pyrazolamines II [wherein G = Ring C or Ring D; Ring C = (un)substituted Ph, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl; Ring D = (un)substituted monocyclic or bicyclic ring selected from aryl, heteroaryl, heterocyclyl, or carbocyclyl; Z1 = N or CR9; Z2 = N or CH; Z3 = N or CRx; Z4 = N or CRY; Rx and Ry = independently TR3, or taken together with their intervening atoms form an (un)satd. fused ring having 1-3 ring heteroatoms; R2 and R2a = independently R, TWR6; or C2R2R2a = (un)substituted fused ring contg. 0-3 heteroatoms; T = a bond or alkylidene chain; W = C(R6)2O, C(R6)2S0-2, C(R6)2NR6, CO, CO2, CR6OCO, CR6OCONR6, C(R6)2NR6CO, C(R6)2NR6CO2, CR6:NNR6, CR6:NO, C(R6)2NR6NR6, C(R6)2NR6SO2NR6, C(R6)2NR6CONR6, or CONR6; R = H or (un)substituted aliph., (hetero)aryl, or heterocyclyl ring; R3 = R, halo, O, OR, COR, CO2R, COCOR, COCH2COR, NO2, CN, SO0-2R, N(R4)2, CON(R4)2, SO2N(R4)2, OCOR, NR4COR, NR4CO2(aliph.), NR4N(R4)2, C:NN(R4)2, C:NOR, NR4CO(R4)2, NR4SO2N(R4)2, NR4SO2R, or OCON(R4)2; R4 = R7, COR7, CO2(aliph.), CON(R7)2, or SO2R7; or N(R4)2 = heterocyclyl or heteroaryl; R6 and R7 = independently H or (un)substituted aliph. group; or N(R6)2 = heterocyclyl or heteroaryl; or N(R7)2 = heterocyclyl or heteroaryl; R9 = R, halo, OR, COR, CO2R, COCOR, etc.] were prepd. as protein kinase inhibitors, esp. as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes, and Alzheimer's disease. Claims cover (heterocyclyl)triazolamines I [wherein Z1 = N or CR9; Z2 = N or CH; R9 is defined above]. Examples include data for approx. 300 invention compds. prepd. by a variety of synthetic methods and bioassay results for the inhibition of GSK-3, Aurora-2, ERK, and Src. For instance, the N-(4-quinazolinyl)-1H-1,2,4-triazol-3-amine III was prepd. and exhibited Ki values of < 0.1 .mu.M for glycogen synthetase kinase 3.beta. (GSK-3.beta.) and 1.0-20 .mu.M for Aurora-2.

IT **404828-30-4P**, (2-Chloroquinazolin-4-yl)(5-methyl-1H-pyrazol-3-yl)amine


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; prepn. of triazolamines, pyrazolamines, and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

09/ 806,836

RN 404828-30-4 CAPLUS

CN 4-Quinazolinamine, 2-chloro-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


IT 404826-20-6P, [2-(3,4-Dichlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-21-7P, [2-(4-Bromophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-22-8P, (2-Biphenyl-4-ylquinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404826-23-9P, [2-(4-Ethynylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-54-2P, (5-Methoxycarbonyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-58-6P, (5-Benzyloxypropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-61-1P, [5-(3-tert-Butoxycarbonylaminopropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404829-04-5P, (5-Methoxycarbonyl-2H-pyrazol-3-yl) [2-(piperidine-1-yl)quinazolin-4-yl]amine

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(protein kinase inhibitor; prepn. of triazolamines, pyrazolamines, and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-20-6 CAPLUS

CN 4-Quinazolinamine, 2-(3,4-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

09/ 806,836

RN 404826-21-7 CAPLUS


CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-22-8 CAPLUS

CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-4-yl-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-23-9 CAPLUS

CN 4-Quinazolinamine, 2-(4-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404828-54-2 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 404828-58-6 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-[5-[3-(phenylmethoxy)propyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-61-1 CAPLUS

CN Carbamic acid, [3-[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-


09/ 806,836

yl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 404829-04-5 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[[2-(1-piperidinyl)-4-quinazolinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



IT 404826-60-4P, (5-Methyl-2H-pyrazol-3-yl) [2-(2-methylphenyl)quinazolin-4-yl]amine 404826-61-5P, [2-(2,4-Difluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-62-6P, [2-(2,5-Dimethoxyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-63-7P, [2-(2-Chlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-64-8P, [2-(2-Methoxyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-65-9P, [2-(2,6-Dimethylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-66-0P, [2-(2-Acetylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-67-1P, [2-(2,3-Dimethylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-68-2P, (5-Methyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-69-3P, [2-(2-Ethylphenyl)quinazolin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine 404826-70-6P, (2-Biphenyl-2-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-71-7P, [2-(2-Hydroxyphenyl)quinazolin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine 404826-72-8P, [2-(2-Ethoxyphenyl)quinazolin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine 404826-73-9P, [5-(Thiophen-2-yl)-2H-pyrazol-3-yl] [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-74-0P,

[4-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-75-1P**, (4-Phenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-76-2P**, (5-tert-Butyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-77-3P**, (5-Phenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-78-4P**, (4,5-Diphenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-79-5P**, (4-Carbamoyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-80-8P**, (2H-Pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-81-9P**, (5-Hydroxy-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-82-0P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-83-1P**, (5-Methoxymethyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-28-7P**, (1H-Pyrazolo[4,3-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-29-8P**, (1H-Pyrazolo[3,4-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-30-1P**, (6-Methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-31-2P**, (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-56-1P**, (5-Methyl-2H-pyrazol-3-yl)[2-(2-naphthyl-1-yl)quinazolin-4-yl]amine **404828-10-0P**, (5-Methyl-2H-pyrazol-3-yl)(2-pyridin-4-yl)quinazolin-4-yl-amine **404828-11-1P**, (7-Chloro-2-pyridin-4-yl)quinazolin-4-yl(5-methyl-2H-pyrazol-3-yl)amine **404828-12-2P**, (6-Chloro-2-pyridin-4-yl)quinazolin-4-yl(5-methyl-2H-pyrazol-3-yl)amine **404828-13-3P**, (2-Cyclohexyl)quinazolin-4-yl(5-methyl-2H-pyrazol-3-yl)amine **404828-14-4P**, (5-Methyl-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-ylamine **404828-15-5P**, [2-(4-Iodophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-16-6P**, [2-(4-Chlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-17-7P**, [2-(3,5-Dichlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-18-8P**, [2-(4-Cyanophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-19-9P**, [2-(3-Iodophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-20-2P**, [2-(4-Ethylsulfanylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-21-3P**, (5-Cyclopropyl-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-ylamine **404828-22-4P**, [2-(4-tert-Butylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-23-5P**, [2-(4-Chlorophenyl)quinazolin-4-yl](5-cyclopropyl-2H-pyrazol-3-yl)amine **404828-24-6P**, (2-Benzo[1,3]dioxol-5-yl)quinazolin-4-yl(5-methyl-2H-pyrazol-3-yl)amine **404828-25-7P**, [2-(4-Dimethylaminophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-26-8P**, [2-(3-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-27-9P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dichlorophenyl)quinazolin-4-yl]amine **404828-28-0P**, [2-(3-Ethynylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-29-1P**, [2-(3-Methylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-31-5P**, [2-(3,5-Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-32-6P**, [2-(3-Chloro-4-fluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-34-8P**, (5-Methyl-2H-pyrazol-3-yl)[2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine **404828-35-9P**, [2-(3-Cyanophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-36-0P**, [2-(3-Isopropylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-37-1P**, (5-Methyl-2H-pyrazol-3-yl)(2-pyridin-3-yl)quinazolin-4-ylamine **404828-38-2P**, [2-(3-Acetylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-39-3P**, [2-(3,5-Bis(trifluoromethyl)phenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-40-6P**, [2-(3-Hydroxymethylphenyl)quinazolin-4-yl](5-methyl-

2H-pyrazol-3-yl)amine **404828-41-7P**, (5-Methyl-2H-pyrazol-3-yl) [2-(3-phenoxyphenyl)quinazolin-4-yl]amine **404828-42-8P**,
 (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3-phenoxyphenyl)quinazolin-4-yl]amine **404828-43-9P** **404828-44-0P**, (2-Phenylquinazolin-4-yl) (2H-pyrazol-3-yl)amine **404828-45-1P**, (2H-Pyrazol-3-yl) (2-pyridin-4-yl)quinazolin-4-yl)amine **404828-46-2P**, (5-Ethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-47-3P**,
 (2-Phenylquinazolin-4-yl) (5-propyl-2H-pyrazol-3-yl)amine **404828-48-4P**, (5-Isopropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-49-5P**, (5-tert-Butyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-50-8P**, (5-tert-Butyl-2H-pyrazol-3-yl) (2-pyridin-4-yl)quinazolin-4-yl)amine **404828-51-9P**,
 (5-Cyclopentyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-52-0P**, (5-Phenyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-53-1P**, (5-Carboxy-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-55-3P**, (5-Hydroxymethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-56-4P**,
 (5-Methoxymethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-57-5P**, [5-(3-Hydroxypropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-59-7P**, [5-(3-Methoxypropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-60-0P**,
 [5-(3-Aminopropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-62-2P**, (5-Isopropylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-63-3P**, (5-Allylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-64-4P**,
 [5-(2-Methoxyethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-65-5P**, (5-Benzylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-66-6P**, (5-Cyclohexylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-67-7P**,
 (5-Diethylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-68-8P**, [5-(Benzylmethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-69-9P**, (2-Phenylquinazolin-4-yl) (5-propylcarbamoyl-2H-pyrazol-3-yl)amine **404828-70-2P**,
 [5-(Ethylisopropylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-71-3P**, (5-Cyclopropylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-72-4P**,
 (5-Isobutylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-73-5P**, [5-((3S)-3-Methoxymethylpyrrolidine-1-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-74-6P**,
 (2-Phenylquinazolin-4-yl) (5-m-tolylcarbamoyl-2H-pyrazol-3-yl)amine **404828-75-7P**, (2-Phenylquinazolin-4-yl) (5-p-tolylcarbamoyl-2H-pyrazol-3-yl)amine **404828-76-8P**, (5-Methylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-77-9P**,
 [5-(Morpholine-4-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-78-0P**, [5-(1-Methylpiperazine-4-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-79-1P**,
 [5-(2-Hydroxyethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-80-4P**, (5-Carbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-82-6P**, (4-Bromo-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-83-7P**,
 (4-Bromo-5-methyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-84-8P**, (4-Cyano-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-85-9P**, (5-Methyl-2H-pyrazol-3-yl) (2-morpholin-4-yl)quinazolin-4-yl)amine **404828-86-0P**, (5-Methyl-2H-pyrazol-3-yl) (2-piperazin-1-yl)quinazolin-4-yl)amine **404828-87-1P**,
 [2-(4-Methylpiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-88-2P**, [2-(4-Methylpiperazin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-89-3P**, (5-Methyl-2H-pyrazol-3-yl) (2-piperidin-1-yl)quinazolin-4-yl)amine **404828-90-6P**,
 [2-(Azepan-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-91-7P**, [2-[4-(2-Hydroxyethyl)piperidin-1-yl]quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-92-8P**,
 (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-methylpiperidin-1-yl)quinazolin-4-


yl]amine **404828-95-1P**, [2-(4-Cyclopentylaminopiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-96-2P**, [2-(4-Hydroxypiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-97-3P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-hydroxy-4-phenylpiperidin-1-yl)quinazolin-4-yl]amine **404828-98-4P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(1,3-dihydroisoindol-2-yl)quinazolin-4-yl]amine **404828-99-5P**, [2-(Azepan-1-yl)quinazolin-4-yl] (5-cyclopropyl-2H-pyrazol-3-yl)amine **404829-00-1P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dihydro-1H-isoquinolin-2-yl)quinazolin-4-yl]amine **404829-01-2P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(2,3-dihydroindol-1-yl)quinazolin-4-yl]amine **404829-02-3P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-hydroxymethylpiperidin-1-yl)quinazolin-4-yl]amine **404829-03-4P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dihydro-2H-quinolin-1-yl)quinazolin-4-yl]amine **404829-05-6P**, 5-(Piperidine-1-carbonyl)-2H-pyrazol-3-yl- [2-(piperidine-1-yl)quinazolin-4-yl]amine **404829-06-7P**, (5-Hydroxymethyl-2H-pyrazol-3-yl) [2-(piperidin-1-yl)quinazolin-4-yl]amine **404829-07-8P**, (5-Carbamoyl-2H-pyrazol-3-yl) [2-(piperidin-1-yl)quinazolin-4-yl]amine **404829-08-9P**, (5-Carbamoyl-2H-pyrazol-3-yl) [2-(4-methylpiperidin-1-yl)quinazolin-4-yl]amine **404829-15-8P**, (2-Phenylquinazolin-4-yl) (1H-pyrazolo[4,3-b]pyridin-3-yl)amine **404829-16-9P**, [5-(3-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-17-0P**, [6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-18-1P**, [5-(4-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-19-2P**, [5-(2,4-Dichlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-21-6P**, [6-Oxo-5-(3-trifluoromethylphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-22-7P**, [6-Oxo-5-(4-Phenoxyphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-23-8P**, [5-(4-Chlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; prepn. of triazolamines, pyrazolamines, and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-60-4 CAPLUS

CN 4-Quinazolinamine, 2-(2-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

09/ 806,836

RN 404826-61-5 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-62-6 CAPLUS

CN 4-Quinazolinamine, 2-(2,5-dimethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-63-7 CAPLUS

CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-64-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-65-9 CAPLUS

CN 4-Quinazolinamine, 2-(2,6-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-66-0 CAPLUS

09/ 806,836


CN Ethanone, 1-[2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-67-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,3-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-68-2 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-69-3 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-70-6 CAPLUS

CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-2-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-71-7 CAPLUS

CN Phenol, 2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA
INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-72-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-73-9 CAPLUS

CN 4-Quinazolinamine, N-[5-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-74-0 CAPLUS


CN 4-Quinazolinamine, N-[4-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-75-1 CAPLUS


CN 4-Quinazolinamine, N-(4-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-76-2 CAPLUS

CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-77-3 CAPLUS


CN 4-Quinazolinamine, N-(5-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-78-4 CAPLUS

CN 4-Quinazolinamine, N-(4,5-diphenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-79-5 CAPLUS

CN 1H-Pyrazole-4-carboxamide, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-80-8 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-81-9 CAPLUS


CN 3H-Pyrazol-3-one, 1,2-dihydro-5-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 404826-82-0 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-83-1 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-28-7 CAPLUS

CN 4-Quinazolinamine, N-1H-pyrazolo[4,3-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-29-8 CAPLUS

09/ 806,836


CN 4-Quinazolinamine, N-1H-pyrazolo[3,4-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-30-1 CAPLUS


CN 4-Quinazolinamine, N-(6-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-31-2 CAPLUS

CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-56-1 CAPLUS

09/ 806,836


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-naphthalenyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-10-0 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-11-1 CAPLUS

CN 4-Quinazolinamine, 7-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-12-2 CAPLUS


CN 4-Quinazolinamine, 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-13-3 CAPLUS

CN 4-Quinazolinamine, 2-cyclohexyl-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA
INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-14-4 CAPLUS

09/ 806,836


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-15-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-16-6 CAPLUS

CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-17-7 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-18-8 CAPLUS

CN Benzonitrile, 4-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-19-9 CAPLUS

CN 4-Quinazolinamine, 2-(3-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-20-2 CAPLUS


CN 4-Quinazolinamine, 2-[4-(ethylthio)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-21-3 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA
INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-22-4 CAPLUS

CN 4-Quinazolinamine, 2-[4-(1,1-dimethylethyl)phenyl]-N-(5-methyl-1H-pyrazol-

09/ 806,836


3-yl) - (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-23-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl) -
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-24-6 CAPLUS

CN 4-Quinazolinamine, 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-1H-pyrazol-3-yl) -
(9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-25-7 CAPLUS


CN 4-Quinazolinamine, 2-[4-(dimethylamino)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-26-8 CAPLUS

CN 4-Quinazolinamine, 2-(3-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-27-9 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dichlorophenyl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-28-0 CAPLUS


CN 4-Quinazolinamine, 2-(3-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-29-1 CAPLUS

CN 4-Quinazolinamine, 2-(3-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-31-5 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-32-6 CAPLUS

CN 4-Quinazolinamine, 2-(3-chloro-4-fluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-34-8 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-35-9 CAPLUS


CN Benzonitrile, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-36-0 CAPLUS

CN 4-Quinazolinamine, 2-[3-(1-methylethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-37-1 CAPLUS

09/ 806,836


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-pyridinyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-38-2 CAPLUS


CN Ethanone, 1-[3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-39-3 CAPLUS

CN 4-Quinazolinamine, 2-[3,5-bis(trifluoromethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-40-6 CAPLUS


CN Benzenemethanol, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-41-7 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-42-8 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)-
(9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-43-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-thienyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-44-0 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazol-3-yl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-45-1 CAPLUS

CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-46-2 CAPLUS


CN 4-Quinazolinamine, N-(5-ethyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-47-3 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-(5-propyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-48-4 CAPLUS

CN 4-Quinazolinamine, N-[5-(1-methylethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-49-5 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-phenyl-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-50-8 CAPLUS

CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-(4-
pyridinyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-51-9 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopentyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA
INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-52-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-53-1 CAPLUS


CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino] - (9CI) (CA INDEX NAME)



RN 404828-55-3 CAPLUS


CN 1H-Pyrazole-3-methanol, 5-[(2-phenyl-4-quinazolinyl)amino] - (9CI) (CA INDEX NAME)

09/ 806,836



RN 404828-56-4 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-57-5 CAPLUS


CN 1H-Pyrazole-3-propanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA
INDEX NAME)



RN 404828-59-7 CAPLUS

CN 4-Quinazolinamine, N-[5-(3-methoxypropyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-60-0 CAPLUS


CN 4-Quinazolinamine, N-[5-(3-aminopropyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-62-2 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-63-3 CAPLUS


CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-2-propenyl- (9CI) (CA INDEX NAME)

09/ 806,836




RN 404828-64-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-methoxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino] - (9CI) (CA INDEX NAME)



RN 404828-65-5 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(phenylmethyl)-5-[(2-phenyl-4-quinazolinyl)amino] - (9CI) (CA INDEX NAME)



RN 404828-66-6 CAPLUS


09/ 806,836

CN 1H-Pyrazole-3-carboxamide, N-cyclohexyl-5-[(2-phenyl-4-quinazolinyl)amino] -
(9CI) (CA INDEX NAME)



RN 404828-67-7 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N,N-diethyl-5-[(2-phenyl-4-quinazolinyl)amino] -
(9CI) (CA INDEX NAME)



RN 404828-68-8 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(2-phenylethyl)-5-[(2-phenyl-4-quinazolinyl)amino] - (9CI) (CA INDEX NAME)

09/ 806,836




RN 404828-69-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-propyl-
(9CI) (CA INDEX NAME)



RN 404828-70-2 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-ethyl-N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-71-3 CAPLUS


09/ 806,836

CN 1H-Pyrazole-3-carboxamide, N-cyclopropyl-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-72-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-methylpropyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-73-5 CAPLUS

CN Pyrrolidine, 3-(methoxymethyl)-1-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

09/ 806,836



RN 404828-74-6 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(3-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-75-7 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(4-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)

09/ 806,836



RN 404828-76-8 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-methyl-5-[(2-phenyl-4-quinazolinyl)amino] -
(9CI) (CA INDEX NAME)



RN 404828-77-9 CAPLUS


CN Morpholine, 4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

09/ 806,836



RN 404828-78-0 CAPLUS


CN Piperazine, 1-methyl-4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 404828-79-1 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(2-hydroxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)

09/ 806,836




RN 404828-80-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-82-6 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-83-7 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-84-8 CAPLUS


CN 1H-Pyrazole-4-carbonitrile, 3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-85-9 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-86-0 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-87-1 CAPLUS


CN 4-Quinazolinamine, 2-(4-methyl-1-piperidinyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-88-2 CAPLUS

CN 4-Quinazolinamine, 2-(4-methyl-1-piperazinyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

09/ 806,836

RN 404828-89-3 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-piperidinyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-90-6 CAPLUS


CN 4-Quinazolinamine, 2-(hexahydro-1H-azepin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-91-7 CAPLUS

CN 4-Piperidineethanol, 1-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-92-8 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(4-methyl-1-piperidinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-95-1 CAPLUS

CN 4-Quinazolinamine, 2-[4-(cyclopentylamino)-1-piperidinyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-96-2 CAPLUS

CN 4-Piperidinol, 1-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-97-3 CAPLUS


CN 4-Piperidinol, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-4-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-98-4 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1,3-dihydro-2H-isoindol-2-yl)- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-99-5 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(hexahydro-1H-azepin-1-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-00-1 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-2(1H)-isoquinoliny)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-01-2 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2,3-dihydro-1H-indol-1-yl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-02-3 CAPLUS


CN 4-Piperidinemethanol, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-03-4 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-1(2H)-quinolinyl)- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404829-05-6 CAPLUS

CN Piperidine, 1-[[5-[[2-(1-piperidinyl)-4-quinazolinyl]amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 404829-06-7 CAPLUS


CN 1H-Pyrazole-3-methanol, 5-[[2-(1-piperidinyl)-4-quinazolinyl]amino]- (9CI)
(CA INDEX NAME)



RN 404829-07-8 CAPLUS


CN 1H-Pyrazole-3-carboxamide, 5-[[2-(1-piperidinyl)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

09/ 806,836




RN 404829-08-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[[2-(4-methyl-1-piperidiny)]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 404829-15-8 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazolo[4,3-b]pyridin-3-yl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-16-9 CAPLUS

09/ 806,836


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(3-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino] - (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-17-0 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[(2-phenyl-4-quinazolinyl)amino] - (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-18-1 CAPLUS

CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino] - (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-19-2 CAPLUS

CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(2,4-dichlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino] - (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-21-6 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-22-7 CAPLUS

CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-phenoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-23-8 CAPLUS

CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(4-chlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)

09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


IT 404828-81-5, 5-(2-Phenylquinazolin-4-ylamino)-1H-pyrazole-3-carboxylic acid 2,5-dioxopyrrolidin-1-yl ester 404828-93-9, (5-Cyclopropyl-1H-pyrazol-3-yl) (2-chloroquinazolin-4-yl)amine

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; prepn. of triazolamines, pyrazolamines, and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)


RN 404828-81-5 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]oxy]- (9CI) (CA INDEX NAME)



RN 404828-93-9 CAPLUS

CN 4-Quinazolinamine, 2-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

L5 ANSWER 9 OF 24 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:220577 CAPLUS

DOCUMENT NUMBER: 136:247579

TITLE: Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease

INVENTOR(S): Knegt, Ronald; Bebbington, David; Binch, Hayley; Golec, Julian; Patel, Sanjay; Charrier, Jean-Damien; Kay, David; Davies, Robert; Li, Pan; Wannamaker, Marion; Forster, Cornelia; Pierce, Albert

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 376 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022601	A1	20020321	WO 2001-US28740	20010914
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				


PRIORITY APPLN. INFO.: US 2000-232795P P 20000915

US 2000-257887P P 20001221


US 2001-286949P P 20010427

OTHER SOURCE(S): MARPAT 136:247579

GI



I



II

AB Title compds. I [wherein G = Ring C or Ring D; Ring C = (un)substituted Ph, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl; Ring D = (un)substituted monocyclic or bicyclic ring selected from aryl, heteroaryl, heterocyclyl, or carbocyclyl; Z1 = N or CR₉; Z2 = N or CH; Z3 = N or CR_x; Z4 = N or CR_y; R_x and R_y = independently TR₃, or taken together with their intervening atoms form an (un)satd. fused ring having 1-3 ring heteroatoms; R₂ and R_{2a} = independently R, TWR₆; or C₂R₂R_{2a} = (un)substituted fused ring contg. 0-3 heteroatoms; T = a bond or alkylidene chain; W = C(R₆)₂O, C(R₆)₂SO-₂, C(R₆)₂NR₆, CO, CO₂, CR₆OCO, CR₆CONR₆, C(R₆)₂NR₆CO, C(R₆)₂NR₆CO₂, CR₆:NNR₆, CR₆:NO, C(R₆)₂NR₆NR₆, C(R₆)₂NR₆SO₂NR₆, C(R₆)₂NR₆CONR₆, or CONR₆; R = H or (un)substituted aliph., (hetero)aryl, or heterocyclyl ring; R₃ = R, halo, O, OR, COR, CO₂R, COCOR, COCH₂COR, NO₂, CN, SO₀₋₂R, N(R₄)₂, CON(R₄)₂, SO₂N(R₄)₂, OCOR, NR₄COR, NR₄CO₂(aliph.), NR₄N(R₄)₂, C:NN(R₄)₂, C:NOR, NR₄CO(R₄)₂, NR₄SO₂N(R₄)₂, NR₄SO₂R, or OCON(R₄)₂; R₄ = R₇, COR₇, CO₂(aliph.), CON(R₇)₂, or SO₂R₇; or N(R₄)₂ = heterocyclyl or heteroaryl; R₆ and R₇ = independently H or (un)substituted aliph. group; or N(R₆)₂ = heterocyclyl or heteroaryl; or N(R₇)₂ = heterocyclyl or heteroaryl; R₉ = R, halo, OR, COR, CO₂R, COCOR, etc.] were prepd. as protein kinase inhibitors, esp. as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes, and Alzheimer's disease. Claims cover pyrimidinyl- and pyridinyl- pyrazolamines and indazolamines I [wherein Z1 = N, CR_a, or CH; Z2 = N or CH; and at least one of Z1 or Z2 = N; Z3 = CR_x; Z4 = CR_y; R_a = halo, OR, COR, CO₂R, COCOR, NO₂, CN, SO₀₋₂R, N(R₄)₂, CON(R₄)₂, SO₂N(R₄)₂, OCOR, NR₄COR, etc.; R and R₄ are defined above]. Examples include data for approx. 300 invention compds. prepd. by a variety of synthetic methods and bioassay results for the inhibition of GSK- β , Aurora-2, ERK, and Src. For instance, the N-(4-pyrimidinyl)-3-pyrazolamine II was prepd. and exhibited K_i values of < 0.1 μ M for glycogen synthetase kinase 3 β . (GSK-3 β) and 0.1-1.0 μ M for Aurora-2.


IT **404828-30-4P**, (2-Chloroquinazolin-4-yl)(5-methyl-1H-pyrazol-3-yl)amine

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; prepn. of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)


RN 404828-30-4 CAPLUS

CN 4-Quinazolinamine, 2-chloro-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


IT **404826-20-6P**, [2-(3,4-Dichlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404826-21-7P**, [2-(4-Bromophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404826-22-8P**, (2-Biphenyl-4-ylquinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine **404826-23-9P**, [2-(4-Ethynylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-54-2P**, (5-Methoxycarbonyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-58-6P**, (5-Benzyloxypropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-61-1P**, [5-(3-tert-Butoxycarbonylaminoethyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404829-04-5P**, (5-Methoxycarbonyl-2H-pyrazol-3-yl) [2-(piperidine-1-yl)quinazolin-4-yl]amine
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (protein kinase inhibitor; prepn. of heterocyclpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)
 RN 404826-20-6 CAPLUS
 CN 4-Quinazolinamine, 2-(3,4-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-21-7 CAPLUS
 CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-(9CI)
 (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-22-8 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-4-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-23-9 CAPLUS

CN 4-Quinazolinamine, 2-(4-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-54-2 CAPLUS


09/ 806,836

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 404828-58-6 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-[5-[3-(phenylmethoxy)propyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-61-1 CAPLUS

CN Carbamic acid, [3-[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 404829-04-5 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[[2-(1-piperidinyl)-4-quinazolinyl]amino]-
, methyl ester (9CI) (CA INDEX NAME)

IT 404826-60-4P, (5-Methyl-2H-pyrazol-3-yl) [2-(2-methylphenyl)quinazolin-4-yl]amine 404826-61-5P, [2-(2,4-Difluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-62-6P, [2-(2,5-Dimethoxyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-63-7P, [2-(2-Chlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-64-8P, [2-(2-Methoxyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-65-9P, [2-(2,6-Dimethylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-66-0P, [2-(2-Acetylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-67-1P, [2-(2,3-Dimethylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-68-2P, (5-Methyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-69-3P, [2-(2-Ethylphenyl)quinazolin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine 404826-70-6P, (2-Biphenyl-2-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-71-7P, [2-(2-Hydroxyphenyl)quinazolin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine 404826-72-8P, [2-(2-Ethoxyphenyl)quinazolin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine 404826-73-9P, [5-(Thiophen-2-yl)-2H-pyrazol-3-yl] [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-74-0P, [4-(Thiophen-2-yl)-2H-pyrazol-3-yl] [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-75-1P, (4-Phenyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-76-2P, (5-tert-Butyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-77-3P, (5-Phenyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-78-4P, (4,5-Diphenyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-79-5P, (4-Carbamoyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-80-8P, (2H-Pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-81-9P, (5-Hydroxy-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-82-0P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-83-1P, (5-Methoxymethyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-28-7P, (1H-Pyrazolo[4,3-b]pyridin-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-29-8P, (1H-Pyrazolo[3,4-b]pyridin-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-30-1P, (6-Methyl-1H-pyrazolo[3,4-b]pyridin-3-yl) [2-(2-

trifluoromethylphenyl)quinazolin-4-yl]amine **404827-31-2P**,
 (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-56-1P**,
 (5-Methyl-2H-pyrazol-3-yl)[2-(2-naphthyl-1-yl)quinazolin-4-yl]amine **404828-10-0P**, (5-Methyl-2H-pyrazol-3-yl)(2-pyridin-4-ylquinazolin-4-yl)-amine **404828-11-1P**, (7-Chloro-2-pyridin-4-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine **404828-12-2P**,
 (6-Chloro-2-pyridin-4-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine **404828-13-3P**, (2-Cyclohexylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine **404828-14-4P**, (5-Methyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-15-5P**, [2-(4-Iodophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-16-6P**, [2-(4-Chlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-17-7P**, [2-(3,5-Dichlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-18-8P**, [2-(4-Cyanophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-19-9P**, [2-(3-Iodophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-20-2P**,
 [2-(4-Ethylsulfanylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-21-3P**, (5-Cyclopropyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-22-4P**, [2-(4-tert-Butylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-23-5P**, [2-(4-Chlorophenyl)quinazolin-4-yl](5-cyclopropyl-2H-pyrazol-3-yl)amine **404828-24-6P**, (2-Benzo[1,3]dioxol-5-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine **404828-25-7P**, [2-(4-Dimethylaminophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-26-8P**, [2-(3-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-27-9P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dichlorophenyl)quinazolin-4-yl]amine **404828-28-0P**, [2-(3-Ethynylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-29-1P**, [2-(3-Methylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-31-5P**, [2-(3,5-Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-32-6P**, [2-(3-Chloro-4-fluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-34-8P**,
 (5-Methyl-2H-pyrazol-3-yl)[2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine **404828-35-9P**, [2-(3-Cyanophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-36-0P**, [2-(3-Isopropylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-37-1P**, (5-Methyl-2H-pyrazol-3-yl)(2-pyridin-3-ylquinazolin-4-yl)amine **404828-38-2P**, [2-(3-Acetylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-39-3P**, [2-(3,5-Bis(trifluoromethyl)phenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-40-6P**, [2-(3-Hydroxymethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-41-7P**, (5-Methyl-2H-pyrazol-3-yl)[2-(3-phenoxyphenyl)quinazolin-4-yl]amine **404828-42-8P**,
 (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3-phenoxyphenyl)quinazolin-4-yl]amine **404828-43-9P** **404828-44-0P**, (2-Phenylquinazolin-4-yl)(2H-pyrazol-3-yl)amine **404828-45-1P**, (2H-Pyrazol-3-yl)(2-pyridin-4-ylquinazolin-4-yl)amine **404828-46-2P**, (5-Ethyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-47-3P**,
 (2-Phenylquinazolin-4-yl)(5-propyl-2H-pyrazol-3-yl)amine **404828-48-4P**, (5-Isopropyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-49-5P**, (5-tert-Butyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-50-8P**, (5-tert-Butyl-2H-pyrazol-3-yl)(2-pyridin-4-ylquinazolin-4-yl)amine **404828-51-9P**, (5-Cyclopentyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-52-0P**, (5-Phenyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-53-1P**, (5-Carboxy-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-55-3P**, (5-Hydroxymethyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-56-4P**,
 (5-Methoxymethyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-57-5P**, [5-(3-Hydroxypropyl)-2H-pyrazol-3-yl](2-

phenylquinazolin-4-yl)amine 404828-59-7P, [5-(3-Methoxypropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-60-0P, [5-(3-Aminopropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-62-2P, (5-Isopropylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-63-3P, (5-Allylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-64-4P, [5-(2-Methoxyethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-65-5P, (5-Benzylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-66-6P, (5-Cyclohexylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-67-7P, (5-Diethylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-68-8P, [5-(Benzylmethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-69-9P, (2-Phenylquinazolin-4-yl) (5-propylcarbamoyl-2H-pyrazol-3-yl)amine 404828-70-2P, [5-(Ethylisopropylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-71-3P, (5-Cyclopropylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-72-4P, (5-Isobutylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-73-5P, [5-((3S)-3-Methoxymethylpyrrolidine-1-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-74-6P, (2-Phenylquinazolin-4-yl) (5-m-tolylcarbamoyl-2H-pyrazol-3-yl)amine 404828-75-7P, (2-Phenylquinazolin-4-yl) (5-p-tolylcarbamoyl-2H-pyrazol-3-yl)amine 404828-76-8P, (5-Methylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-77-9P, [5-(Morpholine-4-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-78-0P, [5-(1-Methylpiperazine-4-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-79-1P, [5-(2-Hydroxyethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-80-4P, (5-Carbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-82-6P, (4-Bromo-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-83-7P, (4-Bromo-5-methyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-84-8P, (4-Cyano-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-85-9P, (5-Methyl-2H-pyrazol-3-yl) (2-morpholin-4-ylquinazolin-4-yl)amine 404828-86-0P, (5-Methyl-2H-pyrazol-3-yl) (2-piperazin-1-ylquinazolin-4-yl)amine 404828-87-1P, [2-(4-Methylpiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-88-2P, [2-(4-Methylpiperazin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-89-3P, (5-Methyl-2H-pyrazol-3-yl) (2-piperidin-1-ylquinazolin-4-yl)amine 404828-90-6P, [2-(Azepan-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-91-7P, [2-[4-(2-Hydroxyethyl)piperidin-1-yl]quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-92-8P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-methylpiperidin-1-yl)quinazolin-4-yl]amine 404828-95-1P, [2-(4-Cyclopentylaminopiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-96-2P, [2-(4-Hydroxypiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-97-3P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-hydroxy-4-phenylpiperidin-1-yl)quinazolin-4-yl]amine 404828-98-4P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(1,3-dihydroisoindol-2-yl)quinazolin-4-yl]amine 404828-99-5P, [2-(Azepan-1-yl)quinazolin-4-yl] (5-cyclopropyl-2H-pyrazol-3-yl)amine 404829-00-1P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dihydro-1H-isoquinolin-2-yl)quinazolin-4-yl]amine 404829-01-2P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(2,3-dihydroindol-1-yl)quinazolin-4-yl]amine 404829-02-3P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-hydroxymethylpiperidin-1-yl)quinazolin-4-yl]amine 404829-03-4P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dihydro-2H-quinolin-1-yl)quinazolin-4-yl]amine 404829-05-6P, 5-(Piperidine-1-carbonyl)-2H-pyrazol-3-yl-[2-(piperidine-1-yl)quinazolin-4-yl]amine 404829-06-7P, (5-Hydroxymethyl-2H-pyrazol-3-yl) [2-(piperidin-1-yl)quinazolin-4-yl]amine 404829-07-8P, (5-Carbamoyl-2H-pyrazol-3-yl) [2-(piperidin-1-yl)quinazolin-4-yl]amine 404829-08-9P, (5-Carbamoyl-2H-pyrazol-3-


yl) [2-(4-methylpiperidin-1-yl)quinazolin-4-yl]amine **404829-15-8P**, (2-Phenylquinazolin-4-yl) (1H-pyrazolo[4,3-b]pyridin-3-yl)amine **404829-16-9P**, [5-(3-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-17-0P**, (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl) - (2-phenylquinazolin-4-yl)amine **404829-18-1P**, [5-(4-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-19-2P**, [5-(2,4-Dichlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-21-6P**, [6-Oxo-5-(3-trifluoromethylphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-22-7P**, [6-Oxo-5-(4-Phenoxyphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-23-8P**, [5-(4-Chlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; prepn. of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-60-4 CAPLUS

CN 4-Quinazolinamine, 2-(2-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-61-5 CAPLUS

CN 4-Quinazolinamine, 2-(2,4-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-62-6 CAPLUS


CN 4-Quinazolinamine, 2-(2,5-dimethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl) -
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-63-7 CAPLUS

CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl) - (9CI)
(CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-64-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-65-9 CAPLUS

CN 4-Quinazolinamine, 2-(2,6-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-66-0 CAPLUS

CN Ethanone, 1-[2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-67-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,3-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-68-2 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-69-3 CAPLUS

09/ 806,836


CN 4-Quinazolinamine, 2-(2-ethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-70-6 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-2-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-71-7 CAPLUS

CN Phenol, 2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA
INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-72-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-73-9 CAPLUS

CN 4-Quinazolinamine, N-[5-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-74-0 CAPLUS


CN 4-Quinazolinamine, N-[4-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Cc1ccc(cc1)N2C(=N)N(C3CCCCC3)C(=N2)N4C=CN(C=C4C5=CC=CC=C5S)N

CN 4-Quinazolinamine, N-(4-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



CN 4-Quinazolinamine, N-(5-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-78-4 CAPLUS


CN 4-Quinazolinamine, N-(4,5-diphenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-79-5 CAPLUS

CN 1H-Pyrazole-4-carboxamide, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolininyl]amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-80-8 CAPLUS

09/ 806,836


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404826-81-9 CAPLUS

CN 3H-Pyrazol-3-one, 1,2-dihydro-5-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 404826-82-0 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-83-1 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-28-7 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazolo[4,3-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-29-8 CAPLUS

CN 4-Quinazolinamine, N-1H-pyrazolo[3,4-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-30-1 CAPLUS


CN 4-Quinazolinamine, N-(6-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-31-2 CAPLUS

CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-56-1 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-naphthalenyl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-10-0 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-11-1 CAPLUS

CN 4-Quinazolinamine, 7-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-12-2 CAPLUS


CN 4-Quinazolinamine, 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-13-3 CAPLUS

CN 4-Quinazolinamine, 2-cyclohexyl-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA
INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-14-4 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX
NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-15-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-16-6 CAPLUS

CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-17-7 CAPLUS

CN 4-Quinazolinamine, 2-(3,5-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-

09/ 806,836


(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-18-8 CAPLUS

CN Benzonitrile, 4-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-19-9 CAPLUS

CN 4-Quinazolinamine, 2-(3-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-20-2 CAPLUS


CN 4-Quinazolinamine, 2-[4-(ethylthio)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-21-3 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-22-4 CAPLUS

CN 4-Quinazolinamine, 2-[4-(1,1-dimethylethyl)phenyl]-N-(5-methyl-1H-pyrazol-

09/ 806,836


3-yl) - (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-23-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl) -
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-24-6 CAPLUS

CN 4-Quinazolinamine, 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-1H-pyrazol-3-yl) -
(9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-25-7 CAPLUS


CN 4-Quinazolinamine, 2-[4-(dimethylamino)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-26-8 CAPLUS

CN 4-Quinazolinamine, 2-(3-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-27-9 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dichlorophenyl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-28-0 CAPLUS


CN 4-Quinazolinamine, 2-(3-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-29-1 CAPLUS

CN 4-Quinazolinamine, 2-(3-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-31-5 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-32-6 CAPLUS

CN 4-Quinazolinamine, 2-(3-chloro-4-fluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-34-8 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-35-9 CAPLUS


CN Benzonitrile, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-36-0 CAPLUS

CN 4-Quinazolinamine, 2-[3-(1-methylethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-37-1 CAPLUS

09/ 806,836


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-pyridinyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-38-2 CAPLUS


CN Ethanone, 1-[3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-39-3 CAPLUS

CN 4-Quinazolinamine, 2-[3,5-bis(trifluoromethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-40-6 CAPLUS


CN Benzenemethanol, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-41-7 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-42-8 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)-
(9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-43-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-thienyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-44-0 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazol-3-yl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-45-1 CAPLUS

CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-46-2 CAPLUS


CN 4-Quinazolinamine, N-(5-ethyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-47-3 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-(5-propyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-48-4 CAPLUS

CN 4-Quinazolinamine, N-[5-(1-methylethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-49-5 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-phenyl-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-50-8 CAPLUS

CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-(4-
pyridinyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-51-9 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopentyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA
INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-52-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-53-1 CAPLUS


CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-55-3 CAPLUS


CN 1H-Pyrazole-3-methanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)

09/ 806,836



RN 404828-56-4 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-57-5 CAPLUS


CN 1H-Pyrazole-3-propanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA
INDEX NAME)



RN 404828-59-7 CAPLUS

CN 4-Quinazolinamine, N-[5-(3-methoxypropyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-60-0 CAPLUS


CN 4-Quinazolinamine, N-[5-(3-aminopropyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-62-2 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-63-3 CAPLUS


CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-2-propenyl- (9CI) (CA INDEX NAME)

09/ 806,836




RN 404828-64-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-methoxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-65-5 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(phenylmethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-66-6 CAPLUS


09/ 806,836

CN 1H-Pyrazole-3-carboxamide, N-cyclohexyl-5-[(2-phenyl-4-quinazolinyl)amino] -
(9CI) (CA INDEX NAME)



RN 404828-67-7 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N,N-diethyl-5-[(2-phenyl-4-quinazolinyl)amino] -
(9CI) (CA INDEX NAME)



RN 404828-68-8 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(2-phenylethyl)-5-[(2-phenyl-4-quinazolinyl)amino] - (9CI) (CA INDEX NAME)

09/ 806,836




RN 404828-69-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-propyl-
(9CI) (CA INDEX NAME)



RN 404828-70-2 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-ethyl-N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-71-3 CAPLUS


09/ 806,836

CN 1H-Pyrazole-3-carboxamide, N-cyclopropyl-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-72-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-methylpropyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-73-5 CAPLUS

CN Pyrrolidine, 3-(methoxymethyl)-1-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

09/ 806,836



RN 404828-74-6 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(3-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-75-7 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(4-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)

09/ 806,836



RN 404828-76-8 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-methyl-5-[(2-phenyl-4-quinazolinyl)amino]-
(9CI) (CA INDEX NAME)



RN 404828-77-9 CAPLUS


CN Morpholine, 4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

09/ 806,836



RN 404828-78-0 CAPLUS


CN Piperazine, 1-methyl-4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 404828-79-1 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(2-hydroxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)

09/ 806,836




RN 404828-80-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-82-6 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-83-7 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-84-8 CAPLUS


CN 1H-Pyrazole-4-carbonitrile, 3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-85-9 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-86-0 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-87-1 CAPLUS


CN 4-Quinazolinamine, 2-(4-methyl-1-piperidiny)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-88-2 CAPLUS

CN 4-Quinazolinamine, 2-(4-methyl-1-piperazinyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

09/ 806,836

RN 404828-89-3 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-piperidinyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-90-6 CAPLUS


CN 4-Quinazolinamine, 2-(hexahydro-1H-azepin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-91-7 CAPLUS

CN 4-Piperidineethanol, 1-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-92-8 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(4-methyl-1-piperidinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-95-1 CAPLUS

CN 4-Quinazolinamine, 2-[4-(cyclopentylamino)-1-piperidinyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-96-2 CAPLUS

CN 4-Piperidinol, 1-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-97-3 CAPLUS


CN 4-Piperidinol, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-4-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-98-4 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1,3-dihydro-2H-isoindol-2-yl)- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-99-5 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(hexahydro-1H-azepin-1-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-00-1 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-2(1H)-isoquinoliny)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-01-2 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2,3-dihydro-1H-indol-1-yl)- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-02-3 CAPLUS


CN 4-Piperidinemethanol, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-03-4 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-1(2H)-quinolinyl)- (9CI) (CA INDEX NAME)




09/ 806,836

*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404829-05-6 CAPLUS

CN Piperidine, 1-[[5-[[2-(1-piperidiny)-4-quinazolinyl]amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 404829-06-7 CAPLUS


CN 1H-Pyrazole-3-methanol, 5-[[2-(1-piperidiny)-4-quinazolinyl]amino]- (9CI)
(CA INDEX NAME)



RN 404829-07-8 CAPLUS


CN 1H-Pyrazole-3-carboxamide, 5-[[2-(1-piperidiny)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

09/ 806,836




RN 404829-08-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[[2-(4-methyl-1-piperidiny)]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 404829-15-8 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazolo[4,3-b]pyridin-3-yl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-16-9 CAPLUS

09/ 806,836


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(3-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-17-0 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-18-1 CAPLUS

CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-19-2 CAPLUS

CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(2,4-dichlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)


09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-21-6 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-22-7 CAPLUS

CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-phenoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-23-8 CAPLUS

CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(4-chlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)

09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


IT 404828-81-5, 5-(2-Phenylquinazolin-4-ylamino)-1H-pyrazole-3-carboxylic acid 2,5-dioxopyrrolidin-1-yl ester 404828-93-9, (5-Cyclopropyl-1H-pyrazol-3-yl) (2-chloroquinazolin-4-yl)amine

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; prepn. of heterocyclpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)


RN 404828-81-5 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]oxy]- (9CI) (CA INDEX NAME)



RN 404828-93-9 CAPLUS

CN 4-Quinazolinamine, 2-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 24 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:514231 CAPLUS

DOCUMENT NUMBER: 135:251424

TITLE: 6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity

AUTHOR(S): Tsou, Hwei-Ru; Mamuya, Nellie; Johnson, Bernard D.; Reich, Marvin F.; Gruber, Brian C.; Ye, Fei; Nilakantan, Ramaswamy; Shen, Ru; Discafani, Carolyn; DeBlanc, Ronald; Davis, Rachel; Koehn, Frank E.; Greenberger, Lee M.; Wang, Yu-Fen; Wissner, Allan
CORPORATE SOURCE: Wyeth-Ayerst Research A Division of American Home Products, Pearl River, NY, 10965-1215, USA

SOURCE: Journal of Medicinal Chemistry (2001), 44(17), 2719-2734


CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



I

AB A series of new 6-substituted-4-(3-bromophenylamino)quinazoline derivs. that may function as irreversible inhibitors of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases have been prepd. These inhibitors have, at the C-6 position, butynamide, crotonamide, and methacrylamide Michael acceptors bearing water-solubilizing substituents. These compds. were prepd. by acylation of 6-amino-4-(3-bromophenylamino)quinazoline with unsatd. acid

chlorides or mixed anhydrides. We show that attaching a basic functional group onto the Michael acceptor results in greater reactivity, due to intramol. catalysis of the Michael addn. and/or an inductive effect of the protonated basic group. This, along with improved water soly., results in compds. with enhanced biol. properties. We present mol. modeling and exptl. evidence that these inhibitors interact covalently with the target enzymes. One compd., (I) was shown to have excellent oral activity in a human epidermoid carcinoma (A431) xenograft model in nude mice.


IT 361392-83-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and structure activity relations of antitumor
(bromophenylamino)quinazolines as putative irreversible inhibitors of
EGFR and human epidermal growth factor receptor (HER-2) tyrosine
kinase)

RN 361392-83-8 CAPLUS

CN 2-Butenamide, N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-4-(1H-pyrazol-1-yl)-, (2E)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 24 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:228867 CAPLUS

DOCUMENT NUMBER: 134:266318

TITLE: Preparation of quinazolines as aurora 2 kinase inhibitors

INVENTOR(S): Mortlock, Andrew Austen; Keen, Nicholas John

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 208 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021597	A1	20010329	WO 2000-GB3593	20000919
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,				

09/ 806,836

CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: GB 1999-22171 A 19990921
OTHER SOURCE(S): MARPAT 134:266318
GI



I



II

AB Title compds. (I) [wherein X = O, S, SO, SO₂, NH, or NR₆; R₆ = H or alkyl; R₅ = (un)substituted 6-membered arom. ring contg. at least one N; R₁-R₄ = independently halo, CN, NO₂, alkylsulfanyl, N(OH)R₇, or R₉X₁; R₇ = H or alkyl; X₁ = a direct bond, O, CH₂, OC(O), CO, S, SO, SO₂, or (un)substituted NHCO, CONH, SO₂NH, NHSO₂, or NH; R₉ = H or (un)substituted hydrocarbonyl, heterocyclyl, or alkoxy; and at least one of R₂ or R₃ is other than H; or a salt, ester, amide, or prodrug thereof] were prepd. as aurora 2 kinase inhibitors for the treatment of proliferative diseases, such as cancer. For example, 2-(N-benzoylamino)-5-aminopyrimidine and 4-chloro-6,7-dimethoxyquinazoline were coupled in i-PrOH to yield II (58%). The latter inhibited the serine/threonine kinase activity of aurora 2 kinase by 50% at a concn. of 0.00785 .mu.M. In addn., II gave 50% inhibition of MCF-7 cell proliferation at 1.7 .mu.M and reduced BrdU incorporation into cellular DNA by 50% at 1.92-2.848 .mu.M.

IT 331795-05-2P 331797-15-0P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compds.; prepn. of substituted quinazoline derivs. as inhibitors of aurora 2 kinase for the treatment of breast and colorectal cancers)

RN 331795-05-2 CAPLUS

CN 2-Pyrimidinecarboxamide, 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(1-methyl-1H-pyrazol-5-yl)- (9CI) (CA INDEX NAME)

09/ 806,836




RN 331797-15-0 CAPLUS

CN Phosphate(1-), hexafluoro-, hydrogen, compd. with 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-[3-(3-methyl-1H-pyrazol-4-yl)propyl]-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331797-14-9

CMF C28 H35 N9 O4




CM 2

CRN 16940-81-1

CMF F6 P . H

09/ 806,836

CCI CCS



● H⁺

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 12 OF 24 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:228866 CAPLUS

DOCUMENT NUMBER: 134:266317

TITLE: Preparation of quinazolines as aurora 2 kinase inhibitors

INVENTOR(S): Mortlock, Andrew Austen; Keen, Nicholas John; Jung, Frederic Henri; Brewster, Andrew George

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 306 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021596	A1	20010329	WO 2000-GB3580	20000918
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: GB 1999-22154 A 19990921
GB 1999-22170 A 19990921

OTHER SOURCE(S): MARPAT 134:266317
GI



I



II

AB Title compds. (I) [wherein X = O, S, SO, SO₂, NH, or NR₁₂; R₁₂ = H or alkyl; R₁-R₄ = independently halo, CN, NO₂, alkylsulfanyl, N(OH)R₁₃, or R₁₅X₁; R₁₃ = H or alkyl; X₁ = a direct bond, O, CH₂, OC(O), CO, CO₂, S, SO, SO₂, or (un)substituted NHCO, CONH, SO₂NH, NHSO₂, or NH; R₁₅ = H or (un)substituted hydrocarbyl, heterocyclyl, or alkoxy; R₅ = NHCO₂R₉, NHCOR₉, NHSO₂R₉, COR₉, CO₂R₉, SOR₉, SO₂OR₉, CONR₁₀R₁₁, SONR₁₀R₁₁, or SO₂NR₁₀R₁₁; R₉-R₁₁ = independently H or (un)substituted hydrocarbyl or heterocyclyl; or R₁₀ and R₁₁ together with the N to which they are attached = (un)substituted heterocyclyl; R₆ = H or (un)substituted hydrocarbyl or heterocyclyl; R₇ and R₈ = independently H, halo, alkyl, (di)alkoxy(methyl), alkanoyl, CF₃, CN, NHY₂, alkenyl, alkynyl, or (un)substituted Ph, PhCH₂, or heterocyclyl; or a salt, ester, or amide thereof] were prepd. as aurora 2 kinase inhibitors for the treatment of proliferative diseases, such as cancer. For example, a 7-step sequence involving (1) alkylation of morpholine with 1-bromo-3-chloropropane (49%), (2) addn. of Et vanillate to yield Et 3-methoxy-4-(3-morpholinopropoxy)benzoate (100%), (3) nitration (86%), (4) redn. to the amine using 10% Pd/C (100%), (5) cycloaddn. with formamide to form the quinazoline (68%), (6) chlorination to give 4-chloro-6-methoxy-7-(3-morpholinopropoxy)quinazoline (60%), and (7) amination with N-benzoyl-4-aminoaniline (58%) yielded II. The latter inhibited the serine/threonine kinase activity of aurora 2 kinase by 50% at a concn. of 0.0193 .mu.M. In addn., II gave 50% inhibition of MCF-7 cell proliferation at 1.06 .mu.M and reduced BrdU incorporation into cellular DNA by 50% at 0.159-0.209 .mu.M.

IT 331770-46-8P 331771-46-1P 331772-08-8P
331773-20-7P 331774-09-5P 331774-72-2P
331775-17-8P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 4-substituted quinazoline aurora 2 kinase inhibitors for treatment of cancer and other proliferative diseases)

RN 331770-46-8 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-1,5-dimethyl- (9CI) (CA INDEX NAME)

09/ 806,836



RN 331771-46-1 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-1,5-dimethyl- (9CI) (CA INDEX NAME)



RN 331772-08-8 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-1,5-dimethyl- (9CI) (CA INDEX NAME)

09/ 806,836



RN 331773-20-7 CAPLUS


CN Benzamide, N-[4-[[6-methoxy-7-[2-[(5-methyl-1H-pyrazol-3-yl)amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331774-09-5 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-[(5-methyl-1H-pyrazol-3-yl)amino]propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


09/ 806,836



RN 331774-72-2 CAPLUS

CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[(5-methyl-1H-pyrazol-3-yl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-17-8 CAPLUS

CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[(5-methyl-1H-pyrazol-3-yl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)



Absolute stereochemistry.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 13 OF 24 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2000:260277 CAPLUS
 DOCUMENT NUMBER: 132:293771
 TITLE: Preparation of quinazolines as VEGF receptor tyrosine kinase inhibitors
 INVENTOR(S): Hennequin, Laurent Francois Andre; Pasquet, Georges
 PATENT ASSIGNEE(S): Zeneca Limited, UK; Zeneca-Pharma S.A.
 SOURCE: PCT Int. Appl., 107 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000021955	A1	20000420	WO 1999-GB3295	19991005
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9961128	A1	20000501	AU 1999-61128	19991005
BR 9914326	A	20010626	BR 1999-14326	19991005
NO 2001001739	A	20010607	NO 2001-1739	20010406
PRIORITY APPLN. INFO.:			EP 1998-402496	A 19981008
			WO 1999-GB3295	W 19991005
OTHER SOURCE(S):			MARPAT 132:293771	
GI				



AB The title compds. [I; ring C = 5-6 membered heterocyclic moiety; Z = O, NH, S, CH₂; R₁ = H, alkyl, alkoxymethyl, etc.; n = 0-5; m = 0-3; R₂ = H, OH, halo, etc.] and their salts which inhibit the effects of VEGF, and therefore useful in the prodn. of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals, were prepd. and formulated. E.g., a multi-step synthesis of quinazoline II was given. Compds. I are effective at 1-50 mg/kg/day.

IT 264207-46-7P 264207-48-9P 264207-50-3P
 264207-52-5P 264207-54-7P 264207-56-9P


09/ 806,836

264207-58-1P 264207-60-5P 264207-62-7P
264207-64-9P 264207-66-1P 264207-68-3P
264207-70-7P 264207-72-9P 264207-74-1P
264207-76-3P 264207-78-5P 264207-80-9P
264207-82-1P 264207-84-3P 264207-86-5P
264207-88-7P 264207-90-1P 264207-92-3P
264207-94-5P 264207-96-7P 264207-98-9P
264208-00-6P 264208-02-8P 264208-04-0P
264208-06-2P 264208-08-4P 264208-10-8P
264208-12-0P 264208-14-2P 264208-16-4P
264208-18-6P 264208-21-1P 264208-23-3P
264208-26-6P 264208-28-8P 264208-31-3P
264208-33-5P 264208-35-7P 264208-38-0P
264208-41-5P 264208-43-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of quinazolines as VEGF receptor tyrosine kinase inhibitors)


RN 264207-46-7 CAPLUS

CN Quinazoline, 6,7-dimethoxy-4-[(5-phenyl-1H-pyrazol-3-yl)oxy]- (9CI) (CA INDEX NAME)



RN 264207-48-9 CAPLUS


CN Quinazoline, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-[[5-(phenylmethyl)-1H-pyrazol-3-yl]oxy]- (9CI) (CA INDEX NAME)




RN 264207-50-3 CAPLUS

CN Quinazoline, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-[(5-phenyl-1H-pyrazol-3-yl)oxy]- (9CI) (CA INDEX NAME)

09/ 806,836




RN 264207-52-5 CAPLUS
CN Quinazoline, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-[(5-phenyl-1H-pyrazol-3-yl)oxy]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 264207-54-7 CAPLUS
CN Quinazoline, 6-methoxy-7-(2-methoxyethoxy)-4-[(5-phenyl-1H-pyrazol-3-yl)oxy]- (9CI) (CA INDEX NAME)



RN 264207-56-9 CAPLUS
CN Quinazoline, 6-methoxy-7-(2-methoxyethoxy)-4-[(5-phenyl-1H-pyrazol-3-yl)oxy]-, hydrochloride (4:3) (9CI) (CA INDEX NAME)


09/ 806,836



●3/4 HCl

RN 264207-58-1 CAPLUS

CN Quinazoline, 4-[[5-(4-fluorophenyl)-1H-pyrazol-3-yl]oxy]-6-methoxy-7-[[3-(4-morpholinyl)propoxy]-, hydrochloride (10:19) (9CI) (CA INDEX NAME)




●19/10 HCl

RN 264207-60-5 CAPLUS

CN Quinazoline, 7-(2-methoxyethoxy)-4-[(5-phenyl-1H-pyrazol-3-yl)oxy]-, hydrochloride (5:3) (9CI) (CA INDEX NAME)


09/ 806,836



●3/5 HCl

RN 264207-62-7 CAPLUS

CN Quinazoline, 7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-[(5-phenyl-1H-pyrazol-3-yl)oxy]-, hydrochloride (2:5) (9CI) (CA INDEX NAME)




●5/2 HCl

RN 264207-64-9 CAPLUS

CN Quinazoline, 6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]-4-[(5-phenyl-1H-pyrazol-3-yl)oxy]-, hydrochloride (20:17) (9CI) (CA INDEX NAME)


09/ 806,836



●17/20 HCl

RN 264207-66-1 CAPLUS


CN Quinazoline, 4-[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 264207-68-3 CAPLUS


CN Quinazoline, 6-methoxy-7-(2-methoxyethoxy)-4-[[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]oxy]- (9CI) (CA INDEX NAME)

09/ 806,836



RN 264207-70-7 CAPLUS


CN Quinazoline, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-[[5-(3-pyridinyl)-1H-pyrazol-3-yl]oxy]- (9CI) (CA INDEX NAME)



RN 264207-72-9 CAPLUS


CN Quinazoline, 4-[[5-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)

09/ 806,836




RN 264207-74-1 CAPLUS

CN Quinazoline, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-[[5-(4-pyridinyl)-1H-pyrazol-3-yl]oxy]- (9CI) (CA INDEX NAME)



RN 264207-76-3 CAPLUS


CN Quinazoline, 6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-[(5-phenyl-1H-pyrazol-3-yl)oxy]- (9CI) (CA INDEX NAME)



09/ 806,836

RN 264207-78-5 CAPLUS

CN 4-Quinazolinamine, 6-methoxy-N-[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]-7-[(1-methyl-4-piperidinyl)methoxy]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 264207-80-9 CAPLUS

CN 4-Quinazolinamine, N-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 264207-82-1 CAPLUS

CN 4-Quinazolinamine, N-[5-(3,4-dichlorophenyl)-1H-pyrazol-3-yl]-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-, hydrochloride (9CI) (CA INDEX NAME)

09/ 806,836




●x HCl

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 264207-84-3 CAPLUS

CN 4-Quinazolinamine, 6-methoxy-N-[5-(4-methylphenyl)-1H-pyrazol-3-yl]-7-[(1-methyl-4-piperidinyl)methoxy]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 264207-86-5 CAPLUS

CN 4-Quinazolinamine, 6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-N-[5-[3-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl]-, hydrochloride (9CI) (CA INDEX NAME)

09/ 806,836




●x HCl

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 264207-88-7 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 264207-90-1 CAPLUS

CN 4-Quinazolinamine, 6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-N-(5-phenyl-1H-pyrazol-3-yl)-, hydrochloride (5:12) (9CI) (CA INDEX NAME)

09/ 806,836




●12/5 HCl

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 264207-92-3 CAPLUS

CN 4-Quinazolinamine, 6,7-dimethoxy-N-(5-phenyl-1H-pyrazol-3-yl)-,
hydrochloride (5:9) (9CI) (CA INDEX NAME)




●9/5 HCl

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 264207-94-5 CAPLUS

CN Quinazoline, 4-[[5-(3-furanyl)-1H-pyrazol-3-yl]oxy]-6-methoxy-7-[3-(4-morpholinyl)propoxy]-, hydrochloride (9CI) (CA INDEX NAME)


09/ 806,836



●x HCl

RN 264207-96-7 CAPLUS


CN Quinazoline, 4-[[5-(2-fluorophenyl)-1H-pyrazol-3-yl]oxy]-6-methoxy-7-[3-(4-morpholinyl)propoxy] - (9CI) (CA INDEX NAME)



RN 264207-98-9 CAPLUS


CN Quinazoline, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-[[5-(3-nitrophenyl)-1H-pyrazol-3-yl]oxy] - (9CI) (CA INDEX NAME)

09/ 806,836




RN 264208-00-6 CAPLUS

CN Quinazoline, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-[[5-(4-nitrophenyl)-1H-pyrazol-3-yl]oxy]-(9CI) (CA INDEX NAME)



RN 264208-02-8 CAPLUS


CN Quinazoline, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-[(5-propyl-1H-pyrazol-3-yl)oxy]-(9CI) (CA INDEX NAME)



09/ 806,836


RN 264208-04-0 CAPLUS

CN Quinazoline, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-[[5-(3-pentenyl)-1H-pyrazol-3-yl]oxy]- (9CI) (CA INDEX NAME)




RN 264208-06-2 CAPLUS

CN Quinazoline, 6-methoxy-4-[[5-(methoxymethyl)-1H-pyrazol-3-yl]oxy]-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 264208-08-4 CAPLUS


CN Quinazoline, 4-[[5-ethyl-1H-pyrazol-3-yl]oxy]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 264208-10-8 CAPLUS


CN Quinazoline, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-[[5-(2-phenylethyl)-1H-pyrazol-3-yl]oxy]- (9CI) (CA INDEX NAME)

09/ 806,836



RN 264208-12-0 CAPLUS


CN Quinazoline, 6-methoxy-4-[[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]oxy]-7-[(1-methyl-4-piperidinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 264208-14-2 CAPLUS


CN Quinazoline, 6-methoxy-4-[[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]oxy]-7-[2-(1H-1,2,3-triazol-1-yl)ethoxy]- (9CI) (CA INDEX NAME)

09/ 806,836



RN 264208-16-4 CAPLUS


CN Quinazoline, 6-methoxy-4-[[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]oxy]-7-[[1-[2-(methylsulfonyl)ethyl]-4-piperidinyl]methoxy]- (9CI) (CA INDEX NAME)



RN 264208-18-6 CAPLUS


CN Quinazoline, 6-methoxy-4-[[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]oxy]-7-[3-(4-methyl-1-piperazinyl)propoxy]- (9CI) (CA INDEX NAME)

09/ 806,836




RN 264208-21-1 CAPLUS

CN Quinazoline, 6-methoxy-4-[[5-(2-methylpropyl)-1H-pyrazol-3-yl]oxy]-7-[3-(4-morpholinyl)propoxy] - (9CI) (CA INDEX NAME)



RN 264208-23-3 CAPLUS


CN Quinazoline, 4-[[5-(isobutyl)-1H-pyrazol-3-yl]oxy]-6-methoxy-7-[3-(4-morpholinyl)propoxy] - (9CI) (CA INDEX NAME)




RN 264208-26-6 CAPLUS

CN Quinazoline, 4-[[5-(n-butyl)-1H-pyrazol-3-yl]oxy]-6-methoxy-7-[3-(4-morpholinyl)propoxy] - (9CI) (CA INDEX NAME)

09/ 806,836




RN 264208-28-8 CAPLUS
CN Quinazoline, 6-methoxy-4-[[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]oxy]-7-[3-(methylsulfonyl)propoxy] - (9CI) (CA INDEX NAME)




RN 264208-31-3 CAPLUS
CN Quinazoline, 6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]-4-[(5-phenyl-1H-pyrazol-3-yl)oxy] - (9CI) (CA INDEX NAME)


09/ 806,836



RN 264208-33-5 CAPLUS
CN Quinazoline, 4-[[5-(3-furanyl)-1H-pyrazol-3-yl]oxy]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 264208-35-7 CAPLUS
CN Quinazoline, 7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-[(5-phenyl-1H-pyrazol-3-yl)oxy]- (9CI) (CA INDEX NAME)




RN 264208-38-0 CAPLUS
CN Quinazoline, 7-(2-methoxyethoxy)-4-[(5-phenyl-1H-pyrazol-3-yl)oxy]- (9CI) (CA INDEX NAME)

09/ 806,836




RN 264208-41-5 CAPLUS

CN Quinazoline, 4-[[5-(4-fluorophenyl)-1H-pyrazol-3-yl]oxy]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 264208-43-7 CAPLUS

CN 4-Quinazolinamine, 6-methoxy-7-[(1-methyl-4-piperidiny)methoxy]-N-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

REFERENCE COUNT:


3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

09/ 806,836

ACCESSION NUMBER: 1999:784082 CAPLUS
DOCUMENT NUMBER: 132:22963
TITLE: Preparation of N-(pyrazolylphenyl)alkanamides and
analogs as IL-2 production inhibitors
INVENTOR(S): Betageri, Rajashekhar; Cywin, Charles L.; Hargrave,
Karl; Hoermann, Mary Ann; Kirrane, Thomas M.; Parks,
Thomas M.; Patel, Usha R.; Proudfoot, John R.; Sharma,
Rajiv; Sun, Sanxing; Wang, Xiao-Jun
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 130 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9962885	A1	19991209	WO 1999-US12295	19990603
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
AU 9942299	A1	19991220	AU 1999-42299	19990603
PRIORITY APPLN. INFO.:			US 1998-88154P	P 19980605
			WO 1999-US12295	W 19990603
OTHER SOURCE(S):		MARPAT 132:22963		
GI				




AB Title compds. [I; R = R4Z1Z; R1,R3 = halo, CF3, alkyl, alkoxy, etc.; R2 = H, halo, Me; R4 = (cyclo)alkyl, alkoxy, alkylamino, etc.; Z = 1,4-phenylene; Z1 = CONH, CO2NH, NH, etc.] were prepd. Thus, I [R = 4-(R5HN)C6H4, R1 = R3 = CF3, R2 = H] (II; R5 = H) was amidated by cyclohexanecarboxylic acid to give II (R5 = cyclohexylcarbonyl). Data for biol. activity of I were given.

IT **251657-95-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents)

RN 251657-95-1 CAPLUS

CN 4-Quinazolinamine, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro-6,7-dimethoxy- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 15 OF 24 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:105843 CAPLUS

DOCUMENT NUMBER: 128:136497

TITLE: Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase

INVENTOR(S): Myers, Michael R.; Spada, Alfred P.; Maguire, Martin P.; Persons, Paul E.

PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Pharmaceuticals Inc., USA

SOURCE: U.S., 19 pp. Cont.-in-part of U.S. 5,480,883.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5710158	A	19980120	US 1994-229886	19940419
US 5480883	A	19960102	US 1993-166199	19931210
WO 9515758	A1	19950615	WO 1994-US14180	19941208
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9513050	A1	19950627	AU 1995-13050	19941208
EP 871448	A1	19981021	EP 1995-904308	19941208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
US 5656643	A	19970812	US 1995-385258	19950208
US 5714493	A	19980203	US 1996-652444	19960604
US 37650	E	20020409	US 2000-496399	20000202

PRIORITY APPLN. INFO.:

US 1991-698420	B2	19910510
US 1992-988515	B2	19921210
US 1993-166199	A2	19931210
WO 1992-US3736	A2	19920506
US 1993-146072	A3	19931108
US 1994-229886	A	19940419
WO 1994-US14180	W	19941208

US 1996-652444 A5 19960604

OTHER SOURCE(S): MARPAT 128:136497

AB This invention relates to the modulation and/or inhibition of cell signaling, cell proliferation, cell inflammatory response, the control of abnormal cell growth and cell reprodn. More specifically, this invention relates to the use of mono- and/or bicyclic aryl or heteroaryl quinazoline compds. in inhibiting cell proliferation, including compds. which are useful protein tyrosine kinase (PTK) inhibitors. The method of treating cell proliferation using said quinazoline compds. and their use in pharmaceutical compns. is described. A no. of compds. were tested for inhibition of PDGF receptor cell-free antophosphorylation procedure.

IT 186138-08-9


RL: BAC (Biological activity or effector, except adverse); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)

(aryl and heteroaryl quinazoline compds. which inhibit EGF and/or PDGF receptor tyrosine kinase)

RN 186138-08-9 CAPLUS

CN 4-Quinazolinamine, 6,7-dimethoxy-N-1H-pyrazol-3-yl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

L5 ANSWER 16 OF 24 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1997:107384 CAPLUS

DOCUMENT NUMBER: 126:113167

TITLE: Protein tyrosine kinase aryl and heteroaryl
quinazoline compounds having selective inhibition of
HER-2 autophosphorylation properties

INVENTOR(S): Myers, Michael R.; Spada, Alfred P.; Maguire, Martin
P.; Persons, Paul E.

PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Pharmaceuticals Inc., USA; Myers,
Michael R.; Spada, Alfred P.; Maguire, Martin P.;
Persons, Paul, E.

SOURCE: PCT Int. Appl., 32 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9639145	A1	19961212	WO 1996-US9606	19960606
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML				

09/ 806,836

US 5656643	A	19970812	US 1995-385258	19950208
US 5721237	A	19980224	US 1995-469147	19950606
AU 9661044	A1	19961224	AU 1996-61044	19960606
AU 696456	B2	19980910		
EP 831831	A1	19980401	EP 1996-918362	19960606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
BR 9608638	A	19990629	BR 1996-8638	19960606
JP 11507355	T2	19990629	JP 1996-501889	19960606

PRIORITY APPLN. INFO.:

US 1995-469147	A	19950606
US 1991-698420	B2	19910510
US 1992-988515	B2	19921210
US 1993-146072	A3	19931108
US 1993-166199	A2	19931210
WO 1996-US9606	W	19960606

OTHER SOURCE(S): MARPAT 126:113167

AB A method is disclosed for the selective treatment of cell growth and differentiation characterized by activity of the human epidermal growth factor receptor type 2 (HER2). More specifically, this invention relates to the use of substituted or unsubstituted mono- or bi-cyclic aryl, heteroaryl, cycloalkyl or heterocycloalkyl compds. in selectively regulating cell growth. Pharmaceutical compns. useful for the selective treatment of cell growth and differentiation are also described.


IT 174892-28-5P 186138-08-9P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein tyrosine kinase aryl and heteroaryl quinazoline compds. with selective inhibition of HER-2 autophosphorylation properties, and compd. prepn.)

RN 174892-28-5 CAPLUS

CN 4-Quinazolinamine, 6,7-dimethoxy-N-1H-pyrazol-3-yl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 186138-08-9 CAPLUS

CN 4-Quinazolinamine, 6,7-dimethoxy-N-1H-pyrazol-3-yl- (9CI) (CA INDEX NAME)

09/ 806,836



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

L5 ANSWER 17 OF 24 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1996:476843 CAPLUS

DOCUMENT NUMBER: 125:142761

TITLE: Quinazoline derivatives

INVENTOR(S): Barker, Andrew John

PATENT ASSIGNEE(S): Zeneca Limited, UK

SOURCE: PCT Int. Appl., 45 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9616960	A1	19960606	WO 1995-GB2768	19951128
W:	AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK			
RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9539330	A1	19960619	AU 1995-39330	19951128
EP 794953	A1	19970917	EP 1995-937126	19951128
EP 794953	B1	19990506		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE			
JP 10509972	T2	19980929	JP 1995-518417	19951128
AT 179708	E	19990515	AT 1995-937126	19951128
US 5955464	A	19990921	US 1997-860088	19970522
PRIORITY APPLN. INFO.:			GB 1994-24233	19941130
			WO 1995-GB2768	19951128
OTHER SOURCE(S):	MARPAT 125:142761			
GI				




AB The invention concerns quinazoline derivs. I ($m = 1, 2$; $R_1 = H, \text{halo, alkyl, alkoxy}$; $n = 1-3$; $R_2 = H, OH, \text{halo, alkyl}$; $R = 5\text{- or }9\text{-membered nitrogen-linked heteroaryl moiety contg. up to four nitrogen heteroatoms, or } R = \text{a } 5\text{-, }6\text{-, }9\text{- or }10\text{-membered nitrogen-linked unsatd. heterocyclic moiety contg. up to three nitrogen heteroatoms which bears one or two substituents selected from oxo and thioxo}$) and the use of the receptor tyrosine kinase inhibitory properties of the compds. in the treatment of proliferative diseases such as cancer. Among the approx. 15 title compds. prepd., 4-(3-methylanilino)-, 4-(3-chloro-4-fluoroanilino)-, 4-(4-benzoyl-3-chloroanilino)-, and 4-[3-methyl-4-(2-pyridylmethoxy)anilino]-6-(1-imidazolyl)quinazolines were claimed.

IT 179552-83-1P 179552-84-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of tyrosine kinase inhibiting imidazolylquinazolines)


RN 179552-83-1 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(4-chloro-1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)



RN 179552-84-2 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(1H-pyrazol-1-yl)- (9CI)
(CA INDEX NAME)



L5 ANSWER 18 OF 24 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1996:304557 CAPLUS

DOCUMENT NUMBER: 125:58433

TITLE: Synthesis and biological activities of some new heterocyclic compounds bearing 2-phenyl-6-iodoquinazolinyl-4-oxy moiety. Part-II

AUTHOR(S): Abdel-Hamide, S.G.; El-Hakim, A.E.; Abdel-Rahman, R. M.

CORPORATE SOURCE: Faculty of Pharmacy, Al-Azhar University, Nasr, Egypt

SOURCE: Indian J. Heterocycl. Chem. (1996), 5(3), 189-192

CODEN: IJCHEI; ISSN: 0971-1627

DOCUMENT TYPE: Journal

LANGUAGE: English


AB Substituted pyridazinonyl, pyrazolonyl, phthalazinyl, pyrazolinyl and triazinonyl systems bearing 2-phenyl-6-iodoquinazolinyl-4-oxy moiety have been prep'd. from reactions of (2-phenyl-6-iodoquinazolinyl-4-oxy)-acetic acid hydrazide with some carbonyl compds. followed by cyclization reactions. All these compds. have been characterized on the basis of spectral studies and anal. data. Some of the new heterocyclic systems have been tested for their biol. activities.

IT 178060-01-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis and biol. activities of some new heterocyclic compds. bearing phenyliodoquinazolinyl oxy moiety)

RN 178060-01-0 CAPLUS

CN 3H-Pyrazol-3-one, 2,4-dihydro-4-[(6-iodo-2-phenyl-4-quinazolinyl)oxy]-(9CI) (CA INDEX NAME)





L5 ANSWER 19 OF 24 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1996:71553 CAPLUS

09/ 806,836

DOCUMENT NUMBER: 124:261073
 TITLE: Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
 INVENTOR(S): Spada, Alfred P.; Myers, Michael R.; Maguire, Martin P.; Persons, Paul E.
 PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Pharmaceuticals Inc., USA
 SOURCE: U.S., 33 pp. Cont.-in-part of U.S. Ser. No. 988,515, abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 7
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5480883	A	19960102	US 1993-166199	19931210
US 5710158	A	19980120	US 1994-229886	19940419
WO 9515758	A1	19950615	WO 1994-US14180	19941208
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9513050	A1	19950627	AU 1995-13050	19941208
EP 871448	A1	19981021	EP 1995-904308	19941208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
US 5656643	A	19970812	US 1995-385258	19950208
US 5795889	A	19980818	US 1995-386271	19950209
US 5646153	A	19970708	US 1995-439027	19950511
US 5721237	A	19980224	US 1995-469147	19950606
US 5714493	A	19980203	US 1996-652444	19960604
US 6057320	A	20000502	US 1997-881991	19970625
US 36256	E	19990720	US 1997-988005	19971210
AU 739382	B2	20011011	AU 1999-65543	19991230
AU 9965543	A1	20000323		
US 37650	E	20020409	US 2000-496399	20000202
PRIORITY APPLN. INFO.:				
			US 1991-698420	B2 19910510
			US 1992-988515	B2 19921210
			WO 1992-US3736	B2 19920506
			US 1993-146072	A3 19931108
			US 1993-166199	A2 19931210
			US 1994-229886	A 19940419
			WO 1994-US14180	W 19941208
			US 1995-439027	A3 19950511
			US 1996-652444	A5 19960604
OTHER SOURCE(S): MARPAT 124:261073				
GI				



III

AB The invention relates to bis mono- and/or bicyclic aryl and/or heteroaryl compds. Ar1XAr2 [I; Ar1, Ar2 = (un)substituted mono- or bicyclic rings with 0-3 substituents; X = (CHR1)0-4 or (CHR1)mZ(CHR1)n; Z = O, NR2, S, SO, SO2; m, n = 0-3; R1, R2 = H, alkyl] exhibiting protein tyrosine kinase inhibition activity. I inhibit abnormal cell proliferation in proliferative disorders by selectively inhibiting EGF and/or PDGF receptor. Approx. 300 compds. I are listed with characterizing data, and biol. data for selected compds. are given. For example, m-ClC6H4OH was treated with NaH in THF, followed by 4-chloro-6,7-dimethoxyquinazoline, to give title compd. II. The claimed quinoxaline deriv. III inhibited PDGF-R cell-free autophosphorylation with an IC50 of 0.02-0.05 .mu.M.


IT 174892-28-5P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of bis mono- and bicyclic aryl and heteroaryl compds. as protein tyrosine kinase inhibitors)

RN 174892-28-5 CAPLUS

CN 4-Quinazolinamine, 6,7-dimethoxy-N-1H-pyrazol-3-yl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

L5 ANSWER 20 OF 24 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1991:478820 CAPLUS

DOCUMENT NUMBER: 115:78820

TITLE: Improvement of the composition and technology of soft dosage forms by means of polymeric excipients

AUTHOR(S): Golovkin, V. A.; Gladyshev, V. V.; Dueva, O. V.; Kravchenko, T. N.; Puchkan, L. A.

CORPORATE SOURCE: Zaporozh. Gos. Med. Inst., Zaporozhe, USSR

SOURCE: Nauchn. Tr. - Vses. Nauchno-Issled. Inst. Farm. (1990), 28, 70-5

CODEN: NTVFES

DOCUMENT TYPE: Journal

LANGUAGE: Russian

AB The release of drugs (Na succinate, quinazopyrine, tiotriazazin, and nitroxoline) from suppositories was dependent on the suppository base and a surfactant used. The best suppository formulation for these drugs appears to be polyethylene glycol 400 and 1500 (1:9) with and without an emulsifying agent.

IT 100330-91-4, Quinazopyrine


RL: BIOL (Biological study)

(suppository formulation for, optimization of and drug release from)

09/ 806,836

RN 100330-91-4 CAPLUS

CN 3H-Pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-2-phenyl-4-(4-quinazolinylamino)- (9CI) (CA INDEX NAME)



L5 ANSWER 21 OF 24 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1990:452266 CAPLUS

DOCUMENT NUMBER: 113:52266

TITLE: Investigation of the antiarrhythmic activity of quinazopyrine

AUTHOR(S): Stets, V. R.; Beregovaya, E. G.; Dunaev, v. V.; Storozhuk, B. G.; Favoritov, V. N.; Stolyarchuk, A. A.; Mazur, A. I.

CORPORATE SOURCE: Dep. Pharmacol., Med. Inst., Zaporozhye, 330074, USSR
SOURCE: Farmakol. Toksikol. (Moscow) (1990), 53(3), 15-17
CODEN: FATOAO; ISSN: 0014-8318

DOCUMENT TYPE: Journal


LANGUAGE: Russian

AB The antiarrhythmic activity of quinazopyrine was studied in rats with calcium chloride- and aconitine-induced arrhythmias, disorders of cardiac rhythm in myocardial infarction produced by isadrine and pituitrin, and also in cats with arrhythmias caused by elec. stimulation of the myocardium and with postinfarction and reperfusion arrhythmias. Quinazopyrine exhibits an antiarrhythmic effect superior to that of anaprilin and novocainamide in arrhythmias induced by calcium chloride and aconitine. In other types of cardiac rhythm disorders its activity is comparable with that of ethmozine, obsidan, and cordarone. Quinazopyrine reduces automatism and contractile function of the myocardium.

IT 100330-91-4, Quinazopyrine
RL: PRP (Properties)
(antiarrhythmic effect of)

RN 100330-91-4 CAPLUS

CN 3H-Pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-2-phenyl-4-(4-quinazolinylamino)- (9CI) (CA INDEX NAME)



L5 ANSWER 22 OF 24 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1988:416724 CAPLUS

DOCUMENT NUMBER: 109:16724

TITLE: Effect of quinazopyrine on reparative regeneration of wounds

AUTHOR(S): Stets, V. R.; Dunaev, V. V.; Mazur, I. A.; Sinyak, R. S.

CORPORATE SOURCE: Zaporozh. Med. Inst., Zaporozhe, USSR

SOURCE: Farmakol. Toksikol. (Moscow) (1988), 51(3), 67-9

CODEN: FATOAO; ISSN: 0014-8318

DOCUMENT TYPE: Journal

LANGUAGE: Russian

AB Acute toxicity and wound-healing effects of quinazopyrine (I) were studied in mice and rats and compared with the effects of methyluracil, Na nucleate, K orotate, riboxin, and pentoxyl. Aseptic and Staphylococcus-infected skin wounds in normal and diabetic animals were treated with 1% paste, 5% powder, rectal suppository, i.m. injection soln., or oral tablets of I. The treatment effect on tensile strength of healing wounds was strongly dose-dependent. I had superior treatment effects in comparison with the other agents. The most effective treatment was achieved with topical and rectal administration of I. The effect of I was assocd. with increased nucleic acid formation and fibroblast maturation. The treatment effect of I was not influenced by the diabetic status.


IT 100330-91-4, Quinazopyrine

RL: BIOL (Biological study)

(wound healing stimulation by, formulation effect on)

RN 100330-91-4 CAPLUS

CN 3H-Pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-2-phenyl-4-(4-quinazolinylamino)- (9CI) (CA INDEX NAME)



L5 ANSWER 23 OF 24 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1986:95337 CAPLUS

DOCUMENT NUMBER: 104:95337

TITLE: Improved technology and study of rectal drug forms.
Part VI. Pharmacokinetic study of bioavailability of
quinazopyrine.AUTHOR(S): Golovkin, V. O.; Puchkan, L. O.; Logvin, P. A.;
Sinyak, R. S.

CORPORATE SOURCE: Zaporozhe Med. Inst., Zaporozhe, USSR


SOURCE: Farm. Zh. (Kiev) (1985), (5), 62-5

CODEN: FRZKAP; ISSN: 0367-3057

DOCUMENT TYPE: Journal

LANGUAGE: Ukrainian

GI



AB Quinazopyrine (I) [100330-91-4] (as HCl salt) (30 mg/kg) was administered to rabbits rectally in suppositories (in PEG base) or as an enema in water soln., or by i.v. injection. Blood concns. of I were detd. (after deproteination by TCA) spectrometrically at 376 nm; in the range 0.7-1.3 mg/100 mL, the relative std. deviation was 1.26% and sensitivity 7 .mu.g/mL. I elimination from blood was fastest after i.v. injection and slowest after administration in suppositories. The bioavailability of I from the suppositories and after the enema was 91.6 and 83.7%, resp., as compared with the bioavailability after i.v. injection. I did not accumulate in the organs of the rabbits.


IT 100330-91-4

RL: PROC (Process)

(bioavailability of, from rectal dosage forms)

RN 100330-91-4 CAPLUS

CN 3H-Pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-2-phenyl-4-(4-quinazolinylamino)- (9CI) (CA INDEX NAME)



L5 ANSWER 24 OF 24 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1983:594917 CAPLUS

DOCUMENT NUMBER: 99:194917

TITLE: Reactions with 4-[p-(substituted cinnamoyl)anilino]-2-phenylquinazolines

AUTHOR(S): Mahmoud, A. M.; El-Sherief, H. A. H.; Esmail, A. A.

CORPORATE SOURCE: Fac. Sci., Assiut Univ., Assiut, Egypt

SOURCE: Acta Chim. Hung. (1983), 113(3), 247-56


CODEN: ACHUDC

DOCUMENT TYPE: Journal


LANGUAGE: English

OTHER SOURCE(S): CASREACT 99:194917

GI



I



II

AB Chalcone analogs I [R = (un)substituted Ph, 1-C₁₀H₇, 2-furyl, 2-thienyl], prep'd. in 68-85% yields by condensation of RCHO with the corresponding acetophenone deriv., were cyclocondensed with N₂H₄.H₂O, PhNHNH₂, and NH₂OH.HCl to give 60-75% and 69-80%, resp., of II [X = NR₁ (R₁ = H, Ph); R = p-BrC₆H₄, p-ClC₆H₄, p-MeOC₆H₄, p-Me₂NC₆H₄] and II (X = O, R = p-ClC₆H₄, p-MeOC₆H₄, p-Me₂NC₆H₄). Addnl. products were obtained from I by bromination and subsequent substitution reactions and by cyclocondensation with MeCOCH₂CO₂Et.


IT 87771-99-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and acylation of)

RN 87771-99-1 CAPLUS

CN 4-Quinazolinamine, N-[4-[5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)

09/ 806,836




IT 87771-98-0P 87772-00-7P 87772-01-8P
87772-02-9P 87772-03-0P 87772-04-1P
87772-05-2P 87772-06-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 87771-98-0 CAPLUS


CN 4-Quinazolinamine, N-[4-[5-(4-bromophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 87772-00-7 CAPLUS


CN 4-Quinazolinamine, N-[4-[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)

09/ 806,836




RN 87772-01-8 CAPLUS

CN 4-Quinazolinamine, N-[4-[5-[4-(dimethylamino)phenyl]-4,5-dihydro-1H-pyrazol-3-yl]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 87772-02-9 CAPLUS

CN 1H-Pyrazole, 5-(4-bromophenyl)-4,5-dihydro-3-[4-[(2-phenyl-4-quinazolinyl)amino]phenyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 87772-03-0 CAPLUS
 CN 1H-Pyrazole, 1-acetyl-5-(4-chlorophenyl)-4,5-dihydro-3-[4-[(2-phenyl-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)

09/ 806,836



RN 87772-04-1 CAPLUS


CN 4-Quinazolinamine, N-[4-[5-(4-bromophenyl)-4,5-dihydro-1-phenyl-1H-pyrazol-3-yl]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 87772-05-2 CAPLUS


CN 4-Quinazolinamine, N-[4-[5-(4-chlorophenyl)-4,5-dihydro-1-phenyl-1H-pyrazol-3-yl]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)

09/ 806,836



RN 87772-06-3 CAPLUS

CN 4-Quinazolinamine, N-[4-[4,5-dihydro-5-(4-methoxyphenyl)-1-phenyl-1H-pyrazol-3-yl]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 15:35:33 ON 02 MAY 2002)

FILE 'REGISTRY' ENTERED AT 15:35:41 ON 02 MAY 2002

L1 STRUCTURE UPLOADED

L2 50 S L1

09/ 806,836

L3 9746 S L1 FUL
L4 249 S L3 AND PYRAZOL?

FILE 'CAPLUS' ENTERED AT 15:38:45 ON 02 MAY 2002
L5 24 S L4

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
107.32	253.33

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-14.87	-14.87

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 15:41:32 ON 02 MAY 2002